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 SUMMARY 
 
 
 
 CYP17 is an ACTH/cAMP inducible gene in the human adrenal cortex encoding a 
cytochrome P450 enzyme with sterol 17α-hydroxylase activity and 17,20 lyase activity essential 
for biosynthesis of cortisol and androgens.  Studies carried out during the past decade have shown 
that acclerated transcription of inducible eukaryotic genes involves sequential chromatin 
modifications by cooperative promoter-specific transcription factors and the class of proteins 
called transcriptional coregulators.  In the present work, we aimed to first identify important 
chromatin modifications and chromatin modifying complexes at the CYP17 transcription start 
site and nearby steroidogenic factor-1 (SF-1) binding site.  Then, we asked what modifications to 
SF-1 occur during the interaction of this nuclear receptor with the CYP17 promoter, and what 
their function may be.  Finally, we asked how ACTH/cAMP signaling affects SF-1-containing 
chromatin-modifying complexes during the early phase of transcriptional induction of CYP17.  
Results from chromatin immunoprecipitation (ChIP) and mammalian two hybrid experiments 
identified complexes including one comprised of SF-1, steroid receptor coactivator-1 (SRC-1), 
and the histone acetyltransferase general control nonderepressed 5 (GCN5) as cAMP-inducible, 
but sensitive to the SF-1 antagonist sphingosine, and able to act in stimulating CYP17 
transcription.  Moreover, ATPases on the promoter coincided with manipulation of nucleosome 
histone H2 dimer content.  Next, we found that SF-1 phosphorylation by glycogen synthase 
kinase 3ß (GSK3ß), reciprocal dephosphorylation by phosphatase(s), and acetylation by GCN5 at 
nearby sites at the ligand binding pocket opening were required for efficient CYP17 transcription.  
This leads us to propose that ligand binding to SF-1 is controlled by these post-translational 
modifications.  Finally, we determined that the corepressors E1A C-terminal binding proteins 
(CtBP) 1 and 2 are protein kinase A (PKA) targets and are sensitive to PKA-dependent NADH 
accumulation.  These effects of PKA activation by ACTH/cAMP in adrenal cortex cells enforce 
CYP17 transcription concomitant with dimerization of CtBP1 and CtBP2.
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 Chapter 1.  Introduction 
 
1.1 Causes and Effects of Induction of Adrenal Cortisol Synthesis  
 
In humans, stress initiates a cascade of physiological responses, including the 
synthesis of the steroid hormone cortisol in the adrenal cortex.  This stress response is 
conserved, with some minor differences, across most vertebrates.  Production of steroids, 
called steroidogenesis, in the adrenal cortex occurs following a cascade of signaling 
through the hypothalamus, the anterior pituitary gland, and the adrenal gland (the HPA 
axis). 
Neural activity initiated by the perception of fear or stress, or the early phase of 
the wake-sleep cycle, causes the hypothalamus to secrete the short-lived peptide hormone 
corticotropin releasing hormone (CRH) into local circulation between the hypothalamus 
and pituitary.  CRH receptors in the anterior pituitary gland couple to Gαs, adenylate 
cyclase, and its product, cyclic adenosine 3’,5’ monophosphate (cAMP).  Cleavage of 
adrenocorticotropic hormone/melanocortin 2 (ACTH/Mc2) from a larger pro-
opiomelanocortin peptide occurs as the hormone is packaged into secretory vesicles (1).  
Following cAMP production, ACTH is released from these vesicles into systemic 
circulation.  The primary target of ACTH is the Mc2 receptor, which is also coupled to 
cAMP production in cells of the innermost layers or zones of the mature adrenal cortex, 
namely zona fasciculata and zona reticularis.  Cells of these respective zones specialize in 
the ACTH- and cAMP-inducible synthesis of cortisol and dehydroepiandosterone 
(DHEA, an androgen). 
 Cortisol is a specific high-affinity agonist for the glucocorticoid receptor (GR), a 
transcription factor of the nuclear receptor superfamily of proteins (NRs).  GR is 
1 
 ubiquitously expressed, with particularly high levels in many cells of the immune system 
(2).  The immune system and inflammatory response is strongly repressed by GR bound 
to cortisol in a mechanism of transcription repression, in which agonist-bound GR 
becomes modified, binds and stabilizes corepressor complexes on repressed gene 
promoters (3).  In addition, through the GR, glucocorticoids activate a transcription 
program on other genes which are essential in altering whole body metabolism and 
signaling to mobilize diverse energy sources to elevate blood glucose.  In particular, 
active GR induces genes required for liver gluconeogenesis (4), muscle proteasome-
mediated catabolism of protein (5) and inhibition of protein synthesis, and adipose tissue 
lipolysis (4), although these effects may depend on the recent food intake of an 
individual.  
 
1.1.1 Steroid Precursor Mobilization and Induced Transcription of Steroidogenic 
Enzymes Are Hallmarks of Acute and Chronic Steroidogenesis 
 
Steroidogenic cells are typically have an ability to take cholesterol as a starting 
substrate; cholesterol then feeds into all steroid hormone-generating pathways.  Such 
cells make up the adrenal cortex, select cells of the gonads, placenta, and brain, although 
the latter two tissues lack an ability to undergo rapidly induced steroid production (6).  
This is because they lack cAMP-inducible transcription of a labile factor that enables the 
high rate of cholesterol conversion to steroid inherent to acute adrenal and gonadal 
steroidogenesis (6, 7).  In steroidogenic cells of the gonads and adrenal cortex, 
cholesterol esters in cytoplasmic lipid droplets are the readily available and locally stored 
form of cholesterol.  The acute response to induction of steroidogenesis by elevated 
cAMP in the adrenal requires hormone sensitive lipase activity (8), whereby these fatty-
2 
 3 
acid esters of cholesterol are hydrolyzed to release free substrate, forming cytoplasmic 
lipid droplets if subsequent steps do not occur.  In the rate-limiting step of 
steroidogenesis, cholesterol is translocated to the inner leaflet of the inner mitochondrial 
membrane through the outer mitochondrial membrane, giving it accelerated access to 
inner leaflet-associated enzymes in a process requiring steroidogenic acute regulatory 
protein (StAR).    During this process, a complex of StAR-associated proteins including 
cAMP-dependent kinase/protein kinase A (PKA) assembles on the outer mitochondrial 
membrane in response to cAMP induced activation of PKA, probably via 
phosphorylation-aided protein-protein interactions with StAR (9, 10).  StAR is the labile 
factor that is rapidly transcribed, then phosphorylated by PKA at the outer mitochondrial 
membrane following cAMP mediated liberation of free cholesterol in steroidogenic cells 
of the gonads and adrenal cortex.  Phosphorylation of StAR at a single residue is required 
for about fifty percent of its mitochondrial cholesterol import capability (9).  It has also 
been shown that StAR is not enriched in mitochondria of cAMP-stimulated steroidogenic 
cells treated with a cholesterol esterase inhibitor (11); this suggests coupling of the lipase 
mediated release of free cholesterol and StAR membrane integration during the transfer 
of that cholesterol into mitochondria. 
 
1.1.2 Cytochromes P450 Are Key Steroidogenic Enzymes 
 
Contacting the inner leaflet of the inner mitochondrial membrane (12), a member 
of the heme-containing monooxygenase superfamily of cytochromes P450 begins the 
enzymatic conversion of cholesterol to steroid (summarized in Figure 1.1).  Specifically, 
P450 side chain cleavage enzyme performs successive oxidations of 
 Figure 1.1  Steroidogenic reactions and enzymes of the three zones of the adrenal cortex.  Adapted from (13).  P450scc, cholesterol side chain cleavage P450; 
3ßHSD, 3ß-hydroxy steroid dehydrogenase, the only non P450 adrenal steroidogenic enzyme; P450c17, steroid 17α-hydroxylase/17,20 lyase; P450c21, steroid 
21α-hydroxylase; P450c11, steroid 11ß-hydroxylase; P450c18, aldosterone synthase; Ac-CoA, acetyl-coenzyme A; HDL, high density lipoprotein particle; SR-
B1, HDL receptor scavenger receptor-BI; LDL, low density lipoprotein particle; LDLR, LDL receptor.  Drawing of human adrenal cortex zonation reproduced 
from 20th US ed. of Grey’s Anatomy of the Human Body (1918). 
 
 cholesterol at C20 and C22, generating pregnenolone, which is then directed along a cell 
type-specific pathway.  Steroidogenic pathways specific to each of the three adrenal 
cortex zones are summarized with respect to cell type and intracellular location of 
steroidogenic enzymes in Figure 1.1. 
P450s are a family of enzymes that act on diverse endogenous and xenobiotic 
substrates, typically increasing water solubility.  Activated oxygen in a steroidogenic 
P450 attacks bound sterol at a site specified by the overall structure and substrate binding 
properties of that enzyme.  Possible reactions by adrenal steroidogenic P450s are the 
oxidation of a C-H bond to a C-OH bond (hydroxylase activity), a C-OH moiety to a 
carbonyl group (C=O), or carbon-carbon bond scission between a vicinal O=C-C-OH 
pair due to oxidation of the remaining hydroxide and rearrangement of a hydrogen atom 
and electrons.  Outside the adrenal, in estrogen (estradiol) producing cells, P450 
aromatase (encoded by the CYP19 gene) catalyzes successive oxidations of the first 
sterol ring (A ring), resulting in loss of the C19 methyl group while making the A ring 
aromatic. 
Each oxidation reaction catalyzed by a P450 requires two electrons, one each 
typically from the reduced form of nicotinamide adenine dinucleotide phosphate 
(NADPH), which does not directly interact with the heme oxygen of eukaryotic P450s 
but rather relays electrons individually via P450 oxidoreductase in the endoplasmic 
reticulum, or adrenodoxin and adrenodoxin reductase in mitochondria.  In some cases, 
cytochrome B5 may relay an electron from NADH to P450s such as to P450c17 for the 
catalysis of 17/20 bond scission (14).  Stimulation of acute steroidogenesis also may 
5 
 increase the availability of electrons for this process, or at least requires that the NADPH-
generating pentose phosphate pathway be fully functional (15). 
 
1.1.3 How Is Cortisol Output Chronically Upregulated in Zona Fasciculata? 
 
Acute ACTH-induced cortisol production by the adrenal cortex is complemented 
by a chronic increased potential for steroidogenic capacity primarily through increased 
transcription of the genes encoding the enzymes required for cortisol production.  
Obligate roles for ACTH receptor, cAMP, and PKA in stimulating steroidogenic gene 
transcription in response to ACTH have been determined in cell lines of mouse and 
human adrenal cortex cells (reviewed in (16)). 
The battery of ACTH-inducible genes in the human adrenal cell nucleus includes 
the genes for StAR, P450scc (CYP11A1), 3ß hydroxysteroid dehydrogenase (3ßHSD), 
P450c17 (CYP17A1), P450c21 (CYP21A1), 11ß-hydroxylase (CYP11B1) (Figure 1.1).  
Unlike active StAR, with a half life of 3-4 hours (17), P450s are longer lived.  For 
example, P450scc in a bovine adrenal cells has a half life in range of 38-42 hours (18).  
Moreover, transcription of P450s such as CYP17A1 (CYP17) is significantly elevated in 
response to the cAMP-coupled gonadotropin, lutenizing hormone, only after two hours in 
ovine theca cells (19), or following activation of cAMP signaling for two hours in a 
human adrenal cortex cell line (20).  On the other hand, StAR mRNA expression 
increases in the rat adrenal within 30 minutes of ACTH stimulation that is insufficient to 
stimulate significant elevation of steroidogenic P450 mRNAs (21). 
The CYP17 gene and the P450c17 enzyme it encodes are unique among the 
steroidogenic P450s in the adrenal because P450c17 expression is restricted to zones 
which respond positively to ACTH/cAMP and its transcription responds negatively to 
6 
 signals which stimulate aldosterone production (22).  Aldosterone synthesis from 
cholesterol in the zona glomerulosa does not require the presence of P450c17 enzyme.  
Thus, zona glomerulosa lacks melanocortin 2 (ACTH) receptors and rather responds 
acutely and chronically to angiotensin II (reviewed in (23)). 
Where expressed, the propensity of P450c17 to catalyze 17α-hydroxylation (for 
cortisol), or 17/20 bond scission (for DHEA) is also zone specifically regulated by cell-
type specific protein-protein interactions (24) and kinase activity (25).  Therefore, along 
with 3ß-hydroxysteroid dehydrogenase expression and activity (which is absent where 
DHEA is produced in the zona reticularis—Figure 1.1 and (26)), CYP17 expression and 
choice of enzyme activity determines functional zonation of the two inner zones of the 
adult adrenal cortex.  Thus, CYP17 is an ideally suited model for the study of 
transcriptional regulation of an ACTH/cAMP-induced gene required for chronic cortisol 
production.  Inducible CYP17 transcription is also determined in gonadal steroidogenic 
cells downstream of cAMP produced in response to other Gαs-coupled receptors which 
are activated by gonadotropins (27), making these studies relevant for CYP17 expression 
in gonads as well. 
 
1.1.4 Steroidogenic Factor-1 Directs Chronic Steroidogenesis in Adrenal Glands 
and Gonads, Enables Their Development, and Functions in the 
Hypothalamus and Pituitary 
 
A major determinant of the transcription of steroidogenic genes including CYP17 
in adrenal cortex ((13), review) and gonads is steroidogenic factor-1 (SF-1; 
NR5A1;Ad4BP).  SF-1 is a primarily nuclear transcription factor which has the ability to 
bind to specific DNA response elements in cooperation with other transcription factors on 
most steroidogenic genes (13).  Although SF-1 expression itself is highly tissue specific 
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 and may be highest in adrenal and gonad cells, tissue specific knockouts have uncovered 
essential roles elsewhere for SF-1 (see below references and others reviewed in (28)).  
For example, SF-1 is found at low levels relative to abundant proteins in cells of the 
ventromedial hypothalamus and pituitary gonadotropes, but nowhere else in the central 
nervous system (29).  In the hypothalamus, SF-1 appears to have a role in controlling 
anxiety, because a central nervous system knockout mouse displays increased anxiety-
like behavior (30).  Pituitary gonadotropes express the identical alpha subunit of 
gonadotropin, lutenizing hormone, follicle stimulating hormone, and thyroid stimulating 
hormone in response to cAMP following transcription mediated by SF-1 (31). 
In development, SF-1 has essential roles in formation of the testes in males, and 
subsequent development of androgen-dependent structures, as well as formation of the 
adrenal gland; in SF-1 global knockout mice, neither the adrenal gland nor testes form 
and both male and female mice die in utero (32).  Thus, SF-1 has important 
developmental and signaling roles in both the HPA and hypothalamic-pituitary-gonad 
signaling axes, as well as a requisite role in the synthesis of steroids.  
 
1.2 Common Characteristics and Differences among Nuclear Receptors:   
NR Classes and Modules 
 
 Like GR, SF-1 is a nuclear receptor (NR), a member of a superfamily of proteins 
that each has as its primary function the regulation of transcription of specific target 
genes (33, 34).  Two major subdivisions of the nuclear receptor superfamily include 1) 
NRs like GR, which homodimerize, translocate from cytoplasm to nucleus, and bind to 
short inverted or direct repeat DNA sequences (hormone response elements) on target 
promoters and 2) those that heterodimerize with the NR retinoid X receptor (RXR) and 
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 are predominantly nuclear, binding to direct repeats (33, 34).  Nuclear translocation, 
dimerization and stabilization of DNA binding may be positively affected by agonist 
ligands which bind to a C-terminal ligand binding domain (LBD) of individual NR 
peptide molecules (35, 36).  A small fraction of some nuclear receptor populations may 
also be anchored to the plasma membrane via palmitoylation of a conserved cysteine in 
the LBD (37), where they can rapidly activate kinase cascades in response to ligand (38).  
This action is termed nongenomic, in contrast to mediation of transcription, a genomic 
effect of NRs. 
  There are, however, two major exceptions to the above general rules for genomic 
NR action.  First, some NRs have sealed or absent ligand binding domains and thus have 
no ligand binding capability, while some NRs that may have the capacity to bind ligand 
have no identified endogenous ligand.  These receptors are referred to as orphan NRs.  
Second, a small number of NRs do not dimerize, and bind DNA as monomers, and this is 
the case for the subfamily of NRs into which SF-1 is classified. 
 NRs bind DNA through a well-conserved zinc-finger containing DNA binding 
domain N-terminal relative to the LBD.  The DNA binding domain and LBD are 
connected by a hinge.  Finally, activation functions are located at amino- (N) and 
carboxy- (C) termini of most nuclear receptors, although the SF-1-containing subfamily 
does not have an N-terminal activation function, which is suited to its monomeric nature, 
since this activation function may play a role in receptor dimerization via interaction with 
the C-terminal LBD (36).  In general, these activation functions are amino acid stretches 
of medium length in the case of ones at the N-terminus or short at the C-terminus which 
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 enable ligand dependent (39-41) and ligand-independent (42) modulation of transcription 
by the NR. 
 
1.2.1 SF-1 Functional Architecture from Amino to Carboxy Terminus 
 
SF-1 shares the common modular domain architecture with other members of the 
nuclear receptor superfamily described above, with some variations.  The isolated 
modules of SF-1, from N terminus to C terminus, are described as follows and are 
pictured as primary and tertiary structures in Figure 1.2.  The N terminus begins with a 
well conserved 75 residue double zinc-finger DNA binding domain, followed by a 35 
residue helical extension, Ftz-F1, found in a small subset of NRs and named for its 
sequence conservation from the Drosophila fushi tarazu nuclear receptor (29).  The zinc-
finger domain has a central role in recognizing the canonical NR-recognized DNA 
sequence AGGTCA, while the Ftz-F1 box improves the affinity and stability of the  
Figure 1.2  Functional domains and solved structures for SF-1.   
 
Domains are described in the text.  Structures were imaged using Accelrys DS Visualizer v2.0 and 
are from protein data bank files 2FF0 (43) and 1YP0 (44). 
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 receptor/DNA complex by extending and refining the DNA sequences that SF-1 
recognizes via minor groove binding and intramolecular interaction with the core DNA 
binding domain ((43) and see Figure 1.6).  Although the Ftz-F1 box of a SF-1 homolog, 
liver receptor homolog 1, does not contact DNA (45), this C-terminal extension of the 
SF-1 DNA binding domain may stabilize its binding to DNA as a monomer rather than a 
NR dimer (43), the common mode of binding for most classes of NR.  The Ftz-F1 box is 
subject to lysine acetylation, which may affect DNA binding capability (46).  In addition, 
there are two DNA-interacting arginine residues in this region at positions 69 and 114 
that are found in motifs that are readily arginine methylated (47). 
Next, a hinge region of about 100 residues connects the N and C terminal 
domains of SF-1.  A small stretch within this region sometimes referred to as the synergy 
control motif is subject to phosphorylation at position S203 (48-50), lysine ε-amino 
SUMOyrlation at K194 (51-53), and modification-sensitive binding to other factors 
and/or intramolecular interactions which enable cooperative transcription regulation (54, 
55).  Finally, a large 240 residue globular ligand binding domain (LBD) is composed 
primarily of helices which form a three-layered sandwich typical of NRs, although SF-1 
contains a 1040-1640 Å3 ligand binding pocket that is relatively large compared to the 
analogous pocket found in most other nuclear receptors, and even the closest relative of 
SF-1 (cf. (44, 56)). 
The twelfth and final helix of the LBD at the C-terminus of SF-1 is a well-
conserved activation function (AF-2) switch, found in all NRs that have the ability to 
enhance transcription (39-41).  The position of this switch and the ability of SF-1 to bind 
transcriptional activation- or repression-associated proteins (coactivators and 
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 corepressors, respectively—generally termed coregulators) is respectively determined by 
occupancy of agonistic or antagonistic ligands in those NRs that have a pocket that is 
ligand accessible (57).  In SF-1, AF-2 is essential for the ability of this factor to induce 
transcription, because deletion of this amphipathic helix or mutations of hydrophobic 
residues reduce transcription by as much as 75 percent (58).  AF-2 point mutation 
likewise decreased CYP17 reporter transcription 79 percent (59).  The AF-2 helix has 
ligand-dependent effects on transcription independent of, i.e. downstream of, DNA 
binding, which is not directly affected by AF-2 mutation or deletion (58, 59).  However, 
it is noteworthy that ligand binding to other NRs has been recently shown to induce post-
translational modification and structural changes in the LBD and hinge regions which can 
affect the ability of NRs to interact with other active transcription regulators (60) and/or 
to target specific novel gene promoters for transcription (61).  In such cases, it is probable 
that an NR is functioning as a coactivator for another unrelated inducible transcription 
factor which is being targeted to its own specific repertoire of promoters (62), and the 
inverse may also be true (63).  Whether an NR directly or indirectly binds to DNA, AF-2 
and its ligand dependent orientation, described in the next subsection, are key in enabling 
transcription.  The roles of post-translational modifications in NR-mediated transcription 
are discussed further in section 1.4. 
 
1.2.2 NR Ligands Induce Protein-Protein Interactions 
by Favoring Specific Modes of Coregulator Binding   
 
Crystal structures show that the SF-1 LBD is accessible to phospholipids that may 
be endogenous ligands, but are also common components of plasma membranes.  These 
include phosphatidylinositol phosphate (64), phosphatidylethanolamine (44, 65), and 
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 possibly phosphatidic acid and phosphatidylcholine with aliphatic fatty acyl chains of 12-
18 carbon length.  In these crystal structures, binding of phospholipids causes AF-2 to be 
closely packed near the LBD, defining one boundary of a nearby hydrophobic cleft.  In 
this configuration, the cleft is just long enough to specifically bind a complimentary 
LxxLL or related helical motif (NR box, (66)) specific to coactivators (44, 64, 65) and 
some competitive corepressors (67).  This agonist bound state of the NR will be referred 
to as its “coactivator binding mode.” 
In general, when a NR LBD is unliganded or occupied by antagonist, AF-2 is 
displaced from the top of the hydrophobic cleft, which is extended and more favorably 
binds another complimentary motif, the CoRNR box (a helical motif related to the 
consensus sequence Lxx(H/I)Ixxx(I/L), (68, 69)).  CoRNR boxes are typically found on 
nuclear receptor corepressors associated with dedicated transcription repression 
activity—they do not contain NR boxes or coactivator enzymatic functions (E. Dammer, 
unpublished observations).  This state of the nuclear receptor and its AF-2 will be called 
the “corepressor binding mode.”  Both modes of LBD binding, shown for NRs with 
otherwise substantially different LBDs, are pictured in Figure 1.3. 
NR coregulators are discussed in more detail in following sections of this 
introduction.  At this point, it is sufficient to note that many of these coregulators are also 
important for regulated transcription.  In addition to their NR-specific interaction modes, 
some, if not most, bind structurally diverse transcription factors not related to NRs (70-
72).  The ultimate function of coregulators may best be described as a multiprotein 
assembly gatekeeper that allows or disallows the chromatin-restricted formation of  
general transcription factor complexes (lacking gene specificity) which ultimately  
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 Figure 1.3  Corepressor and coactivator binding modes of LBDs.  A. The LBD of a NR bound to 
antagonist (grey) with AF-2 (yellow) extending away from the hydrophobic groove has bound a CoRNR-
box peptide (red, with LxxIIxxxL side chains).  B. LBD of SF-1 bound to phospholipid agonist (grey) 
keeps the AF-2 helix (yellow) closely packed to the ligand and the LBD surface.  However, a shorter NR 
box (green, with LxxLL side chains) is ideally suited for binding the part of the hydrophobic grove which 
remains exposed.  X-ray crystal sructures are for peroxisome proliferator activated receptor-α (A) and SF-1 
(B) from protein data bank records 1KKQ 1YP0, and were visualized using Accelrys DS Visualizer v2.0. 
b a 
 
recruit and license RNA polymerase II to initiate transcription of any gene.  The 
interaction of NR with some NR box-containing coactivators is necessary and sufficient 
to stimulate transcription in response to nuclear receptor ligand.  This was elegantly 
demonstrated in one study, in which swapping of a CoRNR box for a NR box in such a 
NR coactivator conferred the ability of an NR antagonist (tamoxifen, an estrogen receptor 
antagonist) to stimulate transcription and cellular proliferation in breast cancer cells (73).  
Transcription was presumably initiated by endogenous, unaltered estrogen receptor (ER, 
an NR).  Chromatin-associated changes following assumption of the coactivator binding 
mode and binding of such coactivators are also required for transcription initiation from 
NR-regulated gene promoters and are considered in below sections 1.3. 
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1.2.3 SF-1 Ligands Enable Corepressor and Coactivator Binding Modes 
 
Endogenous SF-1 ligands have only recently been identified by in vivo studies.  In 
a study by Urs et al, a catabolic product of complex sphingolipid breakdown (and an 
intermediate in the formation of complex sphingolipids), sphingosine, was identified as 
an SF-1 ligand.  Sphingosine bound purified SF-1 with an apparent Kd of 0.325 µM in 
labeled ligand displacement studies (74).  This study also confirmed by tandem mass 
spectrometry that sphingosine copurified with receptor and that its binding decreased in 
response to treatment of human adrenocortical H295R cells with membrane permeable 
cAMP analog, dibutryl cyclic AMP (Bt2cAMP).  Wild type (WT) SF-1 and LBD mutants 
found to alter sphingosine binding of the NR were characterized in an assay of CYP17 
reporter activity.  In this assay, sphingosine treatment of steroidogenic placenta cells 
expressing only exogenous SF-1 demonstrated that sphingosine specifically reduced the 
ability of SF-1 to initiate CYP17 transcription, but only if the LBD was capable of 
binding sphingosine at levels similar to WT receptor (74).  Finally, this study showed that 
sphingosine treatment potentiated the repression of CYP17 reporter by a NR corepressor 
and abrogated activation by a NR coactivator (74).  In total, this study strongly suggests 
that sphingosine is an antagonist of SF-1 transcription factor function on the CYP17 gene 
promoter. 
A recent study failed to verify the role of sphingosine as a bona fide SF-1 
antagonist (75).  Either sphingosine solvation in DMSO (75) rather than ethanol (74) 
prior to treatment of cells, or its intracellular conversion to sphingosine-1-phosphate 
during treatment may explain this discrepancy.  Sphingosine-1-phosphate is an 
autocrine/paracrine activator of CYP17 transcription in H295R cells (76) and possibly of 
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 other SF-1 regulated genes that have roles in sterol metabolism.  Thus, there is mounting 
evidence to indicate that sphingolipid metabolism is interconnected with the cell- and 
gene-specific regulation of SF-1 targets and steroidogenic potential. 
Recently, phospholipid agonists of SF-1 which stimulate the coactivator binding 
mode (Figure 1.3B) were identified in vivo.  Using H295R cells, 26 carbon phosphatidic 
acid specifically copurified with SF-1 from H295R cells (77).  Moreover, phosphatidic 
acid was rapidly produced by nuclear diacylglycerol (DAG) kinase(s) in these cells in 
response to Bt2cAMP.  Knockdown of SF-1-interacting DAG kinase theta reduced 
Bt2cAMP-dependent CYP17 transcription, and in opposition, its overexpression 
stimulated CYP17 transcription initiated by SF-1, but not when NR box motifs in the 
kinase were disrupted by mutation (77).  This study allows one to conclude the following 
with some confidence.  1) One or more forms of DAG kinase is capable of interacting 
with SF-1.  2) This mode of interaction precedes loading of agonist, phosphatidic acid, 
which allows SF-1 to adopt a more stable coactivator interaction mode. 3) Agonist is 
synthesized in response to ACTH/cAMP signaling.  The fact that a NR box is used for 
SF-1 interaction coincides with a feed forward mechanism where colocalization of SF-1 
and its DAG kinase partner increases following agonist production (77). 
SF-1 ligand binding function is positioned in the nucleus of adrenal cortex cells to 
enable transcriptional responses to signaling downstream of ACTH/cAMP.  Mounting 
evidence suggests that the nuclear environment of this tissue integrates lipid metabolism 
and dynamics that occur under basal conditions to antagonize SF-1 (sphingosine 
production as an intermediate in anabolism and catabolism of sphingolipids).  
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 Alternately, lipid metabolism which leads to activation of SF-1 targets is rapidly induced 
by cAMP (sphingosine kinase and DAG kinase activation). 
 
1.3 Induced Transcription Overcomes Multiple Barriers 
through an Ordered Sequence of Events 
 
Most of the SF-1 structure can be assembled from crystallographic (44, 64, 65) 
and NMR (43) data in which DNA recognition and binding and, separately, ligand 
binding, are independently understood.  This raises the question of how DNA binding 
and ligand binding functions interrelate during transcriptional activation, particularly in 
the context of signaling and transcription of genes which are enmeshed in chromatin.   
While SF-1 is nuclear in H295R cells, its subnuclear localization in adrenal cortex 
does vary in the presence and absence of steroidogenic stimuli (78).  In particular, cAMP 
appears to increase dynamic colocalization of SF-1 with the dedicated NR coactivator 
steroid receptor coactivator-1 (SRC-1) (78), and recently, the Sewer lab identified cAMP-
stimulated colocalization of SF-1 and DAG kinase theta (77).  This raises many 
questions.  For example, which coregulators does SF-1 require for transcription?  What 
SF-1 complexes are cAMP/PKA responsive and dependent?  Which of these complexes 
occur on the CYP17 promoter chromatin prior to transcription of this gene, and what is 
the order of events occurring there?  Finally, which of the possible post-translational 
modifications to SF-1 (described in Seciton 1.4) coincide with and enforce this order of 
events?  An ordered sequence of coregulator exchange is consistent with post-
translational modification and remodeling of chromatin, transcription factor, and/or 
chromatin-associated proteins, and this topic and its implications are given special 
attention here and in the three respective results sections of this dissertation. 
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 Considerable progress has been made in the last decade to extend our 
understanding of the mechanisms by which transcription factors including nuclear 
receptors enable a characteristic accelerated rate of transcription induced by diverse 
signals.  In this section, both general functions specific to inducible transcription, and 
specifics of cAMP-induced transcription requiring SF-1/target gene interaction are 
reviewed.  The overlap, differences, and questions raised about SF-1 specific mechanisms 
that arise from comparison between these two sets of results are the context for SF-1-
specific studies described in the following chapters of this dissertation.  In particular, the 
role of chromatin (the packaging of eukaryotic DNA) in gene-specific mechanisms of 
transcription is considered in as much detail as possible.  Chromatin structure and the 
central role of nucleosomes are reviewed in Figure 1.4. 
Transcription factors for inducible genes require specific promoter targeting 
function.  For promoter targeting to occur, barriers are overcome as a result of 
mechanisms conferred by the inducing signal.  Compartmentalization of the transcription 
factor away from its target promoters is overcome by signal-induced disassembly of 
sequestered, inactive complexes and/or assembly of active complexes which have access 
to DNA targets.  For example, GR agonists cause the receptor to dissociate from 
chaperone in the cytoplasm (35), enabling GR homodimerization, nuclear entry, and 
transcriptional activation.  Then, the transcription factor must bind its target promoter 
with high specificity at recognized binding site(s), and somehow increase the 
accessibility of this site.  Both GR and ER overcome precise positioning and arrangement 
of histones within nucleosomes which obstruct the most stable NR-DNA interaction at 
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 Figure 1.4  Chromatin organization and the role of nucleosomes.  A.  DNA double helix (2 nm diameter 
fiber) is wrapped around a cylinder-shaped histone octamer comprised of 2 H2A/H2B dimers and an 
H3/H4 tetramer.  The 147 base pairs (bp) of DNA plus the histone octamer make up a nucleosome.  
Amino-terminal tails of histones H3 and H4 are visible extending beyond the compact nucleosome 
cylinder.  The X-ray crystallographic structure is from protein data bank 1AOI and (79).  B. “Beads on a 
string” have been visualized by electron microscopy and are made up of nucleosomes connected by short 
stretches (~10 bp) of “naked” DNA.  Chromatin in this configuration is called euchromatin.  C. A 30 nm 
solenoid fiber is made up of a two-start helix of nucleosomes linked by the histone linker protein H1 (80); 
alternate geometries may also form and interchange with this configuration (81).  D. Higher order loops of 
solenoid are thought to form, particularly in regions of the genome which are not transcriptionally active, 
aided by additional scaffolding protein(s).  E. The metaphase chromosome is the most highly packed form 
of chromatin, entirely heterochromatin. 
 
gene-specific promoter binding sites (nicely reviewed in (82)).  Recently, positioning of 
nucleosomes was determined to have a strong sequence-dependent thermodynamic 
component (83), although there is also subtle alteration in nucleosome positioning due to 
the tissue context and possibly the frequency of past transcription initiation from a gene 
promoter (84). 
As mentioned, although SF-1 is predominantly localized in the nucleus, its 
subnuclear localization is sensitive to cAMP, which increases interaction with a dedicated 
coactivator (78).  Sewer et al found that in vitro translated SF-1 binds to the human 
CYP17 promoter in the presence or absence of cAMP at the -57/-38 segment (20) which 
includes the element TCAAGGTGA.  This element is similar to the consensus high-
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 affinity SF-1 binding site confirmed by Morohashi et al, (C/T)CAAGG(T/C)CA, 
occuring with some variation on the promoters of all steroidogenic P450 genes with the 
capability of binding SF-1 in vitro (85).  However, Sewer et al found that additional 
nuclear RNA binding proteins, 54 kDa nuclear RNA binding protein (p54nrb) and 
polypyrimidine tract binding protein assocated splicing factor (PSF), formed a higher 
weight complex with SF-1 and perhaps other proteins on the CYP17 DNA element only 
within 120 minutes of Bt2cAMP treatment and only if protein translation was not 
inhibited (20).  It can be concluded that cAMP is a sufficient signal to redeploy SF-1 in 
unique protein complexes with roles in targeting transcription function to CYP17 via a 
SF-1 recognized element. 
 
1.3.1 The Central Role of Chromatin in Cyclic Transcription of Inducible Genes:  
An overview of progressive interactions of promoter chromatin, transcription 
factor(s), and coregulators 
 
 The role of chromatin in transcription has been considered in a number of other 
studies.  In a seminal study, Shang et al identified cyclic patterns of mRNA accumulation 
of three ER-responsive genes in nuclei of ER-containing cells treated for specific times 
with estradiol, the endogenous ER agonist (73).  This nuclear run-on data was considered 
as evidence for cycles of transcription activity, and indeed the timing following estradiol 
treatment at which mRNA accumulated coincided with times when ER was most stably 
associated with the promoter of each gene.  The latter data was obtained using chromatin 
immunoprecipitation (ChIP).  Shang et al concluded that “the regular cycling of the ERα 
transcription complex may represent a mechanism that favors continuous sampling of the 
external milieu.”  That is, transcription cycles ensure that inducible transcription remains 
responsive to the current environment, particularly the loss and gain of inducing signals. 
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 Since that study, cyclic transcription has been observed for multiple inducible 
genes with central roles for cycling of ER (86, 87), androgen receptor (88), thyroid 
hormone receptor (89), vitamin D receptor (90), or other inducible transcription factors 
outside of the NR superfamily, including p53 (91) and NFkB (92).  Invariably in this 
phenomenon, the binding to a promoter by coactivators with different classes of 
chromatin-modifying capability (described in the following section), is followed by the 
binding of general transcription factors required for transcription of any gene (such as 
TATA binding protein and the mediator complex) and RNA polymerase II.  The 
coactivators and general transcription factors do this specifically as and after an inducible 
sequence-specific transcription factor associates with maximum stability at a site that 
includes a sequence recognized by the inducible transcription factor, often also at the 
proximal promoter of the gene being studied. 
Finally, the protein degradation function of the proteasome (86, 88) was found to 
be important in enabling repeatability of this process during subsequent cycles.  When the 
proteasome was disabled (e.g. with MG-132 (73)), when the reversal of post-translational 
chromatin modification was inhibited (e.g. with trichostatin A (86)), or when phospho-
RNA polymerase-mediated elongation was prevented by a kinase inhibitor (5,6-dichloro-
1-ß-D-ribofuranosylbenzimidazole (DRB) (73)), cycles of induced stable transcription 
factor binding and loss stalled, either with high or low binding profiles, depending on the 
specific treatment.  For example, enforcement of static, rather than dynamic, 
hyperacetylation of histones (discussed in the following section) by trichostatin A led to 
the loss of stable binding of polymerase and transcription factor to the promoter after 14 
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 hours, but stalling of these factors on the chromatin could be induced in the presence of 
both trichostatin A and proteasome inhibitor MG-132 (73). 
In total, these ChIP studies and other ground breaking studies (including UV laser 
crosslinking and fluorescence resonance energy transfer experiments reviewed in (82)) 
greatly enhanced our knowledge of the mechanistic basis by which transcription rate is 
determined for inducible genes.  Gene promoters that were inducible in one context 
(“inactive but poised” or “regulated with late accessibility”) may be “constitutive and 
immediately accessible” or “active” in another context, while in other situations, such as 
in cell lines or tissues in which a required inducible transcription factor is absent, the 
gene may be fully repressed (82, 92).  A distinction for inactive but poised genes was also 
made clearly in a study that showed that ER isoforms maintain promoter surveillance for 
an inducing signal on a gene “poised” for transcription even in the absence of agonist by 
cycling on and off of a target promoter, bringing along coactivators and corepressors, 
albeit transiently (93).  This activity keeps chromatin assembly, structure, and 
modifications dynamic, even to the point that general transcription factors can increase 
their association with the transcription start site, albeit nonproductively, i.e., not resulting 
in mRNA transcription (93). 
Métivier and colleagues concluded from a compendium of kinetic ChIP studies of 
inducible gene promoter interaction with transcription factors that there are three phases 
of cyclic transcription on such a promoter (94).  First, there is achievement of 
transcription competence.  Then, productive rounds of transcription occur.  Progress 
during this stage is marked by an increase in histone tail acetylation and other successive 
dynamic covalent modifications to chromatin, which modify nucleosome structure, and 
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 decrease DNA-histone affinity.  Finally, a clearance phase occurs, perhaps to avoid 
stalled or non-specific transcription such as that seen during long term enforced 
acetylation of nucleosome tails; this reverses permissive chromatin modifications, general 
transcription factor accessibility, and possibly results in compaction of chromatin 
structure to the least accessible poised form (e.g. a solenoid configuration, as shown in 
Figure 1.4).  While the first and last phases of the transcription cycle are likely to 
determine the overall rate of transcription, these steps are less understood at a 
mechanistic level than transcription itself.  Even the most complete studies find multiple 
alternate inducible complexes of inducible transcription factor and coactivators (87).  
However, the functions of those coactivators with respect to chromatin post-translational 
modification and structural disruption or ordering are conserved, and are considered in 
detail in subsections 1.3.3-1.3.4. 
 
1.3.2 Transient Behavior of NR-Coregulator Complexes 
 
 NR interactions with coactivators are generally activated by agonist ligand, but 
these occur in an environment of competition among coregulators with similar binding 
criteria, which may be as simple as display by a coactivator of a small amphipathic helix, 
the NR box described in section 1.2.2.  This helix could even form from an otherwise 
unstructured primary sequence as a result of induced fit (94) following NR achievement 
of the coactivator binding mode (95).  Each transcription cycle can last 40 or more 
minutes (87).  However, even RNA polymerase II, which must remain bound to DNA as 
it reads the length of that gene at 15 to 85 percent of the rate at which naked DNA is 
transcribed (96)–which is likely to be between 300 to 1200 or more base pairs per minute 
(97-99)—this transcription requires just a fraction of the time during which the gene’s 
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 chromatin is competent for transcription.  So, multiple rounds of transcription are very 
likely occurring during a single phase of transcription competence in what this 
dissertation considers a transcription cycle.  
Likewise, studies using methods which do not rely on crosslinking of DNA to 
protein (reviewed along with seminal kinetic ChIP studies in (82)) suggest that no one 
NR molecule maintains its hold on a recognized DNA element for more than a small 
fraction of the transcription cycle, perhaps only seconds (100).  So many coactivator-
chromatin interactions can occur with a signature rate of stochastic progress in modifying 
chromatin post-translationally and structurally reordering nucleosomes (100).  It follows 
that, although ligands can increase the DNA binding stability of a NR or the likelihood 
that a NR will recruit coactivators which remodel chromatin for a sufficient period of 
time, the act of modifying chromatin, particularly structural reordering of nucleosomes, 
may necessitate loss from chromatin of the very NR-coactivator complex which started 
that process (100), but this process enables another unique complex to possibly bind with 
greater affinity and act at the same promoter site. 
The above logic and integration of data from study of transcription in vitro, along 
with chromatin kinetics in living cells on a much shorter time scale than ChIP 
experiments permit (2-5 minutes or greater), provide important information about the 
physical nature of the process by which competence for transcription is reached at an 
induced gene promoter.  High-affinity, low specificity interactions with agonist-liganded 
NRs are likely to occur between NR and coactivators near NR binding sites on 
chromatinized DNA.  In this way, NR agonist increases the local concentration of 
multiple coactivator-NR complexes which modify that chromatin stochastically before 
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 competence for assembly of a stable general transcription factor complex occurs, i.e. the 
classical preinitiation complex.  Thus, in the first stage of a transcription cycle (achieving 
competence for transcription), chromatin achieves competence for RNA polymerase II 
activity through the actions of multiple coactivator-NR complexes. 
Now we have the background necessary to fully evaluate the most complete 
studies of transcription cycling by ChIP.  One such study identified at least six unique 
complexes of ER with coactivators on a model ER-responsive gene promoter (87).  This 
was accomplished by performing serial ChIP of protein pairs at times suggested in single-
factor IP kinetic ChIP experiments.  While the authors concluded that these complexes 
are alternately required in order to achieve transcription competence in a transcription 
cycle, given the above logic that these complexes rapidly exchange, it is just as likely that 
each complex has a requisite role in each transcription cycle.  
 
1.3.3 Coregulators Manipulate the Histone Code 
and Nucleosome-DNA Interaction 
 
 What are the functions of NR-coactivator complexes, almost entirely encoded in 
the structure and sequence of the coactivators?  In the review of their own work, the 
Gannon laboratory identified four functions for coregulators, each of which involves 
overcoming chromatin-imposed regulatory constraints on transcription. 
 First, coactivators have the ability to write, “read,” and erase the histone code, and 
to interact with and bridge a NR and multiple chromatin modifying enzymes into a 
functional complex that marks chromatin with a specific set of post translational 
modifications (PTMs).  Histone tails which protrude from nucleosomes and their 
wrapped DNA (Figure 1.4A), and even the core of the nucleosome, are readily modified 
25 
 post-translationally with molecular marks including lysine acetylation, lysine and 
arginine methylation, serine/threonine phosphorylation, and lysine ubiquitination.  These 
PTMs, and in particular, compatible combinations of modifications (101, 102), change 
affinity of the local chromatin for chromatin-associating factors, including coregulators 
of transcription.  Therefore, following combinatorial modification of chromatin initiated 
by early NR-coactivator complexes, chromatin-modifying coactivators which act later do 
not necessarily need to interact with an induced transcription factor directly, but can 
interact with histone tail(s) modified earlier.  The particular pattern of modification of a 
nucleosome or a set of nucleosomes in a region of DNA defines whether that DNA is 
silenced or actively transcribed (if the region encodes a gene (103)), or if that region of 
DNA is prepared to undergo mitotic DNA replication, or in need of damage repair.  
Important PTM sites and covalent modifications of histones related to signaling one of 
these particular states are given in Table 1.  In addition, a second class of modifications is 
listed there.  These modifications are naturally occurring or engineered nucleosome 
structural modifications, some that helped to identify solenoid chromatin geometry, and a 
role for nucleosome repositioning in transcription. 
The second class of histone modifications in table 1.1 primarily relates PTMs to 
changes in nucleosome structure or histone/DNA binding energy and stability.  Indeed, 
the second identified role of a subset of coactivators is to alter nucleosome structural 
integrity, positioning on DNA, and histone/DNA interactions.  This chromatin 
reorganization is ATP dependent and may involve disruption or restitution of 
intermolecular histone interactions, based on in vitro studies (104, 105).  A founding 
class of proteins with such a function was first identified in yeast.  These proteins form  
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 Table 1.1  A list of histone modifications.  See this review (106) by Cosgrove and Wolberger for 
more information on most of the above modifications.  *Formation of solenoid chromatin with 
internucleosome contacts was tested by engineered cystine disulfide crosslinking of histones H4 
and H2A mutated to cysteine at these positions (80). Ac, acetyl; P, phospho; Me, methyl; Ub, 
ubiquitinated. 
 
 
Structural Modifications 
H4K91-Ac Decreased H2B E63 interaction with H4K91 
 
H3K56-Ac near DNA entry/exit site on nucleosome; transcription; H3 exchange 
 
H4R45 DNA minor groove insert, sensitive to H3T118-P 
 
H3T118-P increased DNA mobility 
 
H4 V21, N-terminal tail  required for solenoid formation, interaction with the H2A core   
near globular core of an adjacent nucleosome near H2A E64*  
 
Lateral surface of globular some mutants show SWI/SNF independent transcription 
domain of nucleosome in yeast 
Modification Associated with 
 
H3K9-Me3 HP1 binding, increased heterochromatin properties 
H4K20-Me3 increased heterochromatin properties   
H3K27-Me increased heterochromatin properties; placed by polycomb complex 
 
H3S10-P inhibits or counters H3K9 methylation; stimulates H3K14-Ac 
H2B K123-Ub stimulates H3K79-Me; removed or lost during transcription 
H2A K119-Ub prevents efficient RNA polymerase elongation on some genes;  
 gene silencing; prevents H2A/H2B dimer removal by chaperone(s) 
 
H2A.X S139-P DNA double strand breaks, DNA replication 
H3K4-Me2 or 3 transcription; placed by Set1, stimulated by H2BK123-Ub; turnover of  
  H3K9-Ac, H3K27; recruitment of nucleosome remodelers, coactivators 
 
H3K36-Me3 co-transcriptional histone deacetylation; placed by Setd2 
 
H3K79-Me DNA double strand breaks and checkpoint halt; placed by Dot1L; 
 transcription; stimulated by H2B K123-Ub 
 
H4K20-Me DNA double strand breaks and checkpoint halt 
 
H3K9,14,18, 23, 27 -Ac hyperacetylation of N-terminal tail lysines; decreased DNA binding; 
H4K5, 8, 12, 16, 20 -Ac transcription & conditions favoring nucleosome sliding, H1 dissociation 
 
H4R3-Me2 DNA CpG island methylation boundaries; H4K20-Me2 
 
H3R2-Me2 counters H3K4Me2 or 3 
 
H3R17-Me ER-mediated transcription activation 
Signaling Related Histone Modifications 
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 large complexes and when components of these complexes were functionally inactivated 
by mutations, the corresponding yeast strains were incapable of activating transcription of 
genes required for sucrose fermentation or mating type switching—thus, this set of 
proteins became known as mating type switch/sucrose non-fermenting proteins 
(SWI/SNF) (reviewed with a focus on broader transcription regulation in (107)). 
 SWI/SNF complexes invariably include a member with ATPase catalytic function 
(Brahma or Brahma related gene 1 (BRG1)), and a ubiquitously expressed large 
structural scaffold (BRG1 associated factor (BAF250)/p270/ARID1), as well as other 
structural components which may be required for function.  At least in higher eukaryotes, 
the largest protein in SWI/SNF complexes, BAF250, is rich in NR boxes, which may 
explain a strong positive effect of overexpression of this protein on NR-dependent 
transcription (108, 109).  Other subunits have also been shown to mediate SWI/SNF 
complex interaction with NRs (107).  However, SWI/SNF ATPase overexpression or 
manipulation can positively or negatively regulate transcription of various genes (cf. 
above references, with SWI/SNF roles in NR-mediated repression found in (110, 111)).  
Therefore, ATP-dependent chromatin remodeling has likely roles in both activation and 
loss of transcription competence.   
Perhaps the perfect verification of this was recently published regarding the 
specificity of unique SWI/SNF complexes in GR-mediated effects on gene transcription 
(112).  Recall from section 1 that GR both activates and represses transcription of 
different sets of genes.  The particular direction an ATPase complex acts, i.e. toward or 
away from achievement of transcription competence, is specified in a gene-specific 
manner by the membership of that complex, because while 40 percent of glucocorticoid-
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 activated genes required BRG1 function, only 11 percent of glucocorticoid-repressed 
genes were rescued by dominant negative BRG1 (112).  Therefore, chromatin remodeling 
toward transcription competence is downstream of a gene-specific induction signal, 
which stimulates specific ATP-dependent chromatin remodeling complex(es) with this 
function.  Later in a transcription cycle, and on genes which are repressed by an agonist-
bound NR, recruitment of a functionally distinct repression-specific ATP-dependent 
remodeling complex that revokes transcription competence by remodeling chromatin to a 
compact state must occur.  Either event is likely to be based on the ability of specific 
members of that complex to read a PTM pattern on histones established, respectively, 
following induction or after the last round of transcription in a transcription cycle.  In 
support of the above, conserved domains capable of binding to either acetylated histones 
or methylated histones are prevalent features of subunits of distinct classes of ATP-
dependent remodeling complexes (e.g. the SWI/SNF complex member BAF180 has 
bromodomains capable of binding acetyl-lysine, while Mi-2, a member of a remodeler 
complex which is typically repressive, as well as BAF155/BAF170/SMARCC2 have a 
chromodomain capable of reading methyl-lysine) (113).  At this point, it is highly 
relevant to note that in addition to SWI/SNF complexes, four other classes of ATP-
dependent chromatin remodeling complexes with ATPase subunits related to SWI/SNF, 
but with various differences or similarities in membership by other factors (and some 
with previous species-specific designation) are cross-referenced in this useful review 
(107). 
The in vitro data indicating that disrupted nucleosomes support accelerated 
transcription (104, 105) in conjunction with the established function of ATP-dependent 
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 nucleosome remodeling complexes suggests that these are gatekeepers for gene promoter 
and downstream gene accessibility.  They are functionally positioned to not only 
determine the rate at which a gene promoter becomes transcriptionally competent, but 
also should be able to determine the rate of transcription elongation by RNA polymerases 
through their activity at genes downstream of promoters, and recent work is starting to 
bear out this hypothesis (114). 
A third class of chromatin-associated modification with a role in cyclic 
transcription that has recently been identified by the Gannon laboratory is the reversible 
strand-specific methylation of isolated CpG dinucleotides, found to occur on the region 
of 400 proximal bases of an ER-responsive model promoter (115).  Apparently, this 
modification can occur on a cycling promoter with the recruitment of DNA 
methyltransferases, and this study is also the first to demonstrate eukaryotic methyl-
cytosine deaminase activity of one such methyltransferase, generating thymine at the 
former site of cytosine methylation.  As a transcription cycle proceeds, not only are these 
enzymes sequentially recruited in coactivator complexes, but base-excision repair 
machinery is also required to reverse mismatched base pairs occurring after methyl-
cytosine deamination (115).  The implications for methyl CpG-marked progress through 
transcription cycles are only beginning to be realized. 
The fourth and final class of coactivator-associated functions that the Gannon lab 
listed (94) is histone H1 dissociation and association.  It is evident that the density of 
nucleosomes distributed on a genomic region may underlie the likelihood of histone H1 
and other linker proteins to associate with that region and promote a solenoid 
conformation of chromatin.  H1 binding to DNA, but not necessarily H1 linkage of 
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 nucleosomes into higher order structure, is also affected by an increased affinity for 
methylated linker DNA between nucleosomes, because mobility of H1 increases in cells 
with defective DNA methylation (116).  Other internucleosome-linking proteins like HP1 
are capable of reading methyl-lysine (113), and are enriched on chromatin with histone 
H3K9 methylated (117).  Thus, there is crosstalk between DNA methylation, the histone 
code—particularly histone lysine methylation—and heterochromatin packing.  Given the 
requirement for nucleosome occupancy of solenoid DNA, then nucleosome occupancy at 
promoters and transcription start sites (perhaps with intrinsically lower density at poised 
inducible genes, and definitely at housekeeping genes (118)), underlies the decreased 
propensity for regulatory elements of these genes to exist in solenoid conformation.  
However, it is conceivable that a solenoid conformation is adopted at some point during 
transcription cycles.  Methods which could verify whether a specific region of genomic 
DNA has adopted a solenoid conformation may remain to be developed.  However, 
globally, chromatin conformations can be differentiated and quantified, and surprisingly, 
there is some evidence that histone H1 can regulate expression positively in a gene-
specific manner (119), perhaps by helping fix the positions of specific nucleosomes 
ideally for transcription factor binding. 
In addition to the above four functional classes of coactivator function, it is easy 
to envision three additional coactivator functions which coordinate transcription.  For 
example, it has been found that certain coactivators, and early inducible viral molecular 
interaction hubs are capable of bridging coactivator complexes associated with inducible 
transcription factors to general transcription factors (120, 121). 
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 Next, roles for topoisomerases in relieving transcription-associated supercoiling 
have been clearly implicated with requisite roles in promoting efficient transcription 
(122, 123).  Therefore, it is conceivable that a class of coregulators function during 
achievement of competence for transcription in enhancing topoisomerase access to 
chromatin, perhaps in conjunction with altered H1 linker occupancy (122). 
Finally, a novel function for a small set of corepressor-complex associated factors 
as coregulator exchange factors has been identified as necessary for disassembly of these 
corepressor complexes preceding functional coactivator/NR complex formation on 
specific promoters (124).  Examples of coactivators from all seven classes with roles in 
achieving competence for transcription in cyclic chromatin-mediated transcription are 
listed in table 1.2. 
 
1.3.4 The “Clearance Phase” of Cyclic Transcription: 
Corepressors enable a return to repressive chromatin structure 
 
What causes the transition to repressive chromatin from active transcription of 
competent chromatin after possibly multiple rounds of transcription, and in the continued 
presence of signal capable of inducing transcription?  As mentioned previously, Shang et 
al found that DRB, an inhibitor of casein kinase II and cyclin dependent kinases (CDKs) 
7 and 9 (the latter target RNA polymerase II), stalled ER on promoters indefinitely, while 
low dose α-amanitin (blocking RNA synthesis by polymerase II directly) did not do this 
(73).  A consistent hypothesis is that polymerase II in some configurations (i.e., the last 
round of transcription during a cycle, which, like all RNA elongation events, is inhibited  
by DRB) couples that event to chromatin remodeling that reduces accessibility.  Such a 
process has been found to occur in yeast (125, 126) and mouse (127), where histone 
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 Table 1.2  Representatives of seven classes of induction-specific coregulators associated with cycles of 
transcription.  Homologs refer to mammalian homologs of yeast proteins.  This list is not exhaustive. 
 
 
   
III. DNA Methylation-Associated 
DNMT3a, b  DNA methyltransferases 3a, b deamination of 5’-Me cytosine  
TDG thymine DNA glycosylase cleaves T:G mismatches; base excision; SRC interaction 
p68 p68 RNA helicase demethylation complex member; coactivator function 
IV. Histone H1-Associated Solenoid Formation 
HMGB 1/2 high mobility group B 1/2 acidic tract; may displace linker histones; Wdhd1/AND-1 is 
AND-1 /  Wdhd1  acidic nucleoplasmic DNA binding prot. an HMG factor in a SRC-1 NR coactivator complex 
H1, H5 linker histones of the histone H1 family binds methylated DNA; may help activate select genes 
 
MBF1 multiprotein bridging factor 1 links SF-1 to general transcription factors  
some TFII complexes general transcription factor recruit RNA polymerase II, bridge to TATA binding protein 
mediator complex general transcription factor sometimes considered as a coactivator  
Med1 / TRAP220 / DRIP205 thyroid receptor associated protein bridge NRs to Mediator, TFIID; has NR boxes like NCoAs 
menin  member of MLL1/MLL2 complex H3K4 methylation complex targeting by liganded ER 
ASC-2/AIB3/HoxA7/ NCoA6 activating signal cointegrator-2 MLL3/MLL4 H3K4 Me-transferase; stimulates DNA-PK 
PGC-1, p54, PSF RNA recognition motif domain proteins bridge preinitiation/transcription to splicing machinery, RNA  
E1A  adenovirus early expressed antigen 1A non-mammalian, viral interaction hub; (anti)oncogenic; 
   inhibits acetylation of non-histone substrates 
V. General Transcription Factor (GTF) or Structural Bridging 
VI. Topoisomerase Access 
   Topoisomerase IIß causes double strand break at site of promoter induction 
DNA-PK (Ku70, Ku86) DNA-dep. protein kinase (associated) DNA break associated DNA binding and kinase activities 
PARP-1 poly(ADP-ribose) polymerase 1 DNA-damage associated ADP-ribose polymerization on  
protein substrates, including histones; may deplete NAD+       
VII. Coregulator Exchange 
TBL1 transducin-ß-like 1 Rqd. for signal / ligand-dependent coregulator exchange 
TBLR1 TBL-related 1 …on NR & NR corepressor (NCoR)-regulated promoters
SWI2 / SNF2 homologs brahma, brahma related gene 1 ATPases associated with SWI/SNF, RSC complexes 
SNF2H, SNF2L1 imitation SWI complex ATPases ISWI also repositions/reorders nucleosomes; txn/repression 
BAF250 / p270 / ARID1 large structural subunit of SWI/SNF a subunit of above complexes that binds DNA and NRs 
BAF180 structural subunit of SWI/SNF Ac-lysine binding subunit of above complexes 
Acronym(s) Full Name Associated with 
 
SRC-1 / NCoA1 nuclear receptor coactivator-1 (lysine) acetylation; glucorticoid response; NR boxes 
SRC-2 / GRIP-1 / NCoA2 nuclear receptor coactivator-2 acetylation-associated; female reproduction; NR boxes 
SRC-3 /ACTR/AIB1/NCoA3 nuclear receptor coactivator-3 acetylation; amplified in some breast cancers; NR boxes 
GCN5, human homologs general control nonderepressed 5 acetylation; Ac-lysine binding; neural tube closure 
P/CAF p300/CBP associated factor acetylation; Ac-lysine binding; memory and stress 
CBP CREB binding protein acetylation; Ac-lysine binding; memory 
p300 E1A binding protein p300 acetylation; Ac-lysine binding; hypoxia induced txn. 
TIP60 / HTATIP / ESA1 HIV Tat-interacting protein, 60 kDa acetylation; Me-lysine and/or RNA/DNA binding 
PRMT1, etc. protein arginine methyltransferase 1 arginine methylation at H4R3; 1 of 7 PRMTs; repression 
CARM1 / PRMT4 coactivator arginine methyltransferase 1 arginine methylation at H3R17; ER-mediated transcription 
LSD1 lysine specific demethylase 1 mono- and di-Me lysine demethylation; activation complex 
Set1, human homologs e.g. set-domain containing protein 1A Histone H3K4 mono-, di-, and tri-methylation, activation 
Dot1, human homolog Dot1-like Histone H3K79 methylation; G1 (cell cycle); transcription 
Jmj-c domain family Jumonji-c domain containing proteins Demethylation of H3K9, H3K27; may assoc. with LSD1 
 II. ATP-Dependent Chromatin Remodeling 
I. Histone PTM Enzymes 
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H3K36 methylation occurs cotranscriptionally.  In yeast, this modification enables 
recruitment of a histone deacetylase (HDAC)-containing complex and thereby, a return to 
more compact chromatin, as evidenced by the function this has in preventing 
inappropriate transcription initiation downstream from gene promoters (within genes) 
(126).  The SWI/SNF-related ATPase Mi-2 has been found on promoter chromatin 
during the clearance phase of transcription by ER (87) in a 5’-methyl CpG dependent 
manner (115).  This fits with Mi-2 association in the nucleosome remodeling and 
deacetylase (NuRD) complex, which directs HDAC activity at histone tails, slides 
nucleosomes, and includes methyl-DNA binding proteins (reviewed in (128)).  It is 
possible that an increase in DNA supercoiling or secondary structure occur 
cotranscriptionally, and this could also lead to an altered orientation of post-transcribed 
DNA and nucleosomes (129). 
Regardless of the cause, the effects of promoter clearance are consistent with 
temporary desensitization, then resensitization of chromatin to transcription-inducing 
signal, co-transcriptional PTM of histones, restitution of more compact chromatin 
structure, and masking DNA to prevent spurious transcription factor binding and 
transcription initiation downstream of the appropriate transcription start site(s).  None of 
these functions need be mutually exclusive.  Coregulators and complexes which are 
confirmed or likely participants in the clearance phase of transcription, (as well as having 
roles in repression of genes in other contexts) are divided into the same seven functional 
classes described in the above section and are listed in Table 1.3.  Major complexes, and 
readers and writers of the histone code which enable processing during transcription 
cycling are shown in Figure 1.5. 
 Figure 1.5  Major complexes involved in chromatin modification associated with cyclic NR-chromatin interaction.  The formation of homogeneously packed 
solenoid (heterochromatin) by NR may co-occur with or follow occupancy by NR-corepressor complexes; alternatively, solenoid formation may be more 
heterogeneous, with short tracts of NR-accessible DNA between more highly packed regions.  Refer to tables 1.2 and 1.3 for nomenclature and functions 
associated with the above coregulators. 
 
 Table 1.3  Transcription corepressors associated with static and signal-induced repression, and in some 
cases, the clearance phase of cyclic transcription.  For membership of complexes containing HDACs and 
species cross-referenced protein nomenclature, see this review (130). 
 
  
IV. Histone H1-Associated Solenoid Formation 
H1, H5 linker histones of the histone H1 family binds methylated DNA; bind nucleosome at DNA entry site 
HP1 heterochromatin protein 1 binds H3K9-Me; blocks general txn factor access  
E1A  Adenovirus early expressed antigen 1A non-mammalian, viral interaction hub; (anti)oncogenic 
CtBP1 and 2 E1A C-terminal binding proteins 1 & 2 bridges DNA binding factors to repression machinery; 
    sequesters acetyl-lysine binding and other (co)activators? 
NCoR1, 2 (SMRT)  Nuclear receptor corepressors 1, 2 nucleates HDAC/demethylase complexes; binds NR 
    corepressor mode; SANT domain stimulates HDAC activity 
Sin3A, B complexes homologs A and B of yeast Sin3 well conserved; HDAC-containing; chromosome integrity  
PSF, p54  PTB-associated splicing factor RNA & DNA binding; associated with Sin3A, CoREST 
CoREST  corepressor of RE1-silencing TF Nucleates LSD1, HDAC, CtBP; SANT domain-containing 
RIP140  receptor interacting protein, 140 kDa binds NR coactivator binding mode; HDAC/CtBP assoc.  
LCoR  ligand-dependent corepressor like above, competes with coactivators & binds HDAC/CtBP 
V. General Repression Machinery / Bridging 
VI. Topoisomerase Access 
   
VII. Coregulator Exchange 
Unknown; may only occur during transcription activation  
TBL1, TBLR1 transducin-ß-like (related) 1 part of NCoR and possibly other corepressor complexes; 
   required for stimulated disassembly of these complexes
III. DNA Methylation-Associated 
Acronym(s) Full Name Associated with 
 
HDAC1, 2, 3, 8 (class I) histone deacetylases related to Rpd3 loss of Ac-lysine; CK2 (1, 2, 3) or PKA (8) phosphorylation 
HDAC4, 5, 7, 9 (class IIa) histone deacetylases related to Hda1 14-3-3 binding; signaling; low deacetylase activity 
HDAC 6, 10 (class IIb) tandem domain histone deacetylase (6) ubiquitin binding zinc finger (6); often cytoplasmic (6) 
HDAC 11 (class IV)  similar to class I members, conserved from Monera 
SirT1 (class III HDAC) Sirtuin 1, mammalian homolog of Sir2 loss of Ac-lysine; calorie restricted transcription repression 
PAD4 peptidylarginine demethyliminase 4 arginine demethylimination; conversion to citrulline 
JMJD6 jumonji domain containing 6 arginine demethylation 
JARID1C  jumonji AT-rich interactive domain 1C H3K4-Me3, Me2, or Me demethylase activity 
LSD1 lysine specific demethylase 1 mono- and di-Me lysine demethylation; CoREST complex 
EHMT2 / G9a Euchromatin histone N-MeTransferase lysine methylation of histone H3K9, H3K27, repression 
PcG complexes 2 and 3 polycomb group methyltransferases H3K27 methylation; differentiation 
 
II. ATP-Dependent Chromatin Remodeling 
Mi-2 NuRD complex ATPase gene repression; HDAC and MBD proteins are in complex 
Ino80 INO80 complex ATPase DNA replication 
BAF170 or 155 / SMARCC2 structural subunit of SWI/SNF Me-lysine binding 
DNMT1 DNA methyltransferase 1 maintenance methylation following DNA replication 
DNMT3a, b  DNA methyltransferases 3a, b de novo DNA 5’-cytosine methylation capacity 
DNMT3L inactive paralog of DNMT3 binds specifically to non-H3K4-Me, recruits active DNMT3 
MeCP2 Methyl-CpG binding protein 2 contains a methyl-cytosine binding domain; associates 
     with SWI/SNF during clearance phase of cyclic txn. 
MBD2, 3 Methyl binding domain proteins 2, 3 methyl-cytosine binding domain-containing; assoc. w/ Mi-2 
I. Histone PTM Enzymes 
36 
 1.4 Crosstalk between PTMs, Signaling and NR Transcriptional Mechanisms 
 
PTMs of SF-1 were briefly discussed in relation to the list of functional modules 
of this NR in section 1.2.  The PTM most associated with signaling pathways is 
phosphorylation, however this section will give particular attention to SUMOrylation, 
acetylation, and phosphorylation of NRs and coregulators.  Acetylation and 
SUMOrylation of SF-1 are also PTMs with important functional consequences, only their 
context in signaling pathways was not well established until recently.  Nonetheless, the 
established downstream effects of these modifications on transcription and their potential 
for crosstalk, i.e. regulation of one modification by another, are profound. 
 
1.4.1 SUMOylation / SUMOrylation 
 
Small ubiquitin like modifier (SUMO) conjugation to lysine residues 
(SUMOylation, SUMOrylation) is emerging as a major PTM for functional modification 
of nuclear proteins.  SUMOrylation of the SF-1 hinge affects subnuclear 
compartmentalization, promoting relocalization to regions not involved in active 
transcription following association with a complex (53).  This complex includes a distinct 
RNA-binding protein partner that may bring SF-1 into contact with SUMO-conjugating 
machinery (53), but represses a SUMO-deficient SF-1 mutant nonetheless (131).  The 
transcription repressive role of SF-1 hinge SUMOrylation has been confirmed by three 
studies (51-53) and is in distinction to the effect of estradiol-dependent ER hinge 
SUMOrylation, which activates ER-mediated transcription (132).  Transcription 
activation effects of SUMOrylation are associated with SUMO competition for 
ubiquitination sites and proteasome targeting (e.g., in a cascade which stabilizes p53 and 
increases its activity as a transcription factor (133)), and uncoupling of DNA methylation 
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 and heterochromatin-associated H3K9 methylation (134).  However, direct 
SUMOrylation of transcription factors is more immediately associated with repression in 
most cases other than ER. 
 
1.4.2 Acetylation 
 
 Acetylation on lysine residues of nuclear receptors may occur in a motif which 
mimics histone targets of histone acetyltransferases (HATs), and this motif is conserved 
phylogenetically across most nuclear receptors, the exceptions being NURR1, NGFIB, 
and RXRs (135, 136).  Acetylation of SF-1 by the GCN5 HAT was first reported in 2001, 
and this report suggested that DNA binding domain residues now known to interact with 
DNA were potential acetylation targets (137).  Therefore, mutation of these residues had 
strong effects on transcription (137), probably independent of acetylation.  Residues at 
the end of the Ftz-F1 DNA binding helix were next found to be acetylated by p300 with 
cAMP dependence (46).  These lysine residues are conserved at positions 106, 109 and 
110, and are proximal to an acidic tract at the N terminus of SF-1 (Figure 1.6).  However, 
mutating these and other lysines in the DNA binding domain did not ablate all acetylation 
of SF-1, suggesting additional sites of acetylation outside the DNA binding regions (46).   
Despite the fact that these residues do not interact directly with DNA in the below 
structure (Figure 1.6 and (43)), there was a significant decrease in SF-1 DNA binding in 
vitro and chromatin binding in vivo when these acetylation targets were mutated (46).  
Confocal microscopy enabled the conclusion that the Ftz-F1 box conserved acetylation  
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 site could affect coactivator interaction(s), for example with p300 or other HATs, and 
affected endogenous SF-1 recruitment to p300-enriched foci, which could be sites of 
active transcription (46).  Crosstalk of acetylation with other modifications of SF-1 has 
not been examined. 
Figure 1.6  SF-1 DNA binding domain acetylated residues.  N-terminal residues missing from the structure 
are given on the right.  The three lysine residues K106, 109, and 110 are drawn in stick form at the top left 
of each structure image.  Zinc (green) denotes two zinc fingers.  Images are derived from protein data bank 
2FF0 and NMR data published in (43), and were rendered in Accelerys DS Visualizer v2.0. 
 
1.4.3 Phosphorylation of Factors with a Serine/Threonine-Proline Motif 
 
In addition to AF-2, a region of the SF-1 hinge proximal to the SF-1 LBD was 
found to be necessary for transcription by SF-1 co-activated by SRC-1 (58).  In this 
region, SF-1 can be phosphorylated at S203, and in vitro, ERK2 does so (49) (However, 
ERK1 does not (MB Sewer, unpublished observations)).  Mutation of this site decreased 
SRC-2 coactivator function on a SF-1 responsive promoter (49) and S203 
phosphorylation downstream of estradiol signaling enabled packing (interaction) of the 
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 C-terminal region of the SF-1 hinge with the LBD proper (50).  ERKs and the wider class 
of kinases to which they belong, MAPKs, are proline directed kinases. 
Just recently, a novel approach using phospho-motif specific antibodies identified 
S203 as a proline-directed cyclin dependent kinase (CDK) target without testing 
ACTH/cAMP involvement, and this study called into question the specificity of the 
MAPK pathway inhibitor (48) used in the earlier studies which suggested MAPK 
pathway involvement in phosphorylation of S203 in vivo (49).  CDK7 in particular was 
shown to target SF-1 in vivo, and this kinase is a member of the multifunctional general 
transcription factor complex TFIIH, which directs CDK7 activity toward RNA 
polymerase II at YSPTSPS motifs (the underlined residue is targeted by CDK7, ERK1 
and ERK2 in vitro (138)).  This event promotes the switch from preinitiation to initiation 
of transcription, and mRNA 5’-end capping is also stimulated by CDK7 kinase activity 
(reviewed in (139)). 
Disengagement of SF-1 from regulated promoters demarcates the beginning of the 
clearance phase of efficient transcription cycling.  Therefore, evidence for a stalling of 
this process and a loss of cycling in the presence of the CDK inhibitor DRB presented 
above (73) is extremely relevant to the coupling of NR loss from promoters to events 
following transcription initiation.  These events necessarily involve TFIIH, which 
contains CDK7, with specificity not only for RNA polymerase, but also SF-1.  Building 
evidence for a recently proposed model applicable to multiple NRs (140) suggests that 
CDK7 in TFIIH, or MAPK, phosphorylates a Ser-Pro motif in AF-1 (141, 142) or 
elsewhere in NRs (143, 144) or NR-coactivator complexes (see below).  This somehow 
allows transcription to proceed more efficiently than in the absence of phosphorylation.  
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 Recall that AF-1 is a region N- terminal to the DNA binding domain of ER and many 
other NRs that is not present in SF-1; however, the region of SF-1 hinge phosphorylation 
(PEPYASPP) is increasingly being referred to as AF-1. 
There are a number of opportunities for crosstalk between S203 phosphorylation 
of SF-1 and other functional PTMs.  Like the above motif in RNA polymerase, the 
phospho-Ser203-Pro motif in AF-1 is a likely substrate for the SRC-3 associated NR 
coactivator proline isomerase 1 (145), because this enzyme alters the conformation of the 
peptide backbone at any proline following a phosphorylated serine or threonine residue 
(146).  This is consistent with a reorientation of the SF-1 hinge relative to the LBD in a 
phosphorylation-specific manner (50).  Another effector of proximal phosphorylation 
may be SUMOrylation at K194, as described above for SUMOrylation sites proximal to 
phosphorylation sites.  In this case, phospho-S203 antagonism of K194 SUMOrylation 
and its transcription repressive effect described above would be consistent with the loss 
of function seen in unphosphorylatable S203A SF-1 (see below). 
Unlike the SUMOrylation site, which is well conserved across the fushi tarazu 
family of NRs, the phosphorylation motif of human SF-1 is unique to SF-1 of higher 
vertebrates, with no alignment of this sequence being possible with any other nuclear 
receptor sequence, including the ancestor of SF-1, fushi tarazu (unpublished 
observations).  Coincidentally, the SF-1 paralog and closest relative liver receptor 
homolog-1 is also phosphorylated on the hinge at two serine-proline (Ser-Pro) motifs 
which are further from the conserved SUMOrylation site and from the start of the LBD 
helical bundle, with a similar modest activating effect on transcription (147), arguing 
against SUMOryl-phosphoryl crosstalk on the hinge.  Authors of this study took note of 
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 the general trend that activating phosphorylation in many NRs is much more modest than 
agonist-mediated activation of the same receptors.  This would appear to be true for SF-1, 
because a phospho-site mimetic or site ablation in respective mutant receptors S203E and 
S203A did not affect CYP17 reporter transcription more than 1.5 fold (48), generally 
consistent with an earlier report which found no effect of S203A on SF-1 mediated 
transcription of a short CYP17 promoter-fused reporter (148).  Importantly, studies which 
do find a significant effect of S203A mutation on SF-1 reporter expression (31) used 
other genes with promoters that are long enough (>500bp in this example) to enable 
packaging of the promoter in a manner similar to native chromatin with nucleosomes.  
This would be a requirement to differentiate any effects of S203 phosphorylation on 
cyclic reporter transcription mediated through chromatin modification.  However, 
endogenous mRNA of SF-1 target genes has not been adequately measured in response to 
S203 mutation in any study to date.  This leaves open the possibility that S203 effects are 
gene-specific. 
Metabolic incorporation of labeled phosphate into SF-1 decreases in response to 
cAMP because cAMP activates rapid transcription of phosphatase(s) in the adrenal cortex 
(148, 149).  This contrasts the reasonable expectation that the trans activating role of 
elevated phosphorylation at the major phosphorylation site just described, S203, would 
correlate with both ACTH/cAMP treatment and elevated phosphorylation of SF-1.  In a 
landmark study, Winnay et al identified that this is indeed the case for S203—but at 
particular time points following ACTH stimulation (150).  This study also established 
that a gene promoter—that of the receptor for ACTH—is regulated by phases of cyclic 
SF-1 binding, coregulator recruitment, and chromatin modification in cultured, 
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 synchronized cells, as described in previous sections.  In addition, ChIP of adrenal cortex 
cells taken from mice treated with ACTH for specific acute periods provided the first 
evidence for synchronized populations of cells undergoing induced target gene 
transcription in vivo.  Finally, and most importantly, this study elegantly correlated 
transcription cycle peaks of SF-1 binding to a specific target promoter with the onset of 
increased cell-wide S203 phosphorylation of SF-1 (150).  This supports the model that 
TFIIH (or ERK2) mediates events that precede disengagement of SF-1-coactivator 
complexes from DNA on a large population of induced, cyclic promoters.  Kinetics of 
S203 phosphorylation, ERK2 recruitment, and/or TFIIH-associated specifically with 
promoter chromatin of a given target gene were not determined.  Kinase integration into 
NR transcription cycle-associated complexes is pictured in Figure 1.7. 
 
Figure 1.7  Kinases regulate NR-mediated transcription and other PTMs at multiple levels. 
 
 Dashed lines indicate MAP kinase pathways.  Drawing is based on Rochette-Egly (151). 
43 
 1.4.4 Other Modifications 
In addition to CDK7 and MAPKs, other kinases and PTM-writing enzymes target 
key participants in NR-mediated transcription cycles at different, unique, points during 
phases of those cycles.  One of the most striking examples is NR ligand-dependent 
phosphorylation of corepressor complex members and subsequent dismissal of 
corepressors from NRs and other transcription factors (152).  Specifically following 
ligand stimulation, casein kinase 1, glycogen synthase kinase 3, and protein kinase C 
target coregulator exchange factors (namely, TBLR and TBL)  that respectively reside in 
NCoR and CtBP corepressor complexes ((152) and see tables 1.3 and 1.4 for more 
information)).  This checkpoint preceding transcription by NRs necessarily insures that 
transcription cycles occur in the context of activation of these specific kinases.  
Therefore, it is exciting that there is accumulating evidence for the participation of these 
kinases in proceeding events of transcription cycles:  e.g., a requirement for protein 
kinase C phosphorylation of a NR required for trans activation (153), and glycogen 
synthase kinase 3-dependent ubiquitination and temporary activation of SRC-3 
coactivator function (154). 
As reviewed above, NRs and coregulators are targets for the same PTMs written 
by histone code writing coregulators, e.g., they are targets for acetylation by HATs.  So, 
kinases also integrate signals into a transcriptional response by targeting histone 
modification machinery (transcription coregulators), which in turn modifies not only 
histones but also trans activator modifications.  Termination of SRC-3 coactivator 
function can be caused by coactivator arginine methyltransferase 1 (CARM1)-mediated 
methylation (47), which itself is downstream of kinase inactivation (155).  In a second 
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 example, the HAT p300 is phosphorylated on a conserved residue during metabolic stress 
or localized ATP depletion by AMP-activated protein kinase, specifically decreasing 
p300 interaction with NRs or NR-containing complexes (156). 
The overall goal of studies detailed in the next three chapters of this dissertation 
was to better define the molecular events important for ACTH and cAMP-stimulated 
transcription of the CYP17 gene in a human adrenal cortex cell line.  Because the above 
work demonstrates that chromatin modifications, nuclear receptor modifications, and 
transcription factor coregulator modifications each play a role in transcription of human 
(indeed, many eukaryotic) inducible genes, a chapter is dedicated to broad or specific 
examples of each of these types of modification as it relates to CYP17 transcription.  
While these studies are narrowly focused on CYP17 transcription, it may be useful to 
consider CYP17 as a model inducible steroidogenic gene, and more generally, as a model 
nuclear receptor target gene, particularly with regards to the effects of SF-1 and CtBP 
modification.  
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 Chapter 2.  Materials and Methods 
 
2.1 Reagents.  
  Dibutyryl cAMP (Bt2cAMP) was obtained from Sigma (St. Louis, MO).   D-
erythro Sphingosine was obtained from Avanti Polar Lipids  (Alabaster, AL).  α-
amanitin, H-89, tetrabromobenzotriazole (TBB), recombinant CK1, CK2, GSK3ß, ERK2, 
and the catalytic subunit of PKA were obtained from EMD Biosciences, Inc. (La Jolla, 
CA).  Antibodies utilized in chromatin IP and most experiments are in Table 2.1. 
 
Table 2.1  Antibodies for ChIP experiments and nomenclature cross-reference. 
Source Antibody Definition Alternate Names Cat No. 
 
 
 
 
 
 
 
 
 
 
Upstate 
(Lake Placid, NY) 
 
 
ACTR 
 
CARM-1 
CBP 
 
CtBP1 
GRIP-1 
HDAC1 
HDAC2 
HDAC3 
HDAC4 
HDAC8 
H2B 
H3 Ac-K9,14 
H4 Ac-K5,8, 
           12,16 
H4 Me1-K20 
H4 Me3-K20 
H3 Me3-K4 
NCoR1 
p300 
Pol II 
 
SF-1 
SMRT 
 
SNF2H 
SRC-1 
activator of thyroid and retinoic acid receptors 
 
coactivator arginine methyltransferase-1 
cAMP-responsive element binding protein 
binding protein 
E1A C-terminal binding protein 1 
glucorticoid receptor interacting protein 
histone deacetylases 
 
 
 
 
histone H2B 
histone H3 acetylated at Lys-9 and Lys-14 
histone H4 acetylated at Lys-5, -8, -12, -16 
 
histone H4 monomethylated at Lys-20 
histone H4 trimethylated at Lys-20 
histone H3 trimethylated at Lys-4 
nuclear receptor corepressor 1 
300 kDa histone, factor acetyltransferase 
RNA polymerase II phosphorylated at Ser 5 in 
YSPTSPS repeat 
steroidogenic factor-1 
silencing mediator for retinoic acid and thyroid 
hormone receptors 
sucrose non-fermenting 2, ISWI ATPase  
steroid receptor coactivator 1 
AIB1/TRAM-1/RAC3/ 
p/CIP /SRC-3/NCoA3 
 
 
 
 
SRC-2/NCoA2/TIF2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NR5A1, Ad4BP 
NCoR2 
 
 
NCoA1 
05-490 
 
07-080 
06-294 
 
07-306 
06-986 
06-720 
05-814 
05-813 
07-040 
07-545 
07-371 
06-599 
06-866 
 
07-748 
07-749 
07-473 
06-892 
05-257 
05-623 
 
07-618 
06-891 
 
07-624 
05-522 
BD Biosciences 
(San Diego, CA) 
CtBP1 and 2 
p54nrb 
E1A C-terminal binding proteins 1 and 2 
nuclear RNA and DNA binding protein 
 
NonO 
612042,4 
611278 
 
Santa Cruz 
Biotechnology 
(Santa Cruz, CA) 
BRG-1 
Brm 
GCN5 
P/CAF 
RAC3 
 
RIP140 
mSin3A 
Brahma related gene-1, SWI/SNF ATPase 
Brahma SWI/SNF ATPase 
general control nonderepressed 5 
p300/CBP associated factor, GCN5 paralog 
p160 coactivator 
 
140 kDa receptor interacting protein 
mammalian homolog A of yeast Sin3  
 
 
 
 
ACTR/AIB1/TRAM-1/ 
p/CIP /SRC-3/NCoA3 
NRIP1 
sc-10768 
sc-28710 
sc-20698 
sc-8999 
sc-13066 
 
sc-8997 
sc-994 
Dr. J. Patton 
(Vanderbilt Univ., 
Nashville, TN) 
PSF polypyrimidine-tract binding protein 
associated splicing factor 
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Experiments described in chapter four or five used antibodies including anti-SF-1 
from Millipore (Temecula, CA), anti-FLAG M2 from Stratagene (La Jolla, CA), and anti-
ß catenin phospho-Ser33 and phospho-Ser33 and 37 (GSK3 phospho-substrate) from 
Sigma (St. Louis, MO). 
 Some experiments described in chapter five utilized 5,6-carboxy-2’,7’-dichloro-
dihydrofluoroscein diacetate purchased from Invitrogen (Eugene, OR).  Active PAK6 
was obtained from Millipore. 
 
2.2 Cell Culture.  
 
H295R adrenocortical cells (157, 158) were generously donated by Dr. William 
E.  Rainey (Medical College of Georgia, Augusta, GA) and cultured in Dulbecco's 
modified Eagle's/F12 (DME/F12) medium (Invitrogen, Carlsbad, CA) supplemented with 
10% Nu-Serum I (BD Biosciences, Palo Alto, CA), 0.5% ITS Plus (BD Biosciences), and 
antibiotics.  Jeg3 human choriocarcinoma cells were donated by Dr. Michael R. 
Waterman (Vanderbilt University School of Medicine, Nashville, TN) and cultured in the 
same media as the H295R cells.  CV-1 cells were obtained from ATCC (Manassas, VA) 
and cultured in MEM with 10% fetal bovine serum and antibiotics. 
 
2.3 Plasmids and Mutagenesis. 
 
The CYP17 57-pGL3 plasmid was constructed by ligating double stranded 
oligonucleotides corresponding to the region -57/-2 of the CYP17 5' flank upstream of 
the Firefly luciferase gene in the pGL3 vector (Promega, Madison, WI) as previously 
described (20).  Expression plasmids were generously given by the labs of B.W. 
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 O’Malley (Baylor College of Medicine, Houston TX)-pBKCMV.SRC-1e; M.R. Stallcup 
(University of Southern California, Los Angeles, CA)-pSG5.HA.GRIP-1 full length and 
partial constructs pSG5.HA.GRIP-1(5-1121), pSG5.HA.GRIP-1(1124-1462), and 
pSG5.HA.SRC-1a(977-1441) “SRC-1ΔN”; R.M. Evans (Salk Institute, La Jolla, CA)-
pCMX.ACTR and pCMX.mSMRTaFL; Y. Nakatani (Dana Farber Cancer Institute, 
Harvard Medical School, Boston, MA)-pOZ-N.hGCN5 and pCI.P/CAF; R.H. Goodman 
(Vollum Institute, Oregon Health & Sciences University, Portland, OR)-pRC-
RSV.mCBP; G. Chinnadurai (Institute for Molecular Virology, Saint Louis University 
School of Medicine, St. Louis, MO)-pRC-CMV.CtBP1; K.B. Horwitz (University of 
Colorado Health Sciences Center, Aurora, CO)-pCMX.mNCoR; and P.W. Tucker 
(University of Texas at Austin, Austin, TX)-pCR3.1.NonO and pCDNA3.1.PSF.  Site-
directed mutagenesis to disrupt the human GCN5 (hGCN5) HAT active site residue E214 
homologous to yeast GCN5 E173 (159) was performed using the primer 5’-CCC ACC 
CAG GGC TTC ACG CAG ATT GTC TTC TGT GCT GTC-3’ and the reverse 
complement, generating hGCN5 E214Q.  NADH-binding defective pAct.CtBP1 G183V 
(160) was generated with the primer 5’-TTG GGC ATC ATC GGA CTT GTT CGC 
GTG GGG CAG GCA GTG-3’ and the reverse complement.   WT SF-1 was generously 
provided by Dr. K. Morohashi (National Institute for Basic Biology, Okazaki, Japan) and 
cloned into the pCMV Tag1 vector (Stratagene, La Jolla, CA).  SF-1 mutants and 
phosphorylation sites and dimerization interface site mutants of CtBP1 and 2 were 
prepared using a QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) 
and were confirmed by sequencing.  pRC-CMV.CtBP1, pFH.CtBP2, and 
pFH.CtBP1.NLS were kindly donated by Dr. G. Chinnadurai (Institute for Molecular 
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 Virology, Saint Louis University School of Medicine, St. Louis, MO).  CtBP1 and 2 were 
subcloned into pET42 vector (Novagen, La Jolla, CA). 
 
2.4 Bacterial Expression of SF-1.   
 
Conditions used for cloning, expression, and purification of His-tagged SF-1 have 
been previously described (161). 
 
2.5 In vitro Kinase Assays. 
 
 Purified wild type (WT) or mutant immobilized receptor was incubated with 
recombinant, active CK1, CK2, GSK3ß, ERK2, or the catalytic subunit of PKA and 1 
μCi [γ 32P]ATP (MP Biomedicals, Solon, OH) in an assay buffer optimal for the kinase 
being tested for 1 hour at 30ºC.  Likewise, CtBP1 or 2 bound to GST beads were 
incubated with ERK2, PAK1, PAK6, or the catalytic subunit of PKA.  CK1 and CK2 
were assayed in 20 mM Tris-Cl, pH 7.5, 10 mM MgCl2, and 1 mM dithiothreitol (DTT).  
The reaction buffer for analysis of GSK3ß kinase activity contained 20 mM MOPS, 25 
mM glycerol phosphate, 1 mM DTT, 5 mM EGTA, 25 mM MgCl2, and 1 mM sodium 
orthovanadate.  ERK was assayed in 25 mM Tris-Cl, pH 7.5, 20 mM EGTA, 10 mM 
HEPES, 10 mM MgCl2, and 1 mM DTT, while PKA reaction buffer contained 20 mM 
Tris-Cl, pH 7.5, 100 mM NaCl, 12 mM MgCl2, and 1 mM DTT.  Assay buffer for 
reactions containing PAK6 contained 45 mM HEPES, pH 7.9, 10 mM MgCl2, 2 mM 
MnCl2, and 0.2 mM DTT.  The substrate-bound beads were washed twice with RIPA 
[containing PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and protease 
inhibitor cocktail I (Calbiochem)] and three times with PBS, resuspended in SDS-PAGE 
gel loading buffer and proteins resolved on 10% acrylamide gels.  Dried Coomassie-
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 stained gels were exposed to a phosphorimager screen and phosphorylated SF-1 imaged 
on a Fluor/Phospho-Imager (Fuji Film, Japan).  Positive reactions were obtained for each 
kinase/buffer system in reactions with myelin basic protein (Sigma) or CREB PKA target 
fragment, CREBtide (EMD). 
 
2.6 Chromatin Immunoprecipitation (ChIP). 
 
For ChIP assays (162, 163), H295R cells (subcultured into 100 or 150 mm dishes) 
were pre-treated with 2.5 µM α-amanitin for 2 h, washed twice with PBS, then treated 
with 1 mM Bt2cAMP and/or Sph (5 µM ) for time periods ranging from 15 minutes to 4 
hours.  Cross-linking was performed by the addition of formaldehyde (final concentration 
of 1%) for 10 minutes with gentle shaking.  The reaction was stopped by the addition of 
glycine (0.125 M final concentration) for 5 min, the cells were washed twice in PBS and 
harvested into RIPA buffer.  Lysates were then sonicated to obtain optimal DNA 
fragment lengths of 100 to 1000 base pairs followed by centrifugation for 15 minutes at 
4°C.  Fifty µl supernatant was retained as input.  The purified chromatin solutions were 
cleared with 1 µg rabbit or mouse IgG and immunoprecipitated overnight at 4°C on a 
tube rotator using 5 µg of primary antibody (see Table 1), and protein A/G plus (Santa 
Cruz Biotechnology).  The immobilized protein/DNA complexes were subjected to a 
series of 5 minute washes:  three times in RIPA buffer, three times in RIPA buffer plus 
500 mM NaCl, three times in washing buffer (10 mM Tris-Cl, pH 8, 0.25 M LiCl, 1 mM 
EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, and protease inhibitors), and 
three times in TE buffer, pH 8.0.  The cross-links were reversed and protein digested 
using proteinase K (100 µg/ml).  DNA was purified by phenol:chloroform extraction and 
ethanol precipitation.  Real-time PCR was carried out using 4 µl of output, 1 µl of input 
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 (diluted 1:4), the iTaq SYBR Green Supermix with ROX (Bio-Rad, Hercules, CA), and 
the following primer pairs: forward 5’-GGC TGG GCT CCA GGA GAA TCT TTC TTC 
CAC-3’, reverse 5’-CGG CAG GCA AGA TAG ACA GCA GTG GAG TAG-3’, which 
amplify the region of the CYP17 promoter from position -104 to +43.  For negative 
controls, primers for actin (forward 5’-TGC ACT GTG CGG CGA AGC-3’ and reverse 
5’-TCG AGC CAT AAA AGG CAA-3’) or CYP17 coding regions (forward 5’-GAC 
AAG GGC ACA GAA GTT ATC ATC-3’ and reverse 5’-CAG GGA GGG CAG CTG 
CCC ATC ATC-3’) were used. PCR reactions were as follows:  1) 1 X 94ºC, 5 minutes, 
2) 35 X 95ºC, 1 minutes, 55ºC, 1 minute, 72ºC, 2 minutes, 3) 1 X 72ºC, 10 minutes, 4) 
cool to 4ºC.  Graphical data was normalized to input values.  PCR reactions were also 
resolved by 2% agarose gel electrophoresis. 
In some experiments, cells were treated with 1 mM Bt2cAMP and/or 20 mM LiCl 
for 1 hour.  In studies examining the functional significance of S342 phosphorylation, 
cells (150 mm dishes) were first transfected with 25 μg WT or mutant pCMVTag1-SF-1 
for 48 hours and then treated with α-amanitin for synchronization, followed by treatment 
with 1 mM Bt2cAMP for 30 minutes to 4 hours.  In these experiments, PCR reactions 
were as follows:  1) 1 X 94ºC, 5 min, 2) 45 X 95ºC, 30 sec, 55ºC, 30 sec, 72ºC, 1 min, 3) 
1 X 72ºC, 10 minutes. 
 
2.7 RNA Isolation, Real Time RT-PCR, and RNA Interference. 
 
Cells were cultured onto 12-well plates, treated for the indicated times with 1 mM 
Bt2cAMP in the presence and absence of Sph and total RNA was prepared using TRIzol 
(Invitrogen, Carlsbad, CA).  Real time RT-PCR reactions were performed in the iCycler 
(Bio-Rad), using 100 ng of total RNA, 100nM forward and reverse primers and the One-
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 Step RT-PCR SYBR Green Kit (Eurogentec, San Diego, CA).  The following primers 
were used:  CYP17 (forward 5’-CCG CAC ACC AAC TAT CAG-3’ and reverse 5’-GTC 
CAC AGC AAA CTC ACC-3’) and actin (forward 5’-ACG GCT CCG GCA TGT GCA 
AG-3’ and reverse 5’-TGA CGA TGC CGT GCT GCA TG-3’).  CYP17 expression is 
normalized to α-actin content and calculated using the delta cycle threshold (∆CT) 
method. 
RNA interference detailed in chapter 4 was performed as follows.  Cells were 
sub-cultured into 12-well plates and 24 hours later transfected with 50 nM of small 
interfering RNAs (siRNAs; obtained from Dharmacon) directed against CK2 or GSK3ß 
using HiPerfect Trasfection Reagent (Qiagen, Valencia, CA).  Twenty-four hours after 
transfection, cells were transfected again (50 nM siRNA) and incubated for an additional 
48 hours.  Some cells were treated with 1 mM Bt2cAMP for 16 hours (66 hours after first 
transfection).   Then RNA was harvested and analyzed as described above. 
 
2.8 Transient Transfection. 
 
In experiments performed in chapter three, cells were subcultured onto 12-well 
plates and 24 hours later transfected with 250 ng CYP17 57-pGL3 (the first 57-base pairs 
of the CYP17 promoter upstream of the start site fused to the Firefly luciferase gene) (20) 
using GeneJuice (Novagen, Madison, WI).  Ten to 200 ng of coregulator plasmids were 
cotransfected as indicated.  Cells were co-transfected with 5 ng of the Renilla luciferase 
plasmid (pRL.TK, Promega, Madison, WI) for normalization.  Approximately 24 hours 
later, cells were treated with 1 mM Bt2cAMP and/or 1-5 µM Sph for 16-24 hours and 
harvested for dual luciferase assays (Promega, Madison, WI).   
In chapter 4 experiments, Jeg3 cells were sub-cultured onto 24-well plates 
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 and transfected with 100 ng of pGL3-CYP17-2x57 reporter plasmid (164) and 25 
ng of WT or mutant (T334A, T335A, T338A, S342A, and S346A) pCMVTag1-
SF-1 (Invitrogen, Carlsbad, CA) using GeneJuice (Novagen, Madison, WI).  Cells 
were co-transfected with 1 ng of a Renilla luciferase plasmid (pRL-TK, Promega, 
Madison, WI) for normalization.  Twenty-four hours after transfection, the cells 
were treated with 1 mM Bt2cAMP for 16 hours and the transcriptional activity of 
the CYP17 reporter gene determined using a dual luciferase assay (Promega, 
Madison, WI). 
In chapter five, reporter assays were performed in 24 welled plates and 
transfections relied on per well combinations of the following plasmids, unless 
otherwise indicated:  pGL3.CYP17 2x57 or -300 (150 ng), pCR3.1.SF-1 (30 ng), 
pRC-CMV.CtBP1 (30 ng). 
 
2.9 Mammalian Two-Hybrid. 
 
Coactivators and nuclear receptor genes were cloned into the Mlu I and Xba I sites 
of pBIND and/or pACT vectors (Promega).  Cells were transfected with pG5 firefly 
luciferase reporter in combination with pBIND and pACT vectors expressing fusions of 
Gal4 DBD and VP16 AD, respectively, with SF-1, LRH-1 (liver receptor homolog-1, 
NR5A2) or coregulators.  The ratio of pG5 to pBIND to pACT in transient transfections 
was 50ng:50ng:15ng.  Twenty-four hours later, cells were treated with Bt2cAMP and/or 
other reagents as indicated for 16-24 hours before harvesting and assaying for dual 
luciferase activity. 
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 2.10 Metabolic Labeling. 
 
H295R cells were subcultured onto 100 mm dishes and transfected with 15 μg 
WT or mutant pCMVTag1-SF1.  Forty-eight hours later, media was replaced with 
phosphate-free DMEM containing 10 μCi 32P-phosphorus/ml for 4 hours.  Cells were 
washed twice with PBS and lysates isolated in RIPA for immunoprecipitation with 5 μg 
anti-FLAG and 30 μl of a 50% slurry of protein A/G plus overnight at 4°C with rotation.  
Immunoprecipitants were washed twice with RIPA and twice with PBS and then 
subjected to SDS-PAGE.  Gels were stained overnight with coomassie, destained, and 
exposed to a phosphorimger screen.  Blots were imaged by scanning screens on a 
Fluor/Phospho-Imager (Fuji Film, Japan). 
 
2.11 In vitro Acetylation Assay. 
 
WT or mutant pCMVTag1-SF1 was transiently transfected into H295R cells and 
then treated for 1 hours with 1 mM Bt2cAMP.  Cell lysates were immunoprecipitated 
with an anti-FLAG antibody (Stratagene) and protein A/G agarose (Santa Cruz).  The 
immunoprecipitants were washed three times with RIPA buffer and incubated with E. 
coli expressed GCN5 and 14C-acetyl coenzyme A (MP Biomedicals).  The immobilized 
receptor was washed and subjected to scintillation counting and SDS-PAGE and 
fluorography. 
 
2.12 Confocal Microscopy and Time Lapse Imaging. 
 
A Carl Zeiss LSM 510 (Germany) was used to image live and fixed cells.  
Three µm crosssections were imaged via excitation with 351 nm (UV) or 543 nm 
laser, and emission at 385-470 nm and 560 nm recorded, respectively, for 
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 endogenous autofluorescent pyridine nucleotide or fixed secondary antibody 
conjugated to DyLight 549 (Pierce Biotechnology, Rockford, IL).  Regions of 
interest for nuclear and cytoplasmic CtBP1 and 2 were defined in the Zeiss image 
analysis software and background-subtracted absolute and relative intensities for 
time points were then calculated. 
 
2.13 Coimmunoprecipitation and Western Blotting. 
 
H295R cells were cultured in 100 mm dishes and cytoplasmic and nuclear 
fractions obtained using the NE-PER kit (Pierce), or whole cell extracts were prepared in 
RIPA.  For exogenous CtBP expression, 5 µg of pFH.CtBP1 or 2 (WT or mutant), and/or 
5µg of pACT.CtBP1 were transfected 60 hours before harvest.  For kinetics by 
coimmunoprecipitation (coIP), one hundred µg nuclear extracts, or for other experiments 
an equal fraction or total sample of whole cell lysates, were precleared for 45 minutes at 
4° C and then incubated overnight with protein A/G beads (Santa Cruz Biotechnology, 
Santa Cruz, CA) and 4 µg anti-CtBP1 (BD Biosciences), 3 µg anti-VP16 or 2 µg GCN5 
(Santa Cruz), 2 µg anti-FLAG (Sigma), or 2 µg anti-SF-1 (Millipore).  Beads were 
washed two times in RIPA with protease inhibitors (EMD) and twice in PBS, then boiled 
in SDS-PAGE buffer and separated in 10 % gels before transfer to PVDF membrane 
(Millipore) and western blotting with anti-CtBP2.  Blots were developed with ECF 
(Amersham Biosciences, Piscataway, NJ) and imaged with a FLA-3000 (Fuji Film, 
Japan), then quantified using Fuji Image Gauge v3.0 software. 
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 2.14 Biomolecular Simulation. 
 
Re-creation of the CtBP1 homodimer (165) was performed manually to generate 
the symmetry of the homodimer as displayed in the publication by Kumar, et al, and the 
structures were merged in Swiss PDB Viewer 3.7 (166) and energy minimized.  CtBP2 
was threaded through one of the CtBP1 monomers in this structure and the resulting 
CtBP2 monomer refined using the SWISS-MODEL service (166).  Following energy 
minimization of the resulting heterodimer, peptides comprising CtBP1 residues 133-145 
and/or CtBP2 residues 139-151 were saved as an isolated structure, maintaining dimeric 
contacts.  In silico mutagenesis was carried out in Swiss PDB Viewer followed by 30 
cycles of energy minimization in vacuo, during which the total system free energy was 
determined to plateau within 0.1% of the energy of the previous calculation for at least 5 
cycles of minimization.    
 
2.15 Statistics. 
 
One-way analysis of variance and Tukey’s multiple comparison tests were 
performed for selected data in chapter three using GraphPad Prism 4.03 (GraphPad 
Software, Inc., San Diego, CA).  In chapter five, one sample t-tests were performed in 
GraphPad Prism 5.00 (GraphPad Software, Inc., San Diego, CA).  Significant difference 
from a compared value was defined as p < 0.05.  
56 
  
Chapter 3.  Results—Part I:  Coregulator Exchange and 
Sphingosine-Sensitive Cooperativity of Steroidogenic Factor-1, 
GCN5, p54, and p160 Coactivators Regulate cAMP-Dependent 
CYP17 Transcription Rate 
 
3.1 α-Amanitin, a Valuable RNA Polymerase II (Pol II) Inhibitor 
 
 In sections 1.3, seminal ChIP studies were reviewed which revealed that inducible 
genes undergo cycles of chromatin modification and interaction with transcription factors 
such as nuclear receptors, along with coregulators. We hypothesized that combinatorial 
and sequential recruitment of SF-1 along with coregulators would also occur on the 
CYP17 promoter in adrenal cortex cells in which chronic steroidogenesis is induced by 
ACTH/cAMP.  Some attention must be given to the means by which many of these 
kinetic ChIP studies achieved synchronized populations of cells.  Synchronization 
implies a uniform promoter chromatin structure and a nucleosome modification state that 
is not conducive to transcription competence being achieved.  Then, such conditions are 
reversed, transcription is induced, and ChIP is used to monitor the population-wide trends 
of subsequent chromatin modification and protein factor-DNA binding stabilization.  α-
Amanitin is a cyclic peptide toxin from Amanita species of fungi that blocks dynamic 
movement of RNA polymerase II (Pol II) along the DNA that it is poised to continue 
reading after a phosphodiester bond in a nascent mRNA has been formed (167).  Thus, it 
is not surprising that Pol II does not immediately disengage from DNA at the 
concentrations and treatment times used (~2 µM, 2 hours) in most of these studies—in 
fact, one study which examined the early kinetics of Pol II on histone promoters 
57 
 undergoing timed treatment with 2 µM α-amanitin found that the toxin at this 
concentration doubled stable occupancy of 3’ regions of the H2AB and H3B genes within 
60 minutes, decreasing towards no net change after two hours of treatment, and little 
change in Pol II occupancy on promoters of these genes was noted (123).  Indeed, cyclic 
kinetics of polymerase recruitment and loss in response to estradiol on an ER responsive 
promoter were identical with or without low dose α-amanitin cotreatment (73).  However, 
TATA binding protein near the transcription start sites for H2AB and H3B genes 
decreased in occupancy while histone solenoid linker histone H1 increased slightly in 
occupancy at the beginning of these histone genes (123), suggesting that dynamic Pol II 
competes with histone H1 binding to chromatin and maintains an open chromatin 
conformation at the transcription start site.  Thus, a default or return to partial or full 
solenoid structure may very well occur in the absence of polymerase access to a genomic 
segment.  Of note, histone genes like those studied above may be considered either 
constitutive and immediately accessible, or poised for further induction, e.g. during the 
cell cycle, and in some tissues, with circadian rhythmicity (168). 
At the concentration of 2 or 2.5 µM, α-amanitin inhibition of transcription is fully 
reversible, simply by washing cultured cells (87).  However, at higher concentrations (5-
20µM), used in studies which predated the finding of synchronized, cyclic, transcription, 
Pol II half-life is affected in a DNA dependent manner (169), suggesting the induction of 
polyubiquitination and degradation of a Pol II complex which can no longer undergo any 
dynamic interaction with DNA (170).  Strong repression of cyclic transcription with 
stalling of polymerase is clearly visible upon proteasome inhibition (86).  In addition to 
ameliorating a proclivity of actively engaged transcription complexes to stall, the 
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 proteasome may have other coactivator-like roles that guarantee an accelerated rate of 
transcription during gene induction (88, 171). 
  
3.2 cAMP Induces Cycles of SF-1 Binding to the CYP17 Proximal Promoter 
 
 We have previously shown that cAMP stimulates SF-1 dependent transcription by 
promoting the binding of a complex containing SF-1 and the splicing factors p54nrb and 
PSF to the cAMP-responsive sequence of the CYP17 promoter (20).  Moreover, we have 
also demonstrated that both ligand binding (172) and phosphorylation (148) modulate the 
activity of SF-1.  Various coregulators of transcriptional activation are known to interact 
with SF-1 and modulate its ability to transactivate target genes, especially in response to 
cAMP or PKA (46, 58, 78, 137, 173-175).  In order to examine the kinetics of 
recruitment and combinatorial effects of a panel of coregulators on SF-1 responsive gene 
promoters, we treated α-amanitin synchronized H295R adrenocortical cells with 1 mM 
Bt2cAMP for time periods ranging from 15 to 240 minutes and carried out ChIP for SF-1.   
Primers for ChIP of the CYP17 promoter and transcription start site were designed to 
most likely capture the state of a single nucleosome, with 147 bp of wrapped DNA in a 
canonical model.  In addition, real time PCR requires an amplicon length of more than 
100 bp for maximum sensitivity.  Therefore, the region selected, -104/+43, was chosen to 
match these criteria, with the -57/-37 SF-1 binding site centrally located. 
Both ACTH and Bt2cAMP increased the binding of SF-1 to the CYP17 promoter; 
however, the relative enrichment of SF-1 bound CYP17 promoters mediated by Bt2cAMP 
was greater than that seen for ACTH (Figure 3.1A).   The ACTH-/Bt2cAMP-stimulated 
SF-1 binding initially occurs in 120-minute cycles (Figure 3.1A), though elevated SF-1 
occupancy of the promoter occurs for less than 90 minutes.  Peaks indicate a stochastic 
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 time for maximal recruitment to the promoter within the population of synchronized cells 
(176).  To determine if the periodic binding of SF-1 results in cyclical changes in 
transcription, we quantified the changes in CYP17 reporter gene expression in 
synchronized cells over the same 240-minute time frame.  As shown in Figure 3.1C, both 
ACTH and Bt2cAMP treatment resulted in cyclical increases in CYP17 luciferase 
activity.  However, the periodicity of reporter expression did not overlap with SF-1 
binding to endogenous promoter at early time points.  CYP17 reporter gene activity 
peaked at the 30-, 90-, and 210-minute time points, suggesting that rhythms of 
ACTH/cAMP-stimulated SF-1 binding to the CYP17 promoter correspond with an 
overall increase in P450c17 transcription rate, and these transcription rhythms can be 
brought forward into corresponding rhythmic protein accumulation. 
 
3.3 Trans Activation of CYP17 Follows SF-1 Binding 
 
Basal transcription machinery as well as nuclear receptors are lost (86) and 
promoter histone modifications are uniformly reset to patterns associated with low levels 
of transcription (87) on the promoter when cells are exposed to α-amanitin in the absence 
of signals that induce transcription, so we extended our ChIP assay to examine the 
dynamics of Pol II recruitment to the proximal CYP17 promoter during SF-1 
transactivation, particularly following peaks of SF-1 recruitment at 60 (cycle I) and 180 
(cycle II) minutes of ACTH or Bt2cAMP stimulation.  The antibody used recognizes the 
phosphorylated C-terminal domain heptad repeat.  Sixty minutes of both ACTH and 
Bt2cAMP increase Pol II recruitment which decreases more slowly than Bt2cAMP-
stimuated SF-1 binding; we reference the beginning of SF-1 recruitment until the loss of 
Pol II as transcription cycle I (Figures 3.2A, B).  In cycle II, Bt2cAMP promotes Pol II 
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Figure 3.1  cAMP induces cyclic binding of SF-1 to the CYP17 promoter. 
 
H295R cells were synchronized for 2 hours with 2.5 µM α-amanitin, then treated with 1 mM Bt2cAMP for 
the indicated times and subjected to ChIP using a polyclonal SF-1 antibody.  (A) Real time PCR analysis of 
ChIP DNA.  Output data are normalized to values obtained for 1% input controls, and results are presented 
as percent of baseline value obtained for untreated cells at each time point.  Data graphed represents the 
mean ± SEM from 11 experiments performed in duplicate.  (B) Purified DNA was amplified by PCR with 
primers described in chapter 2 and the samples resolved on a 2% agarose gel.  Results from a representative 
experiment are shown.  (C) H295R cells subcultured onto 24-well plates and transfected with 125 ng 
pGL3-CYP17 2x57 and 2 ng pRL-TK for 48 hours, and then treated with 2.5 µM α-amanitin for 2 hours.  
Synchronized cells were washed twice with PBC, and then treated with ehtier 50 nM ACTH or 1 mM 
Bt2cAMP for 30-240 minutes.  Lysates were isolated and luciferase activity quantified by luminometry.  
Graphed data are expressed as fold of the control group mean for each time point and represents mean +/- 
SEM from two experiments performed in quadruplicate. 
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recruitment with more complex dynamics culminating 30 minutes after peak binding of 
SF-1 on the CYP17 promoter at 180 minutes.  In contrast to the cycle of Pol II 
enrichment seen in response to Bt2cAMP, peak ACTH-stimulated Pol II binding in cycle 
I occurred at the 90-minute time point.  Further, the comparative effect of ACTH on Pol 
II recruitment in cycle II was an earlier increase that was sustained longer as compared to 
Bt2cAMP-stimulated Pol II binding (Figure 3.2A).  SF-1 and Pol II binding after acute 5 
and 15 minute exposure to ACTH or Bt2cAMP revealed no additional early peaks in 
binding prior to the first transcription cycle (data not shown).  Because kinetics of SF-1 
binding to CYP17 promoter is indistinguishable between Bt2cAMP- and ACTH-
stimulation (Figure 3.1A), there is a better incremental burst of protein expression with 
Bt2cAMP (Figure 3.1C), and timed separation of transcription cycles is greater with 
Bt2cAMP than with ACTH (Figure 3.2A), the cAMP analog was used as a surrogate for 
ACTH stimulation in subsequent experiments.  SF-1 binding to the CYP17 promoter in 
response to Bt2cAMP is shown in all subsequent ChIP figures for comparison. 
 
3.4 Histone H3 and H4 Acetylation Precedes Pol II Recruitment 
 
We postulated that histone acetylation is altered during induction of SF-1 
dependent transactivation, and that these changes must precede changes in Pol II 
occupancy of the proximal CYP17 promoter as has been demonstrated for SF-1 
responsive promoters (150, 177), as well as many other genes in their native context of 
chromatin (178).  ChIP with an antibody for acetylated histone H4 correlates with 
subsequent Pol II recruitment in both cycles of SF-1 mediated transcription in response to 
both ACTH and Bt2cAMP, while histone H3 acetylation at Lys 9 and 14 coincides with  
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Figure 3.2  SF-1 transcription cycles correlate with histone acetylation and HAT and Pol II recruitment. 
 
(A) Graphical analysis of relative promoter binding of Pol II.  Assays were performed as described in 
chapter 2 and DNA amplified by quantitative PCR using primers targeted at region -104/+43 of the CYP17 
promoter.  Two transcription cycles (I and II) are indicated. Data graphed represents the mean ± SEM from 
3 experiments performed in duplicate.  (B) Representative ethidium bromide-stained agarose gel of 
temporal ChIP for Pol II binding to the CYP17 promoter.  (C) Temporal ChIP analysis of Bt2cAMP-
stimulated acetylation of histone H3 and histone H4.  Sheared chromatin was immunoprecipitated with 
anti-SF1, anti-acetyl histone H3, or anti-acetyl histone H4 antibodies.  Output data are normalized to delta 
Ct values obtained for 1% input controls, and results are presented as percent of baseline value obtained for 
untreated cells at each time point.  (D) Graphical analysis of temporal ChIP for HAT recruitment to the 
CYP17 promoter during Bt2cAMP stimulation.  α-Amanitin synchronized H295R cells were treated for 
time periods ranging from 30 minutes to 4 hours with 1 mM Bt2cAMP, exposed to 1% formaldehyde and 
purified lysates immunoprecipitated using antibodies directed against SF-1, GCN5, p300, CBP, and P/CAF.  
Output data are normalized to values obtained for 1% input controls, and results are presented as percent of 
baseline value obtained for untreated cells at each time point. Data graphed represents the mean from 2 
experiments performed in duplicate.  (E) Time course of Bt2cAMP-stimulated recruitment of p160 
coactivators to the CYP17 promoter.  ChIP was performed on lysates purified from Bt2cAMP-treated 
synchronized cells using antibodies for SF-1, SRC-1, GRIP-1, ACTR.  Outputs are normalized to delta Ct 
values obtained for 1% input controls, and results are presented as percent of delta Ct values for untreated 
cells at the corresponding time point.  Data graphed represents the mean from 2 experiments performed in 
duplicate. 
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 the presence of Pol II in cycle II (Figure 3.2C).  Histone H4 acetylation is decreased just 
before or as Pol II moves from the -104/+43 region of the promoter, while acetylation of 
H3 remains after cycle II until at least the 240 minute time point.   Thus, histone H4 
acetylation occurs by the time that Pol II binds the proximal promoter, whereas H3 
acetylation is not strictly required for Pol II recruitment but does occur at high levels 
throughout transcription cycle II. 
 
3.5 Histone Acetyltransferase Recruitment Correlates with Histone Acetylation 
 
We next performed temporal ChIP experiments in order to determine the kinetics 
of binding of coactivators with histone acetyltransferase (HAT) activity (Figure 3.2D).  
GCN5 binding peaks at 30 minutes, and again at 180 minutes of stimulation.  GCN5 
recruitment coincides with histone H4 acetylation in both transcription cycles (Figure 
3.2B).  Early in cycle II, p300 rapidly binds between 120-150 minutes, and this binding 
coincides with histone H3 acetylation specific to the second transcription cycle (Figure 
3.2C). 
HAT binding events that occur after peak SF-1 binding vary between the first and 
second transcription cycles.  CBP binds preferentially in cycle I, in phase with SF-1 
(Figure 3.2D), and this binding does not correlate with H3 or H4 acetylation.  The GCN5 
paralog P/CAF binds in phase with GCN5 but with lower abundance in both cycles; yet, 
during cycle II at 210 minutes of stimulation, there is pronounced P/CAF binding 
independent of GCN5 recruitment 30 minutes after peak SF-1 binding, and this 
corresponds with a further increase in H3 acetylation after SF-1 begins to vacate the 
promoter during the second transcription cycle (Figure 3.2C). 
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 3.6 Each Transcription Cycle Has a Unique Profile of p160 Binding 
 
Only two of the three characterized members of the p160 family of coactivators 
[SRC-1, GRIP-1, ACTR (see Table 2.1 for alternate names)] have confirmed intrinsic 
HAT activity (179, 180).  All three p160s serve as scaffolding for recruitment of other 
HATs to nuclear receptors (179-182) thus they are good candidates for bridging HATs 
with weak or no ligand-dependent interaction motifs to the SF-1 activation function-2 
(AF-2) motif.  In temporal ChIP, p160s show binding that mirrors increases in SF-1 on 
the promoter in both cycles, but in the first transcription cycle, SRC-1 rapidly binds 
within the first 30 minutes, while SF-1 is recruited for an additional 30 minutes (Figure 
3.2E).  Notably, only SRC-1 is enriched on the promoter in the first transcription cycle.  
On the other hand, multiple overlaping peaks of lower intensity in the second 
transcription cycle indicate that p160s may be interchangable in the second SF-1 
transcription cycle. 
 
3.7 GCN5 Interaction with SF-1 is Strengthened by p160 Coactivators 
 
Initial GCN5 binding coincides with SRC-1 in intensity and timing (cf. Figures 
3.2D and 3.2E), and GCN5 stimulates expression of a SF-1 responsive reporter only in 
the presence of SRC-1 (Figure 3.3, group 2 vs. group 6) and only with SF-1 that has an 
intact ligand binding pocket (group 6 vs. group 8).  We have previously found that Sph 
inhibits the ability of SRC-1 to coactivate SF-1-dependent transcription (172).  These 
data suggest the possibility of a concomitant GCN5, SRC-1 and SF-1 interaction on the 
promoter.  Such a complex has been shown to form in yeast cells expressing human 
thyroid hormone receptor, GCN5, and SRC-1 or GRIP-1 (183). The ability of SRC-1 to 
mediate the interaction between GCN5 and SF-1 was tested in mammalian two hybrid 
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Figure 3.3   GCN5 coactivation of SF-1-mediated CYP17 expression requires SRC-1.  Cells were 
transfected as indicated with pCDNA3.1.SF-1 or pCDNA3.1.SF-1ΔLBD with pOZ-N.hGCN5, 
pBKCMV.SRC-1e, and/or pSG5.HA.GRIP-1.  Striped bars: cells were treated 24 hours after transfection 
with 1 mM Bt2cAMP.  Data are from a single experiment performed in triplicate. 
 
experiments in H295R cells.  SRC-1 dose-dependently promotes interaction of GCN5 
with SF-1, and this interaction is potentiated by Bt2cAMP (Figure 3.4A).  Bt2cAMP-
stimulated interaction is decreased by cotreatment with the SF-1 antagonist Sph (Figure 
3.4B), suggesting antagonist dissociation is required for cAMP-dependent SRC-1 
recruitment of GCN5.  GRIP-1 was also able to potentiate interaction of SF-1 with GCN5 
(data not shown), however GRIP-1 coexpression with SRC-1 modestly increased CYP17 
reporter expression only in the absence of Bt2cAMP compared to SRC-1 alone, and 
GRIP-1 alone did not potentiate GCN5 coactivation of this reporter (Figure 3.3, group 7), 
consistent with a different interaction mechanism. 
To determine the specificity of the GCN5/SRC-1 interaction with nuclear 
receptors of the NR5A subfamily, we asked whether a complex forms between GCN5,  
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Figure 3.4  p160 dose-dependent interaction of GCN5 with NR5A receptors is mediated by SRC-1 and 
sensitive to SF-1 antagonist.  
 
 (A) Mammalian two hybrid experiments were performed by transfecting H295R cells with 50 ng pG5 
luciferase reporter, 25 ng pBind-SF-1, 15 ng pAct vector or pAct-GCN5, and SRC-1 using Gene Juice.  
Twenty-four hours after transfection, cells were treated with 1 mM Bt2cAMP and lysates harvested 16 
hours later for dual luciferase assays.  (B) Mammalian two hybrid experiments were carried out as 
described in Materials & Methods.  Transfected cells were treated for 16 hours with 1 mM Bt2cAMP in the 
presence and absence of 1 µM Sph and then lysed for dual luciferase assays.  (C) Cells were transfected for 
30 hours with the two-hybrid plasmids pG5, pAct-GCN5, and pBind-LRH-1, and expression plasmids for 
SRC-1, GRIP-1, or ACTR and harvested for dual luciferase assays.  (D) H295R cells were transfected with 
pG5, pBind-SF-1, pAct-GCN5, pAct-GCN5 E214Q, and pBKCMV-SRC-1, then incubated for 16 hours 
with 1 mM Bt2cAMP.  Lysates were isolated and subjected to dual luciferase assays.  Data presented in all 
panels are normalized to Renilla activity (pAct) and represent the mean +/- SEM from 2 experiments 
performed in triplicate.  Statistically significant difference between transfection with the pAct empty vector 
versus transfection with pAct-GCN5 are denoted as follows: ‡, p<0.05;  ‡ ‡ ‡, p<0.001.  Asterisk denotes 
statistically significant effect of SRC-1 overexpression, where *, p<0.05 and ***, p<0.001. #, p<0.05 or # # 
# p<0.001 denote statistically significant difference compared to pAct-GCN5/pBind-SF-1 transfected cells 
with control treatment.  Ampersand denotes statistically significant difference between untreated and 
Bt2cAMP-treated cells, where &, p<0.01 and &&, p<0.01. Caret (^, p<0.05) denotes statistically significant 
difference between cells transfected with wild type GCN5 versus cells transfected with the GCN5 E214Q 
mutant.  Dollar sign, ($$, p<0.01 and $$$, p<0.001) denotes statistically significant effect of Sph. 
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 SRC-1, and the SF-1 ortholog liver receptor homologue-1 (LRH-1).   We tested for p160-  
mediated interaction of GCN5 with LRH-1 in the mammalian two hybrid system in Jeg3 
cells.  This complex does indeed form and SRC-1, but neither GRIP-1 nor ACTR 
potentiates the LRH-1/GCN5 interaction (Figure 3.4C).  The SF-1 specific antagonist 
Sph has no effect on the LRH-1/GCN5 interaction (data not shown). 
 
3.8 GCN5 Acetyltransferase Activity Limits Interaction with SF-1 
 
We hypothesized that acetylation of SF-1 by GCN5 may be a mechanism that 
ensures the SF-1/p160/GCN5 complex is transient, as observed in the ChIP time course 
(Figures 3.2D, E).  To test this hypothesis, we constructed a GCN5 acetyltransferase 
catalytic site defective mutant E214Q (159) and repeated two hybrid experiments in 
H295R cells.  Interestingly, the formation of the SRC-1/SF-1/GCN5 complex was 
strengthened in the mutant (Figure 3.4D).  These data indicate that GCN5 
acetyltransferase activity may destabilize the transient GCN5/SF-1/SRC-1 interaction, 
and suggest that acetylation of SF-1 may be an underlying mechanism.  Collectively, the 
two hybrid data suggest that acetylation of an unknown target by GCN5 promotes 
dissociation of the GCN5/SRC-1/SF-1 complex. 
 
3.9 Class I HDACs Have Two Roles in Transcription Cycles Mediated by SF-1 
 
There are two major classes of HDACs: class I HDACs (human HDACs 1-3, 8), 
which share sequence homology with the yeast transcriptional repressor Rpd3, and class 
II HDACs (human HDACs 4-7, 9 and 10), which are generally larger and more tissue-
specifically expressed, and were identified by their homology to yeast Hda1 (184).  In 
order to determine which class I HDACs are responsible for the loss of histone 
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 acetylation on the CYP17 promoter (Figure 3.2B), we performed temporal ChIP.  
HDAC8 recruitment occurs within 30 minutes of Bt2cAMP stimulation, while an increase 
in HDAC1 recruitment peaks at 90 minutes (Figure 3.5A).  The former peak coincides 
with early coactivator cooperativity while the latter peak coincides with decreases in Pol 
II occupancy (Figure 3.2B) and a loss of histone H4 acetylation at this time (Figure 
3.2C).  At 120 minutes, when SF-1 binding to the promoter is at a minimum, HDAC2 is 
maximally recruited, and while levels of this HDAC decline during SF-1 recruitment in 
the second transcription cycle, they again wax with loss of SF-1 from the promoter at 210 
minutes (Figure 3.4A).  HDAC3 and HDAC8 modestly increase after 120 minutes until 
210 minutes in the second transcription cycle. 
 
3.10 Corepressor Recruitment Reciprocates SF-1 Loss from the CYP17 Promoter 
 
HDACs are often associated with corepressor complexes brought to the promoter 
by scaffold proteins with repression domains such as NCoR or SMRT, which can bind 
nuclear receptors directly in absence of agonist (185, 186), with dependence on partial 
agonist (187) or antagonist (172), or in the case of RIP140, with agonist dependence 
(188).  Notably, temporal ChIP of these nuclear receptor corepressors shows recruitment 
that reciprocates SF-1 loss from the promoter.  NCoR has modest recruitment at 90 
minutes of stimulation coinciding with HDAC1 recruitment (Figure 3.5B).  RIP140 and 
Sin3A may be members of a repression complex that is recruited to the promoter in the 
relative absence of SF-1 at the 120 minute time point, coinciding with initial recruitment 
of HDAC2.  Taken together, these data indicate that HDAC1 and 2 are recruited within 
NCoR and RIP140/Sin3A corepressor complexes, respectively, and these putative 
complexes bind at the CYP17 promoter during cAMP stimulation without dependence on  
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Figure 3.5  Histone deacetylases (HDACs) and corepressors show promoter binding reciprocal to that of 
SF-1 but compatible with an increase in p54nrb and PSF splicing factors. 
 
(A) Temporal ChIP for coregulator protein binding to the CYP17 promoter was carried out as described                    
         (Legend continues next page) 
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 in Materials and Methods (Chapter 2).  Lysates were immunoprecipitated using antibodies against 
SF-1, HDAC1, HDAC2, HDAC3, and HDAC8.  (B) Time course of corepressor recruitment to the 
CYP17 promoter in response to Bt2cAMP stimulation.  α-Amanitin synchronized H295R cells 
were treated for 30 minutes to 4 hours with 1 mM Bt2cAMP and crosslinked using 1% 
formaldehyde.  Purified lysates containing sheared chromatin were immunoprecipitated using anti-
SF-1, anti-NCoR, anti-Sin3A, anti-RIP140, and anti-SMRT antibodies. (C) Temporal ChIP of 
cAMP-dependent binding of p54nrb and PSF splicing factors, SF-1 and Pol II to the CYP17 
promoter. Temporal ChIP for coregulator protein binding to the CYP17 promoter was carried out 
as described in Materials and Methods.  Lysates were immunoprecipitated with antibodies against 
SF-1, p54nrb, PSF and Pol II.  Data graphed in all panels represent the mean from at least 2 
experiments, each performed in duplicate. Outputs are normalized to delta Ct values obtained for 
1% input controls, and results are presented as percent of delta Ct values for untreated cells at each 
time point. 
 
SF-1.  Moreover, these data confirm our previous findings demonstrating that Sin3A  
 
mediates CYP17 repression (20). 
 
 
3.11 Corepressor Clearance Coincides with p54nrb/PSF Recruitment and Precedes 
SF-1 Recruitment 
 
 We have shown that the interaction of p54nrb and PSF splicing factors with SF-1 
on the CYP17 promoter is stimulated by cAMP (20).  Moreover, PSF has been shown to 
mediate nuclear receptor interactions with Sin3A and associated HDACs (189).  Thus, we 
postulated that these splicing factors may be involved in the dynamics of corepressor-
containing complexes and SF-1.  Unexpectedly, PSF and p54nrb binding increase in a SF-
1 independent manner at 150 minutes (Figure 3.5C).  Initial recruitment of splicing 
factors by 150 minutes reciprocates a loss of corepressors and precedes SF-1 binding in 
cycle II, and also parallels an initial increase in Pol II promoter occupancy at this time 
(Figures 3.2A, 3.5C).  PSF and p54nrb remain associated with the promoter as SF-1 and 
Pol II vacate the promoter for the second time by 240 minutes of Bt2cAMP stimulation.  
These findings in combination with our earlier study (20) establish a time course of 
cAMP-dependent assembly of the p54nrb/PSF/SF-1 complex on the -57/-38 region of the 
CYP17 promoter, and suggest that PSF and p54nrb promote or at minimum are retained 
during clearance of RIP140, Sin3A, and HDAC2 while SF-1 is recruited.  Independent 
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 dynamics of promoter occupancy by p54nrb, PSF, and SF-1 indicate unexpected plasticity 
in their interactions with each other and with promoter DNA and/or other coregulatory 
proteins bound to the CYP17 promoter.  
 
3.12 p54nrb Also Enables Assembly of a HAT/p160 Coactivator Complex 
 
GCN5 and p300 occupancy of the promoter increase before that of SF-1 does in 
the second transcription cycle (Figure 3.2D).  Therefore, we considered the possibility 
that these HATs may be recruited to the cAMP-responsive p54nrb/PSF transcription 
complex and together act to initiate the second cycle of SF-1 mediated transcription.  
We tested for Bt2cAMP-dependent interaction of GCN5 with p54nrb in the mammalian 
two hybrid system in H295R cells.  This interaction does occur, and is potentiated by 
SRC-1 but decreased by PSF (Figure 3.6A). 
 
 
 
 
Figure 3.6  GCN5 interaction with SF-1 can also occur via PSF-sensitive complexes containing p54nrb and 
p160 coactivators. 
 
(A) H295R cells were transfected with pG5, pBind-GCN5, pAct-p54nrb, pBKCMV-SRC-1, and pCR3.1-
PSF using Gene Juice.   After Twenty-four h, transfected cells were treated with 1 mM Bt2cAMP and then 
harvested for quantification of reporter gene activity.  (B) Cells were transfected with pG5, pBind-GCN5, 
and pAct-GRIP-1 in the presence and absence of pCR3.1-p54nrb, pCR3.1-PSF and/or pcDNA3.1-SF-1, 
treated with Bt2cAMP, and then harvested for dual luciferase assays.  Data graphed in both panels are from 
2 experiments performed in triplicate and normalized to Renilla expression from the pAct vector +/- SEM.   
                (Legend continues next page) 
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 Statistically significant difference between cells expressing pAct-p54nrb and cells expressing the pAct 
empty vector is denoted as follows: ‡, p<0.05;  ‡ ‡ ‡, p<0.001.  Asterisk denotes statistically significant 
effect of SRC-1 overexpression (A) and statistically significant effect of SF-1 and p54nrb overexpression 
(B) ***, p<0.001.  Ampersand denotes statistically significant difference between untreated and 
Bt2cAMP-treated cells, where &, p<0.05 and &&, p<0.01. Caret denotes statistically significant effect of 
PSF; ^, p<0.05, and ^^, p<0.01, comparison with same treatment and transfection without PSF. 
 
We next asked whether the interaction between a p160 coactivator specific to 
cycle II and GCN5 is fostered by p54nrb using the two hybrid system to detect p54nrb -
dependent assembly of a p160/GCN5 complex.  A higher order complex among these 
factors and SF-1 would coincide with simultaneous occupancy on the promoter in the 
second SF-1 dependent transcription cycle in ChIP time courses, when p54nrb, GCN5, 
and all three p160 coactivators are enriched (see Figures 3.2D, E, 3.5C).  Modest 
Bt2cAMP-dependent interaction between GCN5 and GRIP-1 is strengthened only when 
both SF-1 and p54nrb are coexpressed (Figure 3.6B).  Like the GCN5/p54nrb interaction, 
this complex is sensitive to PSF.  The kinetics of GCN5 binding coincides additively 
with both p54nrb and SF-1 binding from 120 to 210 minute time points (Figures 3.2D 
and 3.5C).  Together, these data implicate the assembly of a GCN5/p54nrb complex on 
the CYP17 promoter in H295R cells during cycle II before recruitment of p160s and 
SF-1.  SF-1 recruitment between 150 and 180 minutes destabilizes PSF interaction with 
the promoter (Figure 3.5C), and further stabilizes GCN5 and p160 binding in the 
complex. 
 
3.13 CtBP Recruitment Corresponds with Exchange of Transcription Activators 
for Repressors on the CYP17 Promoter 
 
CtBP corepressors were initially identified and characterized due to their ability to 
suppress transformation by the E1A viral oncoprotein (190), and may also have a role in 
cases of myeloid leukemia that involve the AML1/MDS1/EVI1 (AME) fusion 
oncoprotein, both to promote oncogenic cellular replication (191) and to enable 
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 oncogenic transformation (192) via repression of AME-dysregulated genes.  A recent 
report by Zhang et al shows that CtBP1 can repress E cadherin via promoter binding, 
inducing cancer cell migration in response to increases in the nuclear NADH:NAD+ ratio, 
which occurs during acute hypoxia or with chemical manipulation of cellular NADH 
levels (193).   This mechanism requires a DNA targeting factor with CtBP interaction 
motifs, and CtBP is thought to bridge such factors to HDACs (194); thus, this repression 
mechanism is sensitive to deacetylase inhibition. 
It is not established if or how intrinsic CtBP activity is involved in mechanisms of 
trans repression by CtBPs.  CtBP1 and 2 bind NADH and/or NAD+ (165, 195-197).  
Upon binding NADH, CtBPs self-associate (160, 196) and/or associate with E1A (165, 
196).  In the absence of NADH, CtBP1 has intrinsic slow dehydrogenase activity (165, 
196) and can promote or inhibit histone targeting of the HAT p300 (160).  There have 
also been reports of NADH-dependent inhibition of CBP HAT activity (198, 199).  It is 
thought that binding of CtBPs to the acetyl-lysine binding bromodomains of these and 
other HATs, resulting in loss of chromatin targeting of HAT activity in an HDAC-
independent manner, is a second mechanism of CtBP trans repression (160). 
In the monomeric form, CtBP1 binds a signature PxD(L/I)(S/K) motif within the 
p300 bromodomain (BrD) (160, 200).  GCN5 and two of the three p160s have potential 
CtBP binding motifs proximal to a conserved NR box (Figure 3.7A).  Other HATs and 
the CBP-related transcription factor CREB show one or more homologous motifs, while 
in p54nrb and PSF, these motifs are near a conserved aromatic residue (underlined in 
Figure 3.7A) that is required for snRNP binding and targeting of splicing function in the 
closely related factor TAT-SF1 (201).  Although CtBP1 lacks a nuclear localization  
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 A 
Transcription   Domain Demonstrated  
Regulator   Included Interaction with CtBPs 
mGRIP-1  873-PRPGQLGRLLPNQNLPLDITLQSPTGAGPFPPIRNSSPYSVIP (NR4) This study 
hSRC-1  684-TERHKILHRLLQEGSPSDITTLSVEPDKKDSASTSVSVTGQVQ (NR4) 
hACTR  732-KENNALLRYLLDRDDPSDALSKELQPQVEGVDNKMSQCTSSTI (NR4) 
hGCN5  396-VKKSEAPDYYEVIRFPIDLKTMTERLRSRYYVTRKLFVADLQR (BrD) (199), This study 
hP/CAF  752-VKRTEAPGYYEVIRFPMDLKTMSERLKNRYYVSKKLFMADLQR (BrD) (199) 
mCBP  295-QLASKQSMVNSLPAFPTDIKNTSVTTVPNMSQLQTSVGIVPTQ  (199), (198) 
 1118-PQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWL (BrD)  
h p300  979-EAKMEVDQPEPADTQPEDISESKVEDCKMESTETEERSTELKT  (199) 
 1081-PQLLGIPDYFDIVKSPMDLSTIKRKLDTGQYQEPWQYVDDIWL (BrD) (160) 
hCREB   296-QLASKQSMVNSLPTFPTDIKNTSVTNVPNMSQMQTSVGIVPTQ  This study, with TSA 
 1117-PQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWL   
hSMRT  945-LTPTGDPRANASPQKPLDLKQLKQRAAAIPPIQVTKVHEPPRE 
hNCoR1 1267-SIKQGLICRALPRGSPHSDLKERTVLSGSIMQGTPRATAESFE 
RIP140  425-TDDSSGDESSYSNCVPIDLSCKHGTEKSESDQPVSLDNFTQSL  (204), (200) 
  550-PVSTPPLLTSSKAGSPINLSQHSLVIKWNSPPYVCSTQSEKLT  (204) 
PSF  290-EKTYTQRCRLFVGNLPADITEDEFKRLFAKYGEPGEVFINKGK (SplFn) 
p54nrb   67-EKTFTQRSRLFVGNLPPDITEEEMRKLFEKYGKAGEVFIHKDK (SplFn) Not detected with CtBP1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7  CtBP dehydrogenases disrupt cycles of cAMP-dependent SF-1 mediated transcription of the 
CYP17 gene via multiple interactions with coregulators.                              (Legend continues next page) 
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 sequence, CtBP1-mediated repression is modulated by factors that facilitate nuclear 
localization of the corepressor (202) in concurrence with that of SR family splicing 
factors, of which PSF and p54nrb are members (203). 
In order to determine whether CtBPs interact with coregulators involved in cAMP 
responsiveness and CYP17 transcription, we performed mammalian two hybrid 
experiments. CtBP1 interacts with GRIP-1 (Figure 3.7B) and GCN5 (Figure 3.7C).  
Similar positive interactions were detected in both Jeg3 and H295R cells (data not 
shown).  We next determined the effect of mutating the NADH binding site, as done by 
Kim et al (160), on the ability of CtBP1 to interact with GCN5.  These experiments 
showed a greater degree of interaction of GCN5 with the CtBP1 dimerization deficient, 
NADH-binding site mutant when compared to wild type CtBP1 (Figure 3.7D).  This 
finding suggests a role for GCN5 binding to CtBP1 in the disruption of CtBP 
oligomerization. 
 Because CtBP1 interacts with a number of factors involved in regulation of 
CYP17 transcription, we next asked whether CtBPs interact with SF-1.  We found that 
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 (A) Alignment of binding motifs in coregulatory proteins.  Interactions that have been experimentally 
confirmed are cited.  Underlined residues:  NR4, the fourth nuclear receptor box interaction motif in these 
p160 coregulators; BrD, conserved acetyl-lysine binding bromodomain residues; SplFn, a conserved 
aromatic residue that is important for the splicing activity of Tat-SF-1, a homologous SR family splicing 
factor (201).  (B-E) Cells were transfected with pG5 and (B) pBind-CtBP1 and pAct-GRIP-1, (C) pBind-
GCN5 and pAct-CtBP1, (D) pBind-GCN5 and pAct-CtBP1 or pAct-CtBP1 G183V, (E) pBind-SF-1 and 
pAct-CtBP1 or pAct-CtBP1 G183V and then treated with 1 mM Bt2cAMP.  Reporter gene activity was 
quantified from cell lysates using dual luciferase assays. Open bars are untreated controls and striped bars 
are treated with 1 mM Bt2cAMP.  Graphed data (panels B-E) represent the mean +/- SEM and are from 2 
experiments performed in triplicate.  Statistically significant difference between cells transfected with 
pAct empty vector versus cells transfected with pAct-GRIP-1 (B) or pAct-CtBP1 (C and E) are denoted 
by ‡, p<0.05 or ‡ ‡ ‡, p<0.001.  Ampersand denotes statistically significant difference between untreated 
and Bt2cAMP-treated cells, where &&, p<0.01 and &&&, p<0.001.  Carets denote statistically significant 
difference between cells expressing wild type CtBP1 versus cells expressing the CtBP1 G183V mutant; 
^^, p<0.01; ^^^, p<0.001.  (F) H295R cells were synchronized for 2 hours with 2.5 M α-amanitin, then 
treated with 1 mM Bt2cAMP for the indicated times and subjected to ChIP using antibodies against SF-1, 
CtBP1, or CtBP2. Outputs are normalized to delta Ct values obtained for 1% input controls, and results 
are presented as percent of delta Ct values for untreated cells at the corresponding time point.  Data 
graphed represents the mean from 2 experiments performed in duplicate. 
 SF-1 interacts with CtBP1, and the interaction signal was weaker in the G183V NADH- 
binding mutant (Figure 3.7E).  Bt2cAMP weakened the interaction of SF-1 with G183V 
CtBP but not wild type CtBP1.  This data suggests that both the NADH-sensitive 
oligomerization of CtBP1 and Bt2cAMP stimulation can affect recruitment of the 
repressor to SF-1-containing complexes.  
To clarify the role of CtBPs in CYP17 transcriptional activation in the context of 
other coregulator interactions on this promoter, we repeated temporal ChIP on the CYP17 
promoter for CtBP1 and 2.  Acute CtBP2 binding between 30 and 60 minutes (Figure 
3.7F) coincides with loss of GCN5 and SRC-1 (cf. Figures 3.2D and E), while loss by 90 
minutes is concurrent with loss of SF-1 promoter occupancy.  CtBP1 also binds to the 
promoter rapidly between the 180 and 210 minute time points (Figure 3.7F), 
corresponding with dissociation of the GCN5/p54nrb/SF-1/p160 complex from the 
promoter (cf. Figures 3,2D, E, 3.5C, and 3.6). 
 
3.14 CtBP1 Alters cAMP Dependent Activation of CYP17 and Basal Interactions 
among SF-1, GCN5, and SRC-1 
 
To assess the ability of CtBPs to regulate CYP17 transcription, we performed 
cotransfections of CtBP1 and other functional coregulators with SF-1 or LRH-1 
and a luciferase reporter with a promoter containing two copies of the CYP17 SF-
1 recognition motif (-57/-37 element) (Figure 3.8A).  Wild type CtBP1 expression 
in H295R cells lowered basal (compare sets 1 and 2) and SF-1-dependent CYP17 
expression (sets 3 and 4), but not LRH-1 dependent expression (sets 6 and 7) with 
or without Bt2cAMP treatment and this repression requires the SF-1 AF-2 
hexamer (sets 4 and 5).  CtBP1 therefore has coregulator function in CYP17 
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 transcription independent of CtBP2, corresponding with increases in promoter 
occupancy by CtBP1 after 90 minutes of Bt2cAMP stimulation (Figure 3.7F).  In 
light of the above results that GCN5 and GRIP-1 interact with CtBP1, and the 
findings of others demonstrating that GCN5 coimmunoprecipitates with CtBP1 
(199), we asked whether SRC-1 coactivator function is also altered by CtBPs.  
Therefore, we tested whether wild type CtBP1 disrupts the GCN5/SRC-1/SF-1 
interaction in the two hybrid system in H295R cells, but found that CtBP1 
overexpression had a stabilizing effect on the trimer (Figure 3.8B).  On the other 
hand, CtBP1 decreased the stability of the acetyltransferase deficient 
Figure 3.8  cAMP- and NADH-dependent CtBP1 modulation of GCN5/SRC-1 cooperativity. 
(A) Cells were transfected with 250 ng pGL3-CYP17 2x57, pcDNA3.1-SF-1, pcDNA3.1-SF1DAF2 
mutant, pCI-LRH1, and/or pRC-CMV-CtBP1, stimulated with Bt2cAMP, and then harvested for dual 
luciferase assays. (B) Mammalian two-hybrid assays were performed as described in Materials and 
Methods by transfecting cells with pBind-SF-1, pAct-GCN5, pAct-GCN5 E214Q, pBKCMV-SRC-1, 
and/or pRC-CMV-CtBP1, then incubated with 1 mM Bt2cAMP for 16 hours.  Interaction was quantified 
using dual luciferase assays. In both panels A and B, open bars represent untreated control and striped bars 
Bt2cAMP treatment.  Graphed data represent the mean +/- SEM and are from 2 experiments performed in 
triplicate.  In panel A, daggers denote statistically significant effect of overexpressed vectors; p<0.01. ‡ ‡ ‡, 
p<0.001.  Statistically significant effects of CtBP1 overexpression are denoted by $$; p<0.01.  Ampersand 
(&&&, p<0.001) indicates statistically significant effect of SF-1 AF-2 deletion.  Asterisks denote 
statistically significant differences between cells transfected with only pBind-SF-1 and pAct-GCN5 
compared to groups also overexpressing SRC-1 and CtBP1; *, p<0.05 or ***, p<0.001. 
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 GCN5 E214Q/SRC-1/SF-1 complex in the absence of Bt2cAMP (Figure 3.8B).   
 
3.15 Chromatin Remodeling Occurs before and after Pol II Interaction with the 
CYP17 Promoter 
 
Studies characterizing cyclical ER-α binding to the pS2 promoter have linked 
ATP dependent chromatin remodeling to 1) time points immediately following receptor 
binding and 2) temporary repressive chromatin structure between cycles of ligand-bound 
ER-α interaction with the promoter (87).  To determine if ATP dependent chromatin 
remodelers act as “gatekeepers” of promoter accessibility for SF-1-mediated Pol II 
recruitment, we examined a panel of three chromatin remodeling complex ATPase 
subunits in assays of temporal CYP17 promoter binding.  We found that the Brahma-
related gene 1 (BRG1) ATPase, a member of some SWI/SNF remodeling complexes, is 
associated with the promoter 30 minutes before peak SF-1 binding in cycle I, and the 
sucrose non-fermenting 2 (SNF2) component of the imitation SWI or ISWI complex 
binds early in cycle II (Figure 3.9A).  As SF-1 binding peaks during this cycle, Brahma1 
(Brm) ATPase exchanges for the BRG1 ATPase.  This Brm binding coincides with 
increased H4 acetylation (Figure 3.2C).  These data suggest that proximal CYP17 
promoter chromatin structure is made permissive to Pol II binding and possibly 
transcription early in transcription cycle I by a SWI/SNF remodeling complex containing 
BRG1.  Additional remodeling by ISWI occurs early in cycle II, reestablishing 
permissive conditions for PSF and p54 binding before chromatin is further remodeled by 
SWI/SNF complexes, concomitant with SF-1 and Pol II binding. 
Each nucleosome is composed of a core tetramer and two histone H2A/H2B  
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Figure 3.9  Chromatin remodeling ATPase recruitment is part of SF-1-dependent CYP17 transcription 
cycles and coincides with rapid loss and gain of histone H2 from promoter nucleosomes. 
    A 
B 
 
(A) Temporal ChIP of chromatin remodeling ATPases on the CYP17 promoter and transcription start site 
was performed.  Lysates were immunoprecipitated with antibodies against SF-1, BRG1, Brm1, and SNF2 
and purified DNA subjected to real time PCR using primers that amplified the -104/+43 region of the 
CYP17 promoter.  (B) Temporal ChIP analysis of Bt2cAMP-stimulated SF-1 and histone H2B binding to 
the CYP17 promoter.  Sheared chromatin isolated from cells treated for 30 minutes to 4 hours was 
immunoprecipitated with antibodies against SF-1 or histone H2B.  Output data are normalized to delta Ct 
values obtained for 1% input controls, and results are presented as percent of baseline value obtained for 
untreated cells at each time point. 
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dimers, which may have a role in stabilizing DNA-nucleosome interaction in inactive 
chromatin.  ATP dependent chromatin remodeling complexes have been shown to 
exchange histone H2 dimers between nucleosomes on different short chromatin templates 
in vitro, and it is thought that removal of these dimers disfavors higher order chromatin 
packing of heterochromatin (104).  We asked whether changes in the composition of 
histone H2 dimers in nucleosomes coincide with remodeling by DNA-interacting 
ATPases in vivo.   Performing temporal ChIP for histone H2B occupancy of the same 
promoter region, we discovered that BRG1 SWI/SNF ATPase recruitment correlates with 
strong depletion of H2B within 30 minutes of Bt2cAMP stimulation (compare Figures 
3.9A and B), which is evidence that H2A/H2B dimers are disrupted during cAMP-
dependent CYP17 activation.  On the other hand, SNF2H recruitment corresponds with 
strong enrichment of H2B at the beginning of cycle II, followed within 30 minutes by 
Brm SWI/SNF ATPase binding and a subsequent return to histone H2 depletion.  Thus, 
we postulate that SWI/SNF ATPases transfer H2B in H2A/H2B dimers to chaperones, or 
are otherwise exchanged from the nucleosome(s) at the proximal promoter of CYP17 
during cAMP-dependent transcription. 
 
3.16 Activating Histone Lysine Methyltransferases are Targeted to the CYP17 
Promoter in Response to Bt2cAMP 
 
Another class of histone modifications that regulate transcription is the 
methylation of histone H3 and histone H4 lysine or arginine residues [for a review, see 
(205)]. Histone monomethylation at K20 on the N terminal tail of histone H4 correlates 
with hyperacetylation of this tail in transcriptionally competent chromatin; trimethylation  
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Figure 3.10  Histone lysine methyltransferases are recruited to the CYP17 promoter during SF-1-
dependent cycles of transcription. 
 
α-Amanitin synchronized H295R cells were treated for time periods ranging from 30 minutes to 4 
hours with 1 mM Bt2cAMP, exposed to 1% formaldehyde and the purified lysates 
immunoprecipitated using anti-SF-1, anti-trimethylated (K4) histone H3, anti-monomethylated 
(K20) histone H4, or anti-trimethylated (K20) histone.  Output data are normalized to values 
obtained for 1% input controls, and results are presented as percent of baseline value obtained for 
untreated cells at each time point. Data graphed represents the mean from 2 experiments 
performed in duplicate. 
 
at this site represses transcription (206).  On the other hand, H3 K4 trimethylation in 
yeast is required for ATP-dependent chromatin remodeling by Isw1p ATPase and 
correlates with recruitment of a factor involved in mRNA maturation (207). 
Using temporal ChIP, we assayed for these Bt2cAMP stimulated changes in 
histone lysine methylation at the CYP17 promoter.  Histone H4 K20 monomethylation is 
upregulated as SF-1 occupancy peaks at 60 and 180 minutes, as well as at 120 minutes 
(Figure 3.10); all three peaks correlate with histone H4 hyperacetylation (cf. Figure 
3.2C).  Repression-associated trimethylation at this site is not upregulated during the first 
four hours of Bt2cAMP stimulation.  Trimethylation at histone H3 K4 occurs transiently 
during cycle I and also appears to be upregulated between 210 and 240 minutes of 
treatment (Figure 3.10); the initial event does in fact precede recruitment of splicing 
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 factors by at least 60 minutes (cf. Figure 3.5C).  Of the panel of ATPases examined in 
temporal ChIP assays (Figure 3.9A), only SNF2H, a mammalian homolog of yeast 
Isw1p, interacts with the promoter during the interval between histone H3 K4 
trimethylation at 60 minutes and upregulation of p54nrb and PSF recruitment between 120 
and 180 minutes (cf. Figures 3.5C, 3.9A, and 3.10).  Thus, our data are consistent with 
roles for at least two histone lysine methylation events already established to correlate 
with (1) promoter histone H4 acetylation and transcriptional competence, i.e. 
monomethylated histone H4 K20, and (2) histone H3 K4 trimethylation, associated with 
subsequent ISWI chromatin remodeling, and then recruitment of factors with roles in 
RNA maturation, a pattern seen in both yeast (207) and in human adrenocortical cells. 
 
3.17 Sph Modulates SF-1-Mediated Transcription Cycles 
 
The SF-1 antagonist Sph decreases Bt2cAMP-dependent transcription of CYP17 
in H295R cells (Figure 3.11A), in line with Sph-mediated disruption of SF-1/SRC-
1/GCN5 cooperativity (Figure 3.4C).  In order to examine the effect of Sph on SF-1-
mediated transcriptional cycling, we repeated synchronized temporal ChIP experiments 
with 5µM Sph treatment.  In the absence of Bt2cAMP, SF-1 in Sph-treated cells 
associated with the CYP17 promoter within 30 minutes of treatment and again increased 
after three hours with a longer delay between increases in binding compared to 
Bt2cAMP-stimulated cycling, and with muted amplitude or binding rate (Figure 3.11B).  
Sph strongly attenuated the ability of Bt2cAMP to initiate the binding of SF-1 to the 
CYP17 promoter in cycle I (Figure 3.11B).  SF-1 recruitment during cycle II was 
relatively unaffected by the antagonist, indicating significant cAMP-dependent release of  
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Figure 3.11  cAMP-stimulated CYP17 mRNA expression and cycles of SF-1-mediated promoter binding 
to the CYP17 promoter are antagonized by Sph. 
 
(A) H295R cells treated with 1 mM Bt2cAMP and/or 1 µM Sph for time periods ranging from 1 hour to 12 
hours.  Total RNA was isolated and subjected to quantitative RT-PCR.   Data graphed are expressed as fold 
change compared to untreated controls and represent the mean +/- SEM of CYP17 mRNA expression 
normalized to the cellular α-actin mRNA content from four experiments performed in triplicate.  (B) α-
Amanitin synchronized H295R cells were treated for time periods ranging from 30 minutes to 4 hours with 
1 mM Bt2cAMP and/or 1 µM Sph, exposed to 1% formaldehyde and the purified lysates 
immunoprecipitated using a polyclonal antibody against SF-1.  Data graphed in all panels represent the 
mean from 3 experiments, each performed in duplicate. Outputs are normalized to delta Ct values obtained 
for 1% input controls, and results are presented as percent of untreated control delta Ct values at each time 
point. 
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 Sph from SF-1 within three hours, consistent with previous results (172). 
In this chapter, we have defined the sequence and cooperativity of various classes 
of chromatin modifying coregulators of CYP17 transcription, including HATs, HDACs, 
ATP-dependent chromatin remodelers, multifunctional RNA and DNA binding splicing 
factors, and finally, bridging-type coregulators, which appear to include the 
multifunctional coregulators of the p160 steroid receptor coactivator family, CtBP 
corepressors, and p54.  Since the transcription of CYP17 in the adrenal cortex cell line 
examined is absolutely dependent upon cAMP stimulation and PKA (references reviewed 
in (16)), many of these coregulators are candidate effectors of cAMP and PKA in this 
context, as are the dynamic chromatin marks they leave in the wake of their productive 
interactions on DNA and nucleosome(s).  Finally, the presence of SF-1 agonist, Sph, is 
overcome by cAMP after three or more hours, enabling transcription (Figure 3.11).  This 
is consistent with opposing abilities of cAMP and Sph to strengthen or weaken 
interaction among members of an early cAMP-stimulated, dynamic SF-1 coactivator 
complex comprised of SF-1, SRC-1, and GCN5 (Figure 3.4). 
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 Chapter 4.  Results—Part II:  Post-Translational Modification of 
Steroidogenic Factor-1 Regulates Periodic Cycles of CYP17 
Transcription 
 
4.1 CKII and GSK3ß Phosphorylate SF-1 in Vitro 
We hypothesized that there may be kinase targets near the entryway to the ligand 
binding pocket of SF-1 and that phosphorylation here regulates receptor-mediated 
induction of transcription.  In order to identify kinases capable of phosphorylating the 
receptor, we carried out in vitro kinase assays using purified SF-1 and either recombinant 
PKA catalytic subunit, CKI, CK2, GSK3ß, or ERK.  As previously found (208), 
incubating the immobilized receptor with the catalytic subunit of PKA had no effect on 
the amount of radiolabeled phosphate associated with SF-1 (Figure 4.1A).  In contrast to 
previous studies by Hammer et al. demonstrating that SF-1 is an ERK target (209), we 
were unable to detect phosphorylation of the receptor by ERK2 in this assay.  However, 
both CK2 and GSK3ß phosphorylated the receptor (Figure 4.1A).  CK2 targets serine or 
threonine residues in a S/TxxE motif whereas GSK3ß targets SxxxS motifs.  Moreover, 
the ability of GSK3ß to phosphorylate these S/TxxxS/T motifs is significantly enhanced 
by the presence of “priming” phosphorylation in the +4 position (210-213).  In silico 
analysis of SF-1 revealed T334, T338, S342, and S346 as potential GSK3ß targets (bold 
letters, Figure 4.1B).  Within this region, T335 is a putative CK2 phosphorylation site 
(boxed). Although the ability of GSK3ß to phosphorylate SF-1 was unaffected by the 
T335A mutation (data not shown), this mutation rendered CK2 unable to phosphorylate 
the receptor (Figure 4.1C).  Mutation of S342 decreased activity of GSK3ß towards SF-1 
(Figure 4.1C), indicating that GSK3ß targets this residue. 
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 Figure 4.1  CK2 and GSK3ß phosphorylate SF-1. 
 
A.  His-tagged SF-1 was incubated with 32P-γATP, the catalytic subunit of PKA, recombinant CK1, CK2, 
GSK3ß, or ERK2 for 30 minutes at 30°C.  The reactions were terminated and subjected to SDS-PAGE and 
radiolabeled SF-1 was detected by phosphorimager scanning.  B. Amino acid sequence of region 334-346 
in human SF-1.  Putative CK2 phosphorylation site at T-335 is boxed and bold lettering indicates putative 
GSK3ß phosphorylation sites.  C. In vitro kinase assays were carried out using WT or mutant receptor, 32P-
γATP, and CK2 or GSK3ß.  D. Jeg3 cells were transfected with pGL3-CYP17-2x57, pRL-TK, and WT or 
mutant pCMVTag1-SF1 for 24 hours and then treated for 16 hours with 1 mM Bt2cAMP.  Data graphed 
represents the fold change in Firefly luciferase (pGL3-CYP17-2x57) activity over Renilla luciferase (pRL-
TK) activity and represents the mean ± SEM of 3 experiments, each performed in triplicate.  *, 
Significantly different from untreated WT, #, significantly different from Bt2cAMP-treated WT, p < 0.05.  
E.  Representative gel of samples obtained from H295R cells that were transfected with WT or mutant 
FLAG-tagged receptor for 48 hours and then incubated in phosphate-free DMEM containing 32P-
phosphorus for 4 hours.  Lysates were immunoprecipiated with anti-FLAG antibody and the immobilized 
receptors subjected to SDS-PAGE, coomassie staining, and phosphorimager scanning.  Parallel 
transfections were carried out and nonradiolabeled lysates separated by SDS-PAGE.  Proteins were 
transferred to PVDF membranes and western blots incubated with a rabbit polyclonal SF-1 antibody.                    
              (Legend continues next page) 
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 We next mutated phosphorylation sites in the GSK3ß-motif-rich region of SF-1 (Figure 
4.1D), generating alanine mutants of T334, T335, T338, S342, and S346 and determined 
the effects of mutation on the transactivation potential of the receptor.  A reporter gene 
plasmid containing two copies of the SF-1 binding site of the human CYP17 promoter 
fused to luciferase (pGL3-CYP17-2x57) was transfected into Jeg3 cells because they lack 
endogenous SF-1 and then treated for 16 hours with 1 mM Bt2cAMP.  Mutation of S342 
increased both basal and Bt2cAMP-stimulated luciferase activity (Figure 4.1D), 
suggesting that phosphorylation of S342 regulates SF-1 binding of the CYP17 promoter, 
and/or interaction with coregulator proteins.  Interestingly, mutation of S346A also 
exhibited higher transactivation activity in unstimulated cells.  Moreover, while T335A 
had no significant effect on luciferase activity in untreated cells, Bt2cAMP-dependent 
activity of these mutant receptors was significantly higher than WT. 
   To determine the effect of the mutations on the phosphorylation status of the 
endogenous receptor, we carried out metabolic labeling on H295R cells that were 
transiently transfected with WT or mutant SF-1 and then incubated in media containing 
32P-phosphorus.  As shown in Figure 4.1E (graphed in Figure 4.1F), mutation of T335, 
T338, and S342 resulted in significant decreases in the amount of radiolabeled phosphate 
 
F.  Graphical analysis of data generated from metabolic labeling of WT and mutant FLAG-tagged SF-1.  
Data represent the mean and standard deviation of two separate experiments, each carried out in duplicate.  
Densities of 32P-labeled bands quantified from phosphorimager scanning are divided by densities of SF-1 
protein imaged by western blotting and fluorometric scanning.  G.  Cells (150 mm dishes) were incubated 
in DMEM media containing 80 μCi/ml 32P-phosphorus for 2 h, pretreated with 10 mM LiCl for 15 minutes 
(lanes 3 and 4)  and then treated for 1 hour with 0.4 mM Bt2cAMP (lanes 2 and 3).  Isolated lysates were 
immunoprecipitated with anti-SF-1 and the purified receptor resolved by SDS-PAGE.  A fraction (5%) of 
lysates was subjected to SDS-PAGE and western blotting for SF-1.  H.  H295R cells were treated with 0.4 
mM Bt2cAMP and/or 20 mM LiCl for 1 hour and total cell lysates isolated for SDS-PAGE and western 
blotting.  PVDF membranes were incubated with anti-pS33 ß-catenin (top) or anti-SF-1 (bottom) and 
expression detected by fluorescence scanning.  I.  CV-1 cells were transfected with WT or mutant FLAG-
tagged receptor for 48 hours and lysates isolated for SDS-PAGE and western blotting using antibodies that 
recognize double phospho-Ser33/Ser37 ß-catenin (top) or FLAG (bottom). 
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 incorporated into the receptor, with S342A exhibiting the greatest decrease in 
phosphorylation when compared to WT.  We also carried out metabolic labeling studies 
to examine the effect of Bt2cAMP and the GSK3ß inhibitor LiCl (214, 215) on the levels 
of phosphorylated endogenous SF-1.  Stimulation with Bt2cAMP for 1 hour increased the 
cellular content of radiolabeled SF-1 and incubation with LiCl significantly reduced this 
increase (Figure 4.1G).  The presence of radiolabeled receptor in untreated cells indicates 
that the receptor is phosphorylated and suggests that the endogenous receptor is 
phosphorylated at multiple sites, possibly by multiple kinases, such as CDK7 (216). 
 Finally, because the region between T334 and T346 (Figure 4.1B) contains 
multiple putative GSK3ß phosphorylation sites, we used antibodies raised against the 
established GSK3ß target ß-catenin phosphorylated at S33 (pS33) or against ß-catenin 
phosphorylated at both S33 and S37 (pS33pS37) to assess the effect of mutations on the 
level of phosphorylated receptor.  First, we determined if the phospho-specific ß-catenin 
antibodies could detect phosphorylated SF-1 by treating H295R cells with Bt2cAMP and 
LiCl for 1 hour.  Western blotting found that the p33 ß-catenin antibody detected 
phosphorylated forms of both endogenous ß-catenin and SF-1 (Figure 4.1H).  Although 
Bt2cAMP had no significant effect on the amount of pS33 ß-catenin (top arrow) in the 
H295R cells, it increased the levels of phosphorylated SF-1 (bottom arrow).  These 
findings are consistent with metabolic labeling studies shown in Figure 4.1G.  As 
predicted, incubation with LiCl prevented detection of phosphorylated ß-catenin (top 
arrow) and attenuated the Bt2cAMP-stimulated increase in phosphorylated SF-1 (bottom 
arrow).  Similar findings were obtained when using an antibody raised against ß-catenin 
phosphorylated at both S33 and S37 (data not shown).  To further examine the effect of 
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 mutations on the phosphorylation status of SF-1, we transfected CV-1 cells with WT or 
mutant FLAG-tagged SF-1 and analyzed the cell lysates by western blotting using anti-
pS33pS37 ß-catenin or anti-FLAG antibodies.  Mutation of T338 and S342 rendered the 
antibody unable to detect phosphorylated SF-1 (Figure 4.1I), further supporting a role for 
GSK3ß in phosphorylating the receptor.  Probing western blots with the p33 ß-catenin 
antibody showed a similar decrease in the detection of the S342A mutant (data not 
shown). 
 
4.2 SF-1 interacts with CK2 and GSK3ß 
 To further characterize the role of CK2 and GSK3ß in modulating SF-1 function, 
we next assessed the subcellular localization of the two kinases in nuclear and 
cytoplasmic extracts isolated from H295R cells treated for 5 to 30 minutes with  
 
 
 
 
 
 
 
 
Figure 4.2  Nuclear translocation of GSK3ß and interaction of SF-1 with CK2 and GSK3ß. 
 
A.  H295R cells were treated with 0.4 mM Bt2cAMP for 5-, 15-, or 30 minutes and nuclear and cytoplasmic 
fractions isolated for SDS-PAGE and western blotting.  Blots were hybridized to anti-CK2 or anti-GSK3ß 
antibodies.  B.  H295R cells (150 mm dishes) were treated for 1 hour with 0.4 mM Bt2cAMP and lysates 
subjected to immunoprecipitation with anti-SF-1 antibody and protein A/G.  The immobilized proteins 
were separated by SDS-PAGE and transferred to PVDF membranes for western blotting.  Blots were 
probed with antibodies directed against CK2 (top) and GSK3b (middle). A fraction (5%) of input lysates 
was subjected to SDS-PAGE and western blotting for SF-1 (bottom). 
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Bt2cAMP.  Intriguingly, cAMP stimulation promoted the nuclear translocation of GSK3ß 
(Figure 4.2A).  We also detected interactions between SF-1 and both kinases in H295R 
cells (Figure 4.2B). 
 
4.3 Effect of LiCl and TBB on Complex Formation and CYP17 mRNA 
Expression 
 
 We next determined the effects of inhibiting the catalytic activity of GSK3ß on 
cAMP-stimulated recruitment of GCN5, SF-1, SRC-1, and Pol II to the CYP17 promoter 
by carrying out ChIP assays.  Synchronized populations of cells were treated for 1 hour 
with 1 mM Bt2cAMP and/or 20 mM LiCl and the isolated chromatin immunoprecipitated 
as previously described (217).  As previously shown (217), Bt2cAMP increased the 
binding of SF-1, GCN5, SRC-1, and Pol II to the promoter (Figure 4.3A).  Although LiCl 
treatment alone increased the binding of GCN5 and SF-1 to the CYP17 promoter, it 
prevented Bt2cAMP-stimulated association of these proteins with the CYP17 gene, 
suggesting that activated signaling through the ACTH/cAMP pathway requires GSK3ß 
activity to promote increased transcription.  Indeed, inhibiting GSK3ß completely 
inhibited the ability of Bt2cAMP to induce the expression of CYP17 mRNA (Figure 
4.3B).  Inhibition of CK2 activity using TBB (218, 219) also dose-dependently attenuated 
Bt2cAMP-stimulated CYP17 mRNA expression (Figure 4.3C), indicating that 
phosphorylation of the receptor by these two kinases is critical for attaining maximal 
CYP17 transcription in response to ACTH/cAMP signaling.  The inhibitory effect of 
chemical CK2 and GSK3ß inhibitors on cAMP-dependent CYP17 mRNA expression was 
mirrored by siRNA oligonucleotides directed against the kinases (Figure 4.3D), which  
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 Figure 4.3  Effect of LiCl and TBB on CYP17 transcription.  
  
A.  Cells were synchronized by treatment with 2.5 μM α-amanitin for 2 hours and then treated with 1 mM 
Bt2cAMP and/or 10 mM LiCl for 1 hour.  Cross-linking was carried out by exposing cells to 1% 
formaldehyde and chromatin lysates isolated for immunoprecipitation using antibodies to GCN-5, SF-1, 
Pol II, and SRC-1. Cross-links were reversed and DNA purified for analysis by real time PCR and gel 
electrophoresis.  Lane 1, control; lane 2, Bt2cAMP; lane 3, Bt2cAMP + LiCl; lane 4, LiCl.  B.  Total RNA 
was extracted from cells that were treated for 16 hours with Bt2cAMP and LiCl (panel B) or TBB (panel 
C).  CYP17 mRNA expression was quantified by real time RT-PCR and normalized to the mRNA content 
of the ß-actin gene.  Data is graphed as fold change in the expression of CYP17 in treated cells when 
compared to the mRNA expression in untreated control cells and represent the mean ± SEM of 4 
experiments, each performed in triplicate.  D.  H295R cells were transfected with 50 nM CK2 or GSK3ß 
siRNA oligonucleotides and 72 hours later harvested for analysis by SDS-PAGE and western blotting.  
Blots were incubated with anti-CK2 (left) or anti-GSK3ß (right) antibodies.  E.  CYP17 mRNA expression 
was quantified in RNA isolated from cells that were transfected with siRNA oligonucleotides directed 
against CK2 or GSK3ß.  Some cells were treated with 0.4 mM Bt2cAMP 16 hours prior to RNA isolation 
(72 hours total incubation time).  Data graphed represent the mean ± SEM of 3 experiments, each 
performed in either triplicate or quadruplicate and is expressed as fold change in CYP17 mRNA expression 
over control group mean, normalized to actin mRNA content. 
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also attenuated the stimulatory effect of Bt2cAMP on CYP17 mRNA transcription 
(Figure 4.3E).   
 
4.4 Phosphorylation of S342 Modulates the Association of SF-1 with the CYP17 
Promoter 
 
 The function of GSK3ß-catalyzed phosphorylation of SF-1 in DNA binding was 
further probed by performing ChIP assays on FLAG-tagged WT or S342A mutant 
receptor from the chromatin lysates of transiently transfected H295R cells.  Primers for 
ChIP of the CYP17 promoter were designed so that the SF-1 binding site (-57/-37) would 
be centrally located within approximately a single nucleosome (220), with regions near 
the 5’ and 3’ ends coinciding with the predicted cis-encoded nucleosome positioning 
code described by Segal, et al (221).  We found that Bt2cAMP increased the binding of 
WT receptor to the CYP17 promoter by 4.9-fold (Figure 4A).  Interestingly, the S342A 
mutant exhibited a 5.3-fold increase in receptor bound to the CYP17 promoter in 
unstimulated cells, consistent with transcriptional stalling and supporting the hypothesis 
that S342 phosphorylation promotes dissociation of SF-1 from the promoter and 
accelerated transcription by potentiating subsequent cycles of transcription.  Both WT 
and S342A mutant FLAG-tagged receptor were expressed at comparable levels (data not 
shown).  
 We next asked if the kinetics of the interaction between the CYP17 promoter and 
S342 mutant SF-1 in response to Bt2cAMP is altered by carrying out temporal ChIP 
assays of the same CYP17 promoter segment.  Our previous studies demonstrated that 
SF-1 cycles on and off the CYP17 promoter in ~60 minute cycles, with GCN5 
recruitment occurring early in each cycle (217).  As previously shown (217), 60 minutes  
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Figure 4.4  Phosphorylation modulates SF-1 interactions with the CYP17 promoter. 
 
A. Cells were transfected with WT or  S342A mutant SF-1 and treated for 1 hour with 1 mM Bt2cAMP.  
Proteins were cross-linked to DNA by incubation in 1% formaldehyde and the purified, sheared chromatin 
lysates sonicated immunoprecipitated with an anti-FLAG antibody.  Cross-links were reversed and DNA 
purified for analysis by real time PCR and gel electrophoresis.  B.  Cells transfected with WT or mutant 
(S342A or S342D) pCMVTag1-SF-1. Forty-eight hours after transfection, cells were synchronized by 
incubation for 2 hours with α-amanitin and then treated for time periods ranging from 30 minutes to 4 
hours with 1 mM Bt2cAMP.  Cells were exposed to 1% formaldehyde and the purified, sheared chromatin 
solutions immunoprecipitated using an anti-FLAG antibody.  Output data are normalized to ∆-Ct values 
obtained for input samples and the results are graphed as fold change in Bt2cAMP-stimulated binding of   
              (Legend continues next page) 
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 WT or S342D mutant receptor to the CYP17 promoter, where 100% represents promoter occupancy in 
untreated control cells at the zero time point.  Data graphed represents the mean from 2 experiments 
performed in duplicate.  C.  α-Amanitin-synchronized cells were incubated with 1 mM Bt2cAMP and 25 
nM OA for 30- to 240-min and then incubated in 1% formaldehyde.  Cell lysates were isolated, sonicated 
and immunoprecipitated with an anti-SF-1 antibody.  Cross-links were reversed and the purified DNA 
subjected to real time PCR. Output data are normalized to values obtained for 1% input controls, and 
results are presented as percent of baseline value obtained for untreated cells at each time point.  Data 
graphed represent the mean of 2 experiments that were performed in duplicate. 
 
Bt2cAMP increased the binding of wild type SF-1 to the CYP17 promoter, however, the 
amplitude of Bt2cAMP-stimulated S342A or S342D SF-1 cycling on and off of the 
promoter was severely blunted compared to the WT receptor (Figure 4.4B), consistent 
with a departure from the kinetics of promoter binding observed with WT SF-1, and 
providing further evidence that dynamic phosphorylation of S342 enables endogenous 
receptor cycling on and off of the CYP17 promoter. 
 
4.5 Phosphatase Activity Is Required for SF-1 Cycling on and off the CYP17 
Promoter 
 
 If phosphorylation enables cycling of SF-1 during iterative rounds of 
transcription, then phosphatase activity may be equally as important in promoting CYP17 
transcription by enabling receptor recycling.  We have previously established that PP2A 
or another okadaic acid (OA)-sensitive Ser/Thr phosphatase is essential for Bt2cAMP-
dependent transcription of steroidogenic genes in the human adrenal cortex, including 
CYP17, CYP11A1, and CYP21 (164, 222).  Moreover, Winnay et al., have shown that 
OA prevents ACTH-stimulated binding of SF-1 to the melanocortin 2 receptor and 
subsequent polymerase recruitment and transcription (223).  Temporal ChIP of α-
amanitin synchronized cells treated with Bt2cAMP in the presence and absence of OA 
showed that periodic binding of SF-1 to CYP17 was inhibited by OA (Figure 4.4C).  
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 4.6 K253 and R255 Modulate the Transactivation of a CYP17 Reporter Gene 
 
 Further inspection of crystallographic data (56, 224-226), revealed the presence of 
two positively charged residues (K253 and R255) in a highly mobile loop near the 
entryway to the ligand binding pocket (Figure 4.5A) that is conserved across numerous 
species (Figure 4.5B).  We refer to this loop, minimally encompassing residues 250-260, 
as the SF-1 “ligand binding gate”, which we hypothesized may interact with phospho-  
S342 and control receptor activity, potentially by enabling further allosteric 
rearrangement.  To test this hypothesis, we mutated K253 and R255 to either alanine or 
aspartic acid and determined the effect of these mutations on SF-1 transactivation of 
CYP17 reporter in transiently transfected Jeg3 cells.  K253D significantly increased basal 
and Bt2cAMP-stimulated luciferase activity (Figure 4.5C).  Both K253A and R255A 
mutants decreased basal reporter gene activity when compared to WT.  The 
K253D/R255D double mutant increased reporter gene activity to a level similar to that of 
the K253D mutant, indicating that the charge of this lysine residue plays a key role in 
modulating the transactivation potential of the receptor. 
 
4.7 Acetylation of SF-1 Modulates the Transactivation Potential of the Receptor 
 We postulated that K253 is also a target for post-translational modification.  
Several nuclear receptors (227, 228), including SF-1 (229-231), and coactivator proteins 
(232) are acetylated.  Moreover, we have demonstrated that CYP17 transcription depends 
on the SF-1/SRC-1/GCN5 AT complex (217).  Based on the location of K253 and the 
effect of mutating this amino acid on receptor function, we speculated that this residue 
might be targeted by GCN5 or another AT, so we determined the acetylation status of SF-
1, by immunoprecipitating it from H295R cells and probing Western blots with anti- 
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Figure 4.5  Mutation of SF-1 at the entryway to the ligand binding pocket alters transactivation potential of 
the receptor. 
 
A.  Ligand binding gate of SF-1 adopted from the crystal structure of Li et al.  Receptor shown with PA 
docked into the ligand binding domain.  Post-translationally modified amino acid residues (S342, T335, 
and K253) are denoted.  B.  Alignment of ligand binding gate across multiple species and human LRH-1 
(liver receptor homologue-1).  C.  Jeg3 cells were transfected with pGL3-CYP17-2x57, pRL-TK, and WT 
or mutant pCMVTag1-SF-1 for 24 hours and then treated with 1 mM Bt2cAMP for 16 hours.  Luciferase 
activities in isolated lysates were quantified by luminometry.  Data is graphed as the fold change in Firefly 
luciferase (pGL3-CYP17-2x57) activity over Renilla luciferase (pRL-TK) activity and represent the mean 
± SEM of 3 experiments, each performed in triplicate.  *, Significantly different from untreated WT, #, 
significantly different from Bt2cAMP-treated WT, p < 0.05.  
97 
 acetyl lysine antibody.  Acetylated lysine residues on SF-1 are present in control and 
Bt2cAMP-treated cells, and acetylation increased after 1 hour Bt2cAMP treatment (Figure 
4.6A).  In vitro acetylation of WT and K253A mutant receptor immunoprecipitated from 
control and Bt2cAMP-treated H295R cells indicated an approximate 55% decrease in 
acetylation of the K253A mutant compared to the WT receptor in untreated cells (Figures  
4.6B and 4.6C).  Stimulation with Bt2cAMP had no significant effect on the ability of the 
WT receptor to be acetylated in vitro by GCN5, however the acetylation of the K253A 
mutant was higher when the receptor was isolated from Bt2cAMP-treated cells when 
Figure 4.6  GCN5 acetylates SF-1 at K253. 
A.  H295R cells were treated for 1 hour with 1 mM Bt2cAMP.  Cell lysates were immunoprecipitated using 
an anti-SF-1 antibody and the immobilized receptor subjected to SDS-PAGE and Western blotting.  Upper 
panel is western blot hybridized to an anti-acetyl lysine antibody and lower blot is 5% of input lysate 
probed using an anti-SF-1 antibody.  Blots were imaged using an ECF Western blotting kit.  B.  
Representative gel showing 14C-labeled SF-1.  FLAG-tagged WT or K253A mutant SF-1 was 
immunoprecipitated from transiently transfected H295R cells that were treated with 1 mM Bt2cAMP for 1 
hour.  The purified receptor was incubated with GCN5 and 14C-acetyl CoA, washed, and subjected to SDS-
PAGE and fluorimetry (top) or western blotting with an anti-FLAG antibody (bottom).  C.  Graphical 
representation of acetylation assay carried out on WT or K253A mutant SF-1 isolated from H295R cells 
and incubated with GCN5 and 14C-acetyl CoA.  Data represents the mean ± STD of four experiments, each 
performed in at least duplicate.  D. Cells were transfected with pGL3-CYP17-2x57, pRL-TK, and WT or 
mutant pCMVTag1-SF-1 then treated with Bt2cAMP.  Lysates were isolated and luciferase activity 
quantified by luminometry. Data graphed represent the mean ± SEM of 3 experiments, each performed in 
triplicate. 
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 compared to isolates from control cells (Figure 4.6C).  These findings identify K253 as 
one of several amino acids targeted by ATs.  If K253 is an AT target, the loss of positive 
charge, rather than the post-translationally modified structure of acetyl-lysine, is expected 
to be integral in modulating receptor activity.  Reporter gene assays using the K253Q 
acetyl-mimic showed a significant decrease in basal transactivation potential of the 
receptor and a complete loss of Bt2cAMP-stimulated CYP17 reporter activity (Figure 
4.6D).  
 In this chapter, we have confirmed that post translational modification of the SF-1 
ligand binding domain is carried out by GSK3ß (Figure 4.3B) and CK2 (Figure 4.3C) 
kinases, and potentially the GCN5 AT (Figure 4.6C).  SF-1 has evolved ligand binding 
domain residues with complementary charge (Figure 4.5B), the context of which (Figure 
4.5A) suggests that they may interact conditionally before acetylation at K253 and after  
phosphorylation at T335 and S342, and thereby affect ligand binding to SF-1 
allosterically.  It is a notable possibility, remaining untested, as to whether these 
interactions are enhanced or enabled when the relevant receptor surface is buried by 
protein-protein interaction and not water accessible, which would presumably shield 
charged residues from each other. 
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 Chapter 5.  Results—Part III:  Phosphorylation of CtBP1 
by PKA Modulates Induction of CYP17 
by Stimulating Partnering of CtBP1 and 2 
 
5.1 ACTH and cAMP Induce Rapid Accumulation of Reduced Pyridine 
Nucleotides via PKA Activation 
 
 The array of pleiotropic effects of PKA induction by ACTH/cAMP in the adrenal 
cortex includes pyridine nucleotide accumulation and a multifaceted, complex 
mechanism of transcriptional induction.  We sought to identify a mechanism of PKA-
induced adrenal cortex transcription which corresponds with the induced formation of 
SF-1:coactivator complexes (233). 
 It is established that ACTH induces accumulation of reduced NADPH in adrenal 
cortex (234, 235), and that NADPH is the major provider of reducing equivalents to 
steroidogenic (15) and other pathways relying on cytochrome P450 enzymes (236, 237).  
In the adrenal cortex, PKA specifically induces metabolic flux through the pentose 
phosphate pathway (234, 238), reducing NADP+.  Based on these previous studies, we 
first verified that ACTH and dibutryl cAMP (Bt2cAMP) stimulate accumulation of 
reduced pyridine nucleotide in cultured H295R human adrenocortical cells by measuring 
the accumulation of NAD(P)H autofluorescence using confocal microscopy (Figure 
5.1A).  Increases in NAD(P)H autofluorescence typically peaked at approximately 16-
fold of the levels in cells prior to stimulation, while unstimulated cells did not show an 
increase in cytoplasmic NAD(P)H autofluorescence for up to 60 minutes (data not 
shown).  The overall ratio of oxidative:reductive reactions in treated cells as measured by  
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Figure 5.1  NAD(P)H levels respond to ACTH/cAMP. 
 
(A) NAD(P)H confocal autofluorescence during ACTH/cAMP treatment of H295R cells.  Reduced 
pyridine nucleotide autofluorescence (blue) with UV laser stimulation was recorded at times following 
addition of 100 nM ACTH or 1 mM Bt2cAMP.  Reactive oxygen indicator, dichlorofluorescein diacetate, 
was imaged separately (green or yellow).  (B) Static nuclear or cytoplasmic regions were defined as regions 
of interest and the signal ratio of nuclear/cytoplasmic autofluorescence was calculated and averaged for 5-9 
cells under each experimental condition.  Pretreatment with H-89 (10 µM) was carried out for 20 hours 
before ACTH stimulation and measurement. 
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dichlorofluorescein, a reactive oxygen species indicator, indicated that cells favored the 
loss of oxidative radicals during acute ACTH/cAMP stimulation (Figure 5.1A). 
 We next asked whether ACTH/cAMP stimulates differential pyridine nucleotide 
reduction in distinct subcellular compartments by defining nuclear and cytoplasmic 
regions of each cell in the above time courses and calculating the average ratio of nuclear 
to cytoplasmic NAD(P)H in the timecourses shown in Figure 5.1B.  Nuclear levels of 
NAD(P)H, which are initially one third to one half of cytoplasmic levels, increase at a 
faster rate than cytoplasmic levels, but ultimately reach similarly elevated levels.  PKA 
inhibition with 10µM H-89 severely blunted increased NAD(P)H, and prevented 
nucleocytoplasmic redistribution (Figure 5.1B).  We conclude that ACTH/cAMP 
activates NAD(P)+ reduction and redistribution in H295R cells primarily, though not 
exclusively, via PKA-stimulated metabolism.  
 
5.2 Pyridine Nucleotides Activate Nuclear-Cytoplasmic CtBP1/CtBP2 Shuttling 
 
 NADH, the established cofactor for the CtBP1 dehydrogenase (165, 195) 
involved in its homodimerization (160), could be influenced by ACTH/cAMP along with 
NADPH.  By serving as a substrate for lactate dehydrogenase, pyruvate depletes NADH, 
thereby maintaining a high NAD+/NADH ratio (193, 239).  In order to validate the use of 
pyruvate for the purpose of manipulating NAD(P)H, we confirmed that exogenous lactate 
rapidly (within 15-30 minutes) stimulates NAD(P)H autofluorescence in H295R cells, 
and that application of a slightly higher concentration of pyruvate more rapidly (within 1 
minute) quenches this signal below initial levels (Figure 5.2A). 
The ability of CtBP1 to interact with other cellular proteins is affected by NADH 
binding (160, 195). In addition, CtBP1 partner switching is known to affect its subcellular 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2  Pyridine nucleotide metabolism affects CtBP1 and 2 localization in H295R cells. 
 
(A) Confocal measurement of NAD(P)H autofluorescence during a treatment time course following addition of 3.3 mM sodium lactate, then immediately 
following 3.8 mM sodium pyruvate addition is shown.  Some cells were detached during addition of pyruvate.  (B) and (C) CtBP1 and 2 in nuclear and 
cytoplasmic extracts from stimulated H295R cells.  Following indicated treatment with 1 mM Bt2cAMP and/or 5 mM pyruvate supplemented media and 
fractionation, 25 µg protein from nuclear or cytoplasmic extracts was analyzed by SDS-PAGE and western blotting of CtBP1 (B) or CtBP2 (C).  Western blots of 
25 µg nuclear or cytoplasmic H295R cellular extracts were analyzed with paired controls and the ratio of nuclear to cytoplasmic CtBP1 from western blot 
densitometry normalized to this ratio in paired controls was calculated and plotted as a function of time.  The experiment was performed twice in triplicate.  
Pyruvate treatments in these panels and other figures are expressed as amount of sodium pyruvate supplementing the 2 mM standard media concentration.
 
 localization (202, 203).  Thus, we asked whether nuclear/cytoplasmic shuttling of CtBP1 
and 2 occurs in response to ACTH/cAMP-evoked NAD(P)H changes.  We also tested the 
effect of NAD(P)H depletion by incubating cells with excess pyruvate.  H295R cells 
were treated with Bt2cAMP or pyruvate for times ranging from 5 to 120 minutes and then 
fractionated into nuclear and cytoplasmic extracts for analysis by western blotting. 
Intriguingly, both CtBP1 and 2 were found to oscillate between nucleus and 
cytoplasm (Figures 5.2B, C).  CtBP2 oscillation in response to Bt2cAMP matched that of 
CtBP1 during this time period.  Pyruvate also stimulates CtBP1 and 2 shuttling, 
indicating a role for ACTH-induced modulation of pyridine nucleotide metabolism in the 
oscillatory fluxes of CtBP proteins across the nuclear envelope. 
 
5.3 Pyruvate Modulates SF-1 and CtBP1 Binding to the CYP17 Promoter 
 
As discussed earlier, CYP17 activation by Bt2cAMP involves both SF-1 and CtBP (233).  
In order to determine whether pyruvate can affect SF-1 binding to the CYP17 promoter, 
we performed ChIP of the promoter using SF-1 antibody (233) after 12 hours of exposure 
to 30 mM pyruvate.  Excess pyruvate increased SF-1 binding to the promoter (Figure 
5.3A), consistent with either stalled binding or enhanced transcription.  We asked 
whether oscillation in the kinetics of the CtBP proteins and SF-1 on the CYP17 promoter 
(233) corresponds with nuclear-cytoplasmic oscillation of CtBP.  Endogenous SF-1, 
CtBP1, and CtBP2 binding to this segment of the CYP17 promoter, -104/+43, was 
examined at half-hour intervals following synchronization with α-amanitin, then 
treatment with 5 mM pyruvate above standard concentration (Figure 5.3B).  CtBP2 
oscillation on the promoter corresponds with bulk nuclear/cytoplasmic flux of this protein 
seen in cells treated with 30 mM pyruvate, waning with nuclear export at 30 minutes  
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 Figure 5.3  Pyruvate affects CtBP and SF-1 interaction on the CYP17 gene.  (A) ChIP measuring SF-1 
binding to CYP17 -104/+43 following 12 hour treatment with 30 mM pyruvate.  (B) Temporal ChIP of SF-
1, CtBP1, and 2 measuring SF-1 binding to CYP17 -104/+43 following treatments with 5 mM pyruvate for 
indicated times.  Output is normalized to paired controls (actin).  (C) Quantitative RT-PCR of CYP17 
normalized to actin and expressed as fold of controls was calculated for mRNA from H295R cells treated 
with media supplemented with 0, 2, 5, 15, or 30 mM pyruvate, as indicated for 18 hours.  Experiment was 
repeated 4 times in quadruplicate, except for cotreatment data, from one experiment. * indicates significant 
difference from control. 
 
pyruvate stimulation and returning by 60 minutes, consistent with a return of CtBP2 to 
the nucleus (Figures 5.2C, 5.3B).  However, CtBP1 binding to the CYP17 promoter at 
120 minutes does not correspond with nuclear enrichment of this protein. 
 Stalling of SF-1 on the CYP17 promoter is expected to repress CYP17 mRNA 
accumulation, while cycling of SF-1 and coregulators is consistent with transcription.  
We determined that pyruvate stimulates endogenous adrenal cortex CYP17 transcription 
in the absence or presence of ACTH/cAMP signaling (Figure 5.3C), consistent with 
pyruvate promoting cyclic binding of SF-1 and CtBPs to the CYP17 promoter (Figure 
5.3A). 
 
5.4 PKA Phosphorylates CtBP1 Dehydrogenase Domain Distal from the NADH 
Binding Site 
 
Having identified CtBP1 as key for basal repression of CYP17 transcription 
(233), we postulated that activation of the ACTH pathway may play a role in attenuating 
the repressor function of the CtBP proteins.  CtBP1 is phosphorylated by PAK1 at S158, 
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 a modification that may decrease CtBP1 dehydrogenase activity in the homodimer (240).  
We predicted that post-translational modification by PKA (or PAK) could alter CtBP 
corepressor function.  Using bacterially expressed GST-CtBP1 and 2 nuclear isoforms, 
we found that PKA phosphorylates both CtBP1 and CtBP2 in vitro (Figure 5.4).  While 
PAK1 has been found to phosphorylate CtBP1 (240), we found that PAK6 
phosphorylates both CtBP1 and CtBP2 (Figure 5.4).  Consistent with the findings of 
Barnes et al (240), mutation of S158 to alanine substantially reduced the amount of 
radiolabeled phosphate incorporated into CtBP1 (Figure 5.4), though the same mutation 
in a parallel assay did not decrease PKA phosphorylation (data not shown).  Therefore, 
we conclude that PKA and PAK6 target unique sites in CtBP1. 
T144, a consensus PKA (RxT motif) and possible minor PAK (RxxT motif)  
 
phosphorylation site, is conserved in both CtBP1 and 2.  This site is on the NADH- 
 
dependent CtBP1 homodimerization interface (165), on a surface of the dehydrogenase  
 
domain opposite to the NADH binding site and is distal to a hydrophobic cleft on the  
 
substrate binding domain that enables binding of some CtBP partner proteins (241).  
 
Figure 5.4  PAK6 and PKA phosphorylation of CtBP1 and 2. 
 
An in vitro kinase assay was performed with GST-CtBP1 (WT or S158A), GST-CtBP2 (WT) expressed in 
E. coli, bound to glutathione beads, and incubated with active PAK6 or the catalytic subunit of PKA, and 
γ[32P]-ATP.  Coomassie staining (loading) and autoradiogram (32P labeling) of the GST-CtBP1 or 2 are 
shown as labeled.  The same assay was also performed with S100A and T144A CtBP1 mutants bound to 
nickel-affinity beads. 
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S100 in CtBP1 is in a PAK motif that is exposed to the NADH binding site on the 
substrate binding domain and is in direct van der Waals contact with NADH in the crystal 
structure (165).  In vitro kinase assays using a T144A mutant exhibited a decrease in the 
amount of radiolabeled 32P incorporated into CtBP1 when compared to WT or S100A 
when PKA was the kinase.  Conversely, PAK6 was still able to phosphorylate the T144A 
mutant, while exhibiting a decreased phosphorylation of the S100A mutant (Figure 5.4).  
We conclude that CtBP1 is differentially targeted by PKA and PAK6 and that T144 is a 
PKA target while S158 and S100 are PAK6 targets. 
 
5.5 The CtBP Helical Bend is a Phosphorylation-Dependent Heterodimerization 
Motif 
 
 T144 in CtBP1 and T150 in CtBP2 are located at the dimerization interface so we 
further examined dimerization regions of both proteins.  Manually docking and energy 
minimizing a CtBP1 homodimer from the available monomeric structure (165), CtBP2 
was modeled using one of the CtBP1 monomers as a threading template, and the regions 
of interest from contacting monomers were excised as shown in Figure 5.5A.  We then 
mutated select residues in silico to the lowest scoring rotamer using Swiss-PDB viewer 
(166) and energy minimized resulting structures 30 times (Figure 5.5B).  We found that 
T144D (CtBP1) or T150D (CtBP2), stabilized dimerization at the helical bend via 
hydrogen bonding with the backbone at N138.  We also noted that a N138G mutant or a 
C134A/N138G double mutant drastically increased the predicted free energy of 
dimerization, consistent with a loss of dimerization potential.  These calculations suggest 
that the helical bend of CtBP1 and 2 is a heterodimerization motif, and that the specific 
conformation required for dimerization is favored by phosphorylation of T144, and  
107 
  
 
 
 
 
 
 
Figure 5.5  The dimerization motifs of CtBP1 and 2. 
 
(A) Peptides of CtBP1 and CtBP2 which form the core of the interface between the two proteins oriented in 
a heterodimer, created as described in methods.  (B) Minimized energy of the two peptide system with 
CtBP1 or CtBP2-specific residues or mutations interfering with packing of the peptides, or improving their 
interaction (T144D, mimicking phosphorylation).  (C) CoIP of WT or C134A/N138G double mutant 
FLAG-CtBP1 with endogenous CtBP2 from H295R whole cell lysates.  Cells treated with Bt2cAMP for 90 
minutes show a 28 % decrease in levels of endogenous CtBP2. 
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 disfavored by mutation of the helical bend motif, at C134 and N138.  For reference, this 
motif is conserved as CxxxNxYRRxT, and occurs at a bend in an otherwise continuous 
helix between the two arginines in dimeric crystal structures of CtBP1 (165) and CtBP2 
(Pilka et al, unpublished).  To test this model experimentally, we performed coIP of WT 
FLAG-tagged CtBP1 and C134A/N138G (double mutant) with endogenous CtBP2 and 
found that the double mutant exhibits decreased binding to CtBP2, both in the presence 
and absence of Bt2cAMP (Figure 5.5C). 
 
5.6 PKA-Catalyzed Phosphorylation of T144 Regulates CtBP Partnering 
 
We have previously found that the coactivator GCN5 preferentially interacts with 
the monomeric, NADH-binding deficient CtBP1 G183V mutant (233).  This G183V 
mutant of CtBP1 has also been shown to exhibit increased affinity for the coactivator 
p300 when compared to WT, supporting a role for NADH-sensitive CtBP1 sequestration 
of bromodomain containing acetyltransferases (160).  We hypothesized that 
phosphorylation of CtBP1 by PKA at T144 disfavors GCN5 interaction with CtBP1 by 
inducing dimerization of CtBP1 and CtBP2 (160, 233).  The hinge created in the N138G 
mutant could mimic the helical bend induced by phosphorylation (Figure 5.5B).  
Additional mutants were also made to test the role of confirmed PAK6 targets S100 and 
S158.  To determine the effect of these CtBP1 mutants on the ability of the corepressor to 
interact with GCN5, we carried out mammalian two hybrid assays using GAL4:GCN5 
and WT or mutant VP16:CtBP1.  GAL4:GCN5 interacts strongly with VP16:CtBP1 and, 
loses a modest albeit significant 8 percent of interaction strength upon stimulation with 
Bt2cAMP (Figure 5.6A).  Mutation of the PKA phosphorylation site increases interaction 
whereas the N138G mutant significantly disfavored interaction with GCN5.  Effects of 
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 mutation of helical bend arginines on the interaction are shown in Figure 5.6B.  Alanine 
substitution of the PAK6-targeted site S100 severely compromises GCN5 interaction, 
perhaps because a decrease in side chain volume encourages more stable binding of 
pyridine nucleotide cofactor to CtBP1, which we have established is likely to disfavor 
interaction with GCN5 (233). The other PAK target, S158, had no significant effect on 
GCN5 interaction in the S158A mutant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6  CtBP1 dimerization motif mutations affect GCN5:CtBP interaction. 
 
(A) and (B) Mammalian two hybrid interaction of GAL4.GCN5 and VP16.CtBP1 (WT or mutants) in 
H295R cells in the presence or absence of Bt2cAMP is shown +/- SEM.  pG5 reporter, GAL4:GCN5, and 
VP16:CtBP1 plasmids were transfected in the ratio 50 ng : 50 ng : 50 ng; n=3; N=2. Symbols indicate 
significant difference from control (*) or Bt2cAMP stimulated (†) interaction with WT CtBP1. 
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5.7 SF-1:CtBP1 Interaction and CYP17 Induction Respond to CtBP1 and CtBP2 
Dimerization Interface Mutations 
  
Since CtBP1 also interacts with SF-1 (233), we next determined if 
phosphorylation of CtBP1 at T144 modulates interaction with the receptor.  As shown in 
Figure 5.7A, the S158A mutant strengthened the SF-1:CtBP1 interaction compared to 
WT.  However T144A did not affect interaction, suggesting that the absence of T144 
phosphorylation does not affect the interaction with SF-1.  The S100A mutation 
weakened interaction signal to background levels, similar to the effect on GAL4:GCN5.  
These data suggest that phosphorylation of CtBP1 at distinct sites differentially affects 
the interaction between SF-1 and CtBP1 versus GCN5 and CtBP1.  It is likely that 
arginines define the PKA phosphorylation site at T144.  CtBP1 helical bend arginine 
charge neutralization had no significant effect on SF-1 interaction, while the R141E 
charge reversal did significantly increase SF-1:CtBP1 interaction (Figure 5.7B). 
We have previously shown that CtBP1 represses CYP17 reporter gene activity in 
H295R cells (233). To test whether CtBP interaction mutants affect CYP17 transcription, 
we examined the effect of the mutants on reporter gene activation.  N138G and 
C134A/N138G significantly inhibited Bt2cAMP-mediated activation (Figure 5.7C), 
consistent with a requirement for CtBP1 dimerization in the loss of CtBP1-mediated 
repression of CYP17.  S158A CtBP1 repressed CYP17 reporter more effectively than 
WT, while S100A lost the ability to repress the reporter.   
CtBP2 partnering with CtBP1 is predicted to be energetically favorable to CtBP1 
homodimerization (Figure 5.5B).  Therefore, we used the reporter gene assay to 
determine effects of mutating residues in the dimerization domain of CtBP2 on CYP17 
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Figure 5.7  Interaction of SF-1 with CtBP1 helical bend mutants. 
 
(A) and (B) mammalian two hybrid SF-1:CtBP interaction with WT CtBP1 or mutants near the helical 
bend were measured.  Plasmids were transfected as in Figure 5.6, and experiments were performed in 
triplicate and results are displayed with SEM.  *, differs significantly from basal SF-1: WT CtBP1 signal.  
(C) and (D) CYP17 -300 reporter (125 ng) activity was measured in the presence of SF-1 (25 ng), and WT 
or mutant CtBP1 or homologous site mutants of CtBP2 (25 ng).  Symbols indicate significant difference 
from basal (^) or Bt2cAMP-stimulated (‡)SF-1 induced reporter activity in the absence of overexpressed 
CtBP. 
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 transcription. CtBP2 overexpression significantly represses CYP17.  Mutation of CtBP2 
T150 (CtBP1 T144) which we predicted facilitates CtBP1:CtBP2 heterodimerization 
(Figure 5.5B), strongly attenuates CYP17 transcription.  Mutation of the CtBP2 residue 
S164 (CtBP1 S158) reverses repression.  Our findings indicate that CtBP1:CtBP2 
heterodimerization may be required in efficient CYP17 transcription. 
The effects of CtBP1 and 2 arginine mutations of the dimerization interfaces are shown in 
Figure 5.7D.  The R142A mutation, which significantly strengthened GCN5:CtBP1 
interaction (Figure 5.6B), also significantly enhances repression of CYP17 during 
Bt2cAMP stimulation. 
 
5.8 Endogenous Interactions of CtBP1 and 2 with SF-1 and GCN5 are Sensitive 
to Bt2cAMP and Pyruvate 
 
Our data suggest that ACTH/cAMP-stimulated phosphorylation promotes CtBP1 
partner switching and the nuclear export of CtBP1:CtBP2 heterodimers.  To further 
examine this phosphorylation-induced partner shuffling, we carried out coIP assays for 
endogenous CtBP1, 2, and SF-1 interactions in H295R cells and found that CtBP1, but 
not CtBP2, strongly interacts with SF-1, while CtBP2 prefers to interact with CtBP1 
rather than SF-1 (Figure 5.8A).  Bt2cAMP and pyruvate decreased interaction of CtBP1 
with SF-1, while only Bt2cAMP decreased the GCN5:CtBP1 interaction (Figure 5.8B).  
Consistent with previous findings implicating NADH binding in CtBP1 function (160, 
233), Bt2cAMP and pyruvate additively impacted the SF-1:CtBP1 interaction.  
 
5.9 Kinetics of Endogenous Nuclear CtBP Heterodimerization in Response to 
Bt2cAMP 
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 To further explore the roles of ACTH/cAMP-induced pyridine nucleotide 
accumulation and PKA-catalyzed phosphorylation in CtBP1:CtBP2 heterodimerization, 
we quantified Bt2cAMP-stimulated interaction kinetics between CtBP proteins in coIP 
experiments using the nuclear fraction of H295R cells.  As shown in Figure 5.8C, CtBP1 
and 2 interaction increases in nuclei within 30 minutes, peaks at 90-120 minutes, and 
proceeds to decay after 120 minutes, concomitant with flux of both proteins into the 
nucleus by 30 minutes (Figures 5.2B, C).  Conditions favoring CtBP heterodimerization 
remain for up to 120 minutes, though this does not maintain positive flux of CtBP1 or 2  
into the nucleus throughout this period (Figures 5.2B, C).  We next determined the effect 
of excess pyruvate on CtBP1:CtBP2 interaction, repeating coIP experiments using lysates 
isolated from cells treated with 30 mM pyruvate.  Pyruvate decreased the CtBP1:CtBP2 
interaction by 25 and 19 percent in the absence and presence of Bt2cAMP, respectively 
(Figure 5.8D). 
SF-1 coIP with a tagged CtBP1 T144A mutant also revealed a 77 percent 
decrease in binding compared to WT, while Bt2cAMP increased interaction only with the 
phosphodeficient mutant by 3-fold (Figures 5.8E and F).  In contrast, while basal CtBP2 
interaction was much weaker, T150A mutation increased SF-1 binding 48 percent 
compared to WT CtBP2, and Bt2cAMP still decreased interaction with this mutant by 
more than two-thirds. 
 
5.10 A Model of CtBP-Mediated CYP17 Repression and Relief by Kinase 
Signaling 
 
Bt2cAMP induces CtBP1 and 2 heterodimerization in the nucleus (Figure 5.8C).   
 
We asked what the combined effect of CtBP1 T144 and CtBP2 T150 mutation is on their 
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 Figure 5.8  CtBP1 interaction with CtBP2 and SF-1 in H295R extracts. 
 
A, coIP was performed on H295R whole cell lysates.  B, coIP of GCN5 or SF-1 with CtBP1 was performed 
on whole cell lysates following the indicated treatments for 90 min:  control, 1 mM Bt2cAMP and/or 5 mM 
pyruvate.   C, excess protein A/G beads and CtBP1 antibody were incubated with 70 µg of H295R nuclear 
extracts taken following the indicated Bt2cAMP treatments.  Western blots of washed beads were  
                 (legend continues next page) 
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 quantified via densitometry for CtBP2 signal and are expressed as coIP output.  D, CtBP1 from cells treated 
as indicated for 4 hours was immunoprecipitated from nuclear extracts and interaction with CtBP2 was 
quantified by westen blot of washed outputs.  E, western blots of SF-1 following coIP of VP16-CtBP1 or 
FLAG-CtBP2 from H295R whole cell lysates.  F, quantification of coIP results, including coIP of SF-1 
with FLAG-CtBP1 not shown in E.  G, western blots of tagged CtBP2 following coIP of VP16-CtBP1 in 
whole cell lysates of transfected cells. 
 
 
heterodimerization by performing coIP of tagged WT or T144 CtBP1 and found that the 
T144A mutation weakened CtBP1:CtBP2 heterodimerization (Figure 5.8G).  Further 
mutation of the corresponding PKA phosphorylation site in CtBP2 (T150) also resulted in 
decreased interaction, supporting our hypothesis that phosphorylation of CtBP proteins in 
response to ACTH signaling promotes partner switching and CYP17 induction. 
Our results indicate that CtBP switches partners and subcellular localization 
concomitantly, and that CtBP heterodimers form in response to Bt2cAMP.  Therefore, we 
propose a model of allosteric changes in CtBP1 which control the nuclear concentration 
of monomer available for regulating exchange of CYP17 coactivators from their active 
complexes containing SF-1 and GCN5.  Nuclear export of CtBP heterodimers prevails in 
response to ACTH/cAMP and allows induction of CYP17 transcription (Figure 5.9). 
In this chapter, we have shown that reduced pyridine nucleotide can accumulate 
rapidly in the nucleus in response to PKA activation (Figure 5.1), and pyridine nucleotide 
manipulation causes shuttling of CtBP1 and 2 across the nuclear envelope (Figure 5.2B 
and C), and dynamic CYP17 promoter binding (Figure 5.3B).  Significantly, PKA 
directly phosphorylates CtBP1 and 2 (Figure 5.4), and phosphorylation of the target site 
at T144 in CtBP1 has the capacity to improve the stability of the CtBP dimer (Figure 
5.5B).  GCN5 and SF-1 interactions with CtBP1 are sensitive to T144 mutation, as well 
as mutation of other CtBP dimerization motif residues.  We conclude from these results 
that PKA mediated phosphorylation of T144, and the increase in nuclear pyridine 
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nucleotides, probably NADH, stimulates CYP17 transcription promoting dissociation of 
CtBP from SF-1 coactivator complex members, thereby enabling formation of the early 
cAMP-induced SF-1/SRC-1/GCN5 complex which is involved in CYP17 transcription 
cycles in response to cAMP. 
 
 
 
 
 
Figure 5.9  Working model of CYP17 induction by PKA.  PAK6 and NADH differentially affect the 
ability of SF-1 and GCN5 to interact with CtBP1. 
 
PKA phosphorylates CtBP1 (and possibly 2), causing oligomerization of CtBP proteins in the nucleus.  
Reversal of PKA phosphorylation at T144 or T150 and/or oxidative conditions may prevail as cytochrome 
P450-mediated steroidogenesis proceeds, may cause the system to revert to its initial state.
 Chapter 6.  Discussion 
 
6.1 Finding Determinants of Induced, Accelerated, Transcription Rate  
 
Transcription of eukaryotic genes proceeds through an ordered process of 
chromatin modification orchestrated by transcription factors which obligatorily interact 
with transcriptional coregulators on promoter chromatin (Sections 1.3).  Genes that are 
not constitutively expressed must be induced during and following developmental 
differentiation.  This is of particular interest because there is an implication for a 
mechanism or mechanisms which monitor conditions (indeed, any inducing signal) and 
transduce that signal into a transcriptional response.  The machinations of this process 
have ostensibly co-evolved over the course of more than a billion years along with 
chromatin (242).  In the case of the CYP17 gene in tissues capable of acute 
steroidogenesis (adrenal cortex and gonads) (Sections 1.1), the process of transcriptional 
induction is concomitant with the cAMP-dependent induction of SF-1 transcription factor 
function.  SF-1 is a member of the nuclear receptor superfamily of transcription factors 
(Sections 1.2) that are found in sponges and most, if not all, animalia descended from a 
common ancestor; even yeast has proteins that (via convergent or divergent evolution) 
structurally and functionally resemble the ligand-binding control apparatus of nuclear 
receptors (243).  Nuclear receptors are subject not only to ligand-mediated regulation 
(Section 1.2.2), but also respond with unique transcription programs affecting specific 
sets of target genes when they are post-translationally modified (Section 1.4).   
In the studies detailed in chapters three, four, and five, we respectively asked the 
following questions. 1) What is the order of events which occur on CYP17 promoter 
chromatin (nucleosome(s)) near the transcription start site, and what are some proteins 
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 and conditions that cooperate in stimulating these ordered events?  2) What role(s) does 
post translational modification of the SF-1 LBD have in coordinating these events, and 
how essential is it?  3) How does an incompletely characterized SF-1 coregulator protein 
(CtBP) help integrate the monitoring of signals which regulate and enforce ordered 
events during induced transcription of CYP17? 
In chapter three, a fascinating team of cooperative protein players with broad 
roles in chromatin modification were described and related to one another through their 
kinetics of interaction with the CYP17 promoter and/or transcription start site.  A specific 
coregulator complex involving SF-1, SRC-1, and GCN5 was identified as a candidate 
dynamic complex which has an early role in cAMP-induced chromatin modification on 
the CYP17 promoter.  In chapter four, diverse molecular biological methods were used to 
identify the essential role for phosphorylation and acetylation of the SF-1 LBD in 
regulating the above kinetics of cooperation.  In chapter five, kinase cascades and 
dehydrogenase metabolism involving pyridine nucleotides were demonstrated to also 
play a central role in CYP17 transcription.  These parameters are monitored by a set of 
two conditionally monomeric general transcriptional corepressors, CtBP1 and CtBP2, 
which differentially interact with each other, or a number of essential CYP17 activators, 
including SF-1 and the acetyltransferase GCN5. 
 
6.2 Key Events during CYP17 Transcription Cycles Are Reflected by Changes 
in Protein/DNA Interactions 
 
 Nucleosome structure, modification, position, and time-dependent coregulator 
complex assembly are integrated during ACTH/cAMP-induced transcription of the 
CYP17 gene in the adrenal cortex.  Select coactivator complexes assemble or are 
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 stabilized in the nucleus in response to ACTH/cAMP.  One such complex which forms 
and binds CYP17 promoter within thirty minutes of stimulation is the transcription 
factor/HAT complex comprised of SF-1, SRC-1, and GCN5.  Such complexes in turn 
direct a cascade of chromatin remodeling at the CYP17 promoter (Figure 6.1), including 
reorganization of histone H2A/H2B by ATP-dependent chromatin remodeling 
complexes.  Recall that histone H2 dimers can interact with histones on neighboring 
nucleosomes (80), and with the linker histone H1 (244).  Evidence for remodeling of H2 
dimers on the CYP17 promoter is given by the loss of H2B occupancy of the promoter 
upon cAMP stimulation, followed by a 600 percent gain at the 150 minute time point 
(Figure 6.9B).  This may reflect not only an ISWI-dependent return of H2 dimer, but also 
formation of higher-order chromatin structure at the promoter. 
p54, PSF, and SF-1 begin to co-locate on the promoter during the second 
transcription cycle in what has been defined as a hallmark of cAMP-dependent CYP17 
transcription (20).  Other cAMP-dependent promoters rely on p54 as a bridging factor to 
RNA polymerase II (245), and in the case of CYP17, kinetics of this factor relative to 
other coregulators suggest it has a role during the switch from repression to activation 
(Figure 6.1). 
 Our findings in chapter three suggest opposing activities of SWI/SNF and ISWI-
containing chromatin remodeling complexes (246).  Our data (Figure 3.9) is consistent 
with the former ATPases causing disruption and the latter ATPase, reformation, of 
H2A/H2B dimers within the nucleosome at the CYP17 transcription start site, 
respectively.  Based on the crystal structure of Luger et al. (79), it would be expected that 
reorganization of H2A/H2B dimers within the DNA-nucleosome complex could alter 
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Figure 6.1   Model of coregulator dynamics on the CYP17 promoter during cAMP stimulation in 
steroidogenic cells. 
 
cAMP initiates formation of a SF-1/SRC-1/GCN5 trimer that associates with the CYP17 promoter (-57/-
37) followed by acetylation of histone H4 and another component of the complex.  CtBP (not shown) 
mediates complex disruption, thereby facilitating recruitment of transcription activating factors (TAFs) and 
Pol II (transition 1).  Corepressors bind in the absence of SF-1 during cAMP-mediated cycling (transitions 
2-4), followed by exchange of the corepressor complex for a complex containing p54nrb and p300 and/or 
GCN5 (transition 5).  This is followed by acetylation and monomethylation of histone H4, which promotes 
SWI/SNF-dependent remodeling and enables the cooperative binding of SF-1, p160s, and GCN5 (transition 
6).  Additional remodeling by BRG1 re-enables binding of Pol II and TAFs (transition 7) followed by 
dismissal of SF-1 and coactivators and the initiation of p54nrb/PSF mediated splicing (transition 8).  **, 
cAMP-dependent interactions confirmed by this study; Ac, acetylation. 
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 DNA contact with remaining histones in the core nucleosome.  Since H2 dimers have the 
ability to contact histones of neighboring nucleosomes (See Table 1.1), it is also likely 
that their loss or gain reflects the propensity for chromatin reorganization at the level of 
the transition from euchromatin to heterochromatin. 
In concert with the possibility of nucleosome repositioning, histone H2 dimer 
disruption alters accessibility of cis elements, directing the sequential recruitment of other 
trans factors to DNA, culminating in a transcription-competent complex including RNA 
polymerase II (Pol II).  Transcription rate is further tuned by corepressor binding to and 
post-translational modification of the same region.  This includes GCN5 acetyltransferase 
activity, which aids in disassembly of the SF-1/SRC-1/GCN5 complex (Figure 3.4D). 
 
6.2.1 A CYP17 Transcriptional Clock Encoded in cis Determines Energetic 
Transitions in Nucleosome Organization 
 
 Post translational modification of trans factors, including histones in chromatin, 
transcription factors, and coregulators is a straightforward means by which to alter the 
cooperativity of trans factors during transcription preinitiation.  However, results in 
chapter three also lend credence to the idea that chromatin organization intrinsic to the 
proximal promoter sequence is responsible for the timing and sequential nature of 
coregulator processing of the CYP17 proximal promoter chromatin during transcription 
cycles.  Recently, an exhaustive study of nucleosome positioning presented a statistical 
model by which a simple 140 bp pattern within any DNA sequence can encode steady 
state nucleosome position or absence of association with nucleosomes.  In this model, a 
dyad of two juxtaposed A:T pairs enables tight DNA wrapping around a nucleosome if 
repeated with periodicity in a double stranded DNA sequence (83). 
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This model (Figure 6.2) was used to make a template and applied to the region of 
the CYP17 gene used in ChIP experiments, which suggested that nucleosome positioning 
is strongly favored over the region -140/-90 of the CYP17 gene.  However, alignment of 
the template 3’ of the region suggests alternate modes of chromatin organization around 
the remainder of the DNA binding tract of this nucleosome (Figure 6.3C, D, E).   I 
propose three modes of nucleosome-DNA interaction, and three transitions between them 
during a complete transcription cycle.  The first is a low energy conformation favored 
thermodynamically by the promoter sequence (Figure 6.3C).  A region of the proximal 
promoter is excluded from nucleosome wrapping and would be accessible to SF-1 and 
SF-1/coactivator complexes detected on the CYP17 promoter at the beginning of the 
transcription cycle.  Transition to a higher energy state would be encouraged by histone 
H2 dimer extrusion from the nucleosome (Figure 6.3D), consistent with 80 percent loss 
of H2B occupancy early in the transcription cycle (Figure 3.9B).  Nucleosome-DNA 
contacts along the promoter even 3’ to the original loop would be lost, including at the 
transcription start site.  This event would likely be aided by nucleosome disorganization 
 
 
 
 
 
 
 
 
 
 
Figure 6.2  A 140 bp nucleosome positioning template. 
 
The template for nucleosome positioning on the CYP17 proximal promoter was derived from statistical 
data of global nucleosome positioning relative to AA, TT, and TA dyads described in Segal et al (83) and 
shown in this figure.  These dyads, when positioned correctly, kink the DNA helix and stabilize steady state 
nucleosome wrapping.  A:T dyads in the CYP17 sequence were manually aligned to match peaks and avoid 
strong troths in the template from -140 to -42 and from +22 to +64.  Thermodynamically stable (“tight”) 
nucleosome wrapping of CYP17 -42 to +23 appears to be disfavored. 
Adapted by permission from Macmillan Publishers Ltd: Nature (Segal et al (83)), copyright 2007.
  
Figure 6.3  Possible alternate nucleosome wrapping states of the CYP17 promoter proximal to the transcription start site.   
 
A. Crystal structure 1AOI of a nucleosome wrapped with 146 bp palindromic human DNA.  B. Representation of CYP17 proximal promoter with nucleosome 
wrapping and 5’ positioning based on strong adherence to statistical/thermodynamic sequence requirements for optimal nucleosome positioning/organization in 
whole genome chromatin of chicken (83);  ‘0’ denotes the center of this DNA segment, corresponding to position -71 on the CYP17 promoter.  Low adherence to 
favored A:T dyad positioning at the 3’ end (Figure 6.1) disfavors this model. C. Stable nucleosome wrapping predicted by the best alignment of the CYP17 
proximal promoter and coding start region bend-capable sites to nucleosome positions which best accommodate these bends.  D. Reduced nucleosome wrapping 
(shown without H2 dimers) enables read-through of transcription machinery. E. Tightest winding of CYP17 3’ DNA, locking in the second H2 dimer (H2A, 
magenta; H2B, red) with bend sites (TT) favoring 2bp slack 3’ to CYP17 -57 bp.  Over time, possibly a consistent, predictable number of minutes, molecular 
“breathing” of this structure would be expected to favor motions which return the conformation to the one shown in C. 
 
 catalyzed by the SWI/SNF remodeling complex which includes BRG1 early in the first 
transcription cycle (Figure 3.9A).  Occupancy of RNA polymerase II would then 
increase.  Later, intrusion of H2 dimers (Figure 3.9B) occurs following corepressor 
enrichment on the CYP17 promoter at 120 minutes Bt2cAMP treatment.  Modification of 
the histone code further encourages the recruitment of SNF2H ATP-dependent chromatin 
remodeling activity at the 150 minute time point (Figure 3.9A).  This would effectively 
end the first transcription cycle as a fully wrapped nucleosome/DNA assembly is formed 
(Figure 6.3E).  The third and final transition would occur spontaneously, as kinetic 
breathing motions of the DNA-nucleosome complex return it to the thermodynamically 
favored conformation pictured in Figure 6.3A.  During this time, p54nrb would be one of 
the first factors to gain access to its recognized binding element on the promoter DNA, 
thus starting the second transcription cycle with a unique pattern of trans activator 
recruitment differing from the first cycle.  Temporal ChIP data in chapter three, 
particularly variation over time of the chromatin occupancy of Pol II and H2B, as well as 
the procession of p54nrb/PSF binding leading to SF-1 recruitment in cycle II, corresponds 
very well with this sequence of chromatin structural rearrangements. 
 
6.2.2 The Cooperativity Principle of Transcription and Sequential versus 
Concurrent Promoter Recruitment of Cooperative Transcription Factors 
 
 Extension of temporal ChIP methodology to other factors which have been 
confirmed to interact with SF-1 (below references) may yet reveal that some of these 
trans factors interact with the -104/+43 CYP17 gene segment only in cooperation of SF-
1.  Such factors may include other transcription factors which have been shown to 
synergize with SF-1, including ß-catenin (247), Sp1, NF1, and CCAAT enhancer binding 
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 protein(s) (248, 249).  For example, cooperativity between SF-1 and GATA-6 is required 
for the most efficient transcription of CYP17 (250).  Mechanisms for transition of 
nucleosome/promoter interaction likely underlie sequential recruitment of factors.  The 
above reasoning and evidence for SF-1/GATA synergy pigeonholes an expected time of 
possible GATA recruitment to the CYP17 promoter closely following that of 
transcription-permissive remodeling ATPase recruitment, but preceding peak RNA 
polymerase II recruitment.  Other genes originally thought to be strictly under SF-1-
mediated control, such as anti-mullerian hormone, also may consistently involve GATA 
as an equal partner in transcription activation (251, 252). 
 These studies (251-253) in combination with the data presented in chapter three 
provide examples that help define a central principle of SF-1 function:  cooperativity with 
coactivators or other transcription factors regulates transcription.  Some of this 
cooperativity is gene-specifically encoded in cis, as is the case for GATA and SF-1 on 
CYP17.  However, simultaneous accessibility of multiple elements is brought about 
through nucleosome remodeling, while protein-protein interactions among cooperating 
factors must be also be enabled by ligand-mediated switching of nuclear receptor 
coregulator binding modes, by bridging factors, and by post-translational modifications 
(discussed in the following section). 
 
6.3 A Phospho-Acetyl Switch and Ligand Retention / Exchange Mechanism 
is Controlled by ACTH/cAMP 
 
 Based on our data on SF-1 phosphorylation presented in chapter four (Figure 
4.4B), we propose that positively charged K253 acts to promote closure of the SF-1 
ligand binding pocket in response to phosphorylation of T335 and S342.  Further, 
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 reversible acetylation and deacetylation of this residue is key in modulating receptor 
activation (Figure 4.6D), possibly by controlling ligand binding, ligand exchange, and/or 
modulating coregulator binding modes. 
 Consistent with rapid increased colocalization of SF-1 and acetyltransferases, 
particularly GCN5, in response to stimulation of the ACTH pathway (78, 233), our data 
suggests that target gene activation by agonist liganded SF-1 is enabled by K253 
acetylation, then later in the transcription cycle is reversed by K253 deacetylation. 
 Deacetylation of SF-1 is consistent with the prevalence of deacetylases acting on the 
CYP17 promoter later in the transcription cycle, when SF-1 cannot maintain stable 
occupancy upon the promoter (233).   
 The requirement of histone deacetylase (HDAC) activity in transcription cycles is 
consistent with the findings of Winnay and Hammer, in which trichostatin A prevented 
ACTH-stimulated phospho-RNA polymerase II binding to the ACTH receptor gene 
(223), possibly due to stalling of SF-1 on the promoter.  In that study, HDAC-1 and -7 
bound the promoter in Y1 mouse adrenocortical cells in response to ACTH, while we 
found that HDAC-1, -2, and -8 bind to the CYP17 promoter during Bt2cAMP-mediated 
transcription cycles in H295R cells (217).  Despite these species- or gene-specific 
differences, these data and current findings indicate that while SF-1 K253 is not the sole 
target of acetyltransferase activity, it is a key acetylation target that modulates the ability 
of the receptor to induce target gene transcription.   
 Since we previously found that SF-1 binds to several sphingolipids and 
phospholipids (74, 77), we envision that the ability of SF-1 to adopt an active 
conformation upon ACTH/cAMP-stimulated SPH dissociation and PA binding is 
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 controlled by the phosphorylation and acetylation status of the receptor.  By opening and 
closing the ligand binding gate, acetylation and phosphorylation, respectively, should 
enforce ligand exchange and retention.  Such a mechanism is consistent with our findings 
in chapter four, where transcription cycles mediated by SF-1 are potentiated by dynamic 
acetylation of the SF-1 ligand binding gate (Figure 4.6).  This mechanism is also 
consistent with the late onset of cAMP-stimulated transcription cycling in the presence of 
excess sphingosine (Figure 3.11B), because sphingosine discourages acetyltransferase 
interaction with SF-1 (Figure 3.4B), probably by causing SF-1 to adopt a corepressor, 
rather than coactivator binding mode (74).  Finally, the activity of OA sensitive 
phosphatases are required for optimal cycling (Figure 4.4C).   
 Thus, we propose that the changes in the strength of the electrostatic attraction 
between modified and unmodified K253 and S342 create a “phospho-acetyl switch” 
(254) that ensures PTM-coordinated monitoring of ligand occupancy by regulating 
opening and closing of the ligand binding gate (Figure 6.4).  The nature of the 
mechanistic consequences for interplay of this switch operating on the ligand binding 
gate with agonist/antagonist balance, such as suggested at the beginning of this section, 
remains an open question. 
 However, it is clear that this phospho-acetyl switch is key in selecting which 
coregulator binding mode SF-1 adopts for a given time, and that this switching is 
mandatory during efficient induction of CYP17 transcription cycles.  Specifically, S342 
and T335 phosphorylation by GSK3ß and CK2, respectively, are required for cyclic, 
transient interaction with the CYP17 promoter.  Ser/Thr phosphatase inhibition alone is 
sufficient to disallow cyclic association of SF-1 with the CYP17 promoter (Figure 4.4C 
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 and (223)), supporting a role for the reciprocal actions of kinase and phosphatase 
activities in controlling the transactivation potential of the receptor.  A SF-1 crystal 
structure with bound phospholipid is in the coactivator binding mode when the ligand 
binding gate is open (44).  So, it is reasonable to conclude that one or more of the three 
open gate configurations in our model (Figure 6.4) predominate during the phase of the 
transcription cycle involved with achieving transcription competence.  We conclude that 
these post-translational modifications underlie SF-1 receptor cycling on the human 
CYP17 promoter and ensure optimal levels of gene transcription in response to 
ACTH/cAMP signaling, while also monitoring the presence of acetyl-coA, the mandatory 
cofactor for acetyltransferases acting on SF-1. 
 
6.3.1 The Complex Pattern of Basal and cAMP-Responsive SF-1 Phosphorylation  
 
 Of note, the inability of mutations to completely inhibit phosphorylation of SF-1 
in metabolic labeling studies (Figures 4.1E and 4.1G) indicates that the receptor is 
phosphorylated at multiple sites.  The recent findings by Lewis et al., provide compelling 
evidence for CDK7 in modulating both the transactivation of SF-1 and the ability of the 
receptor to bind ligand (216).  It is possible that CDK7 regulates the phosphorylation of 
SF-1 at S203 in the absence of ACTH signaling, while GSK3ß triggers phosphorylation 
of additional sites in response to increased intracellular cAMP.  Notably, our metabolic 
labeling studies demonstrate that Bt2cAMP increases phosphorylation of SF-1 (Figure 
4.1G), and this correlates with phospho-specific western blotting of SF-1 (Figure 4.1H).  
These studies are in contrast to our metabolic labeling studies carried out in cells treated 
with Bt2cAMP for 12 hours (164).  The one hour stimulation time used in chapter four is 
consistent with the rapid nuclear translocation of GSK3ß (Figure 4.2A) and the cycling of 
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Figure 6.4  Model for regulation of SF-1 function by post-translational modifications.   
 
ACTH/cAMP promotes modification of SF-1 by stimulating phosphorylation of the receptor (T335 and 
S342) and dynamic interactions between charged amino acid residues (K253 and R255) at the entryway to 
the LB pocket.  Recruitment of GCN5 modulates access to the LB pocket by acetylating K253.  Dynamic 
transcriptional cycling is achieved by protein phosphatase (PPase) and deacetylase (DAC) activities. 
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 SF-1 on the CYP17 promoter (Figure 4.4 and (217)).  However, it is likely that the 
receptor undergoes several temporally distinct changes in its phosphorylation status 
during ACTH signaling and CYP17 transcription. 
 Mass spectrometric studies aimed at comprehensive identification of 
phosphorylated residues on SF-1 are ongoing.  Interestingly, these mass spectrometric 
experiments have detected several tyrosine residues that are phosphorylated on the 
receptor (Dammer and Sewer, unpublished observations), however, further study is 
required to determine the functional significance of these phosphorylation events and to 
identify the kinase(s) that targets these residues. 
 
6.4 Global and Gene Specific Chromatin Modification Changes and a 
Coregulator Cooperativity Switch Are Integrated Outputs of CtBP 
Involved in Transcription Regulation 
 
CtBP1 and 2 repress transcription of numerous genes via participation in master 
regulatory complexes of transcription corepressors (194, 255).  These corepressors 
promote chromatin compaction via association with histone deacetylase (256) and 
methyltransferase enzymes (194).  It is equally likely that the CtBPs serve as general 
repressors of transcription by sequestering a wide array of histone acetyltransferases that 
are required for promotion of heterochromatin to euchromatin, via a conserved 
interaction motif in bromodomains (160).  By sequestering acetyl-lysine binding proteins, 
CtBP can regulate and inhibit a likely mechanism for histone acetyltransferase feed 
forward that would otherwise enable histone hyperacetylation following a single 
acetylation event. 
The gene specificity of CtBP repression, however, is conferred by specific 
protein-protein interactions with trans factors and depends on the trophic status of a cell 
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 and NAD+/NADH ratio.  CtBP1 interacts with a growing list of gene-specific DNA 
binding factors (193, 257-259), to which we add the nuclear receptor SF-1.  The 
divergent effects of mutagenesis of the CtBP dimerization motif on the interaction with 
SF-1 (Figures 5.6A, 5.7E) versus the interaction with GCN5 (Figure 5.5), as well as of 
mutating the Rossman fold (233) suggest that conditions favoring SF-1 interaction are 
unique from the ones favoring GCN5 (Figure 5.9).  The exception, however, is that both 
this SF-1 interaction and the GCN5 interaction with CtBP proteins are reduced by 
Bt2cAMP treatment (Figure 5.8B), in a mechanism which requires T144 (Figures 5.6, 
5.8E, F).  Bt2cAMP treatment also effectively, though temporarily, increases CtBP 
heterodimerization (Figure 5.8C), while allowing stronger GCN5/SRC-1/SF-1 interaction 
(Figure 3.4).  Therefore, in addition to cAMP-dependent switching of SF-1 coregulator 
binding mode, the cAMP-dependent switch in CtBP-mediated interactions which occurs 
with the switch from monomeric to dimeric CtBP, particularly heterodimerization, 
provides for an expanded nuclear population of SF-1 and free coactivators available for 
participation in the coactivator binding mode. 
In other words, PKA-mediated phosphorylation (Figure 5.4) and NAD(P)H 
modulation (Figure 5.1) are responsible for enforcing alternate protein-protein interaction 
networks involving CtBP, which depend on the homo- and hetero-dimerization of CtBP 
proteins.  We term this the “CtBP coregulator cooperativity switch.”  The complete list of 
differential bridging functions of which CtBP1 and 2 are capable in monomeric, 
homodimeric and heterodimeric forms will greatly aid in the prediction of how CtBP 
proteins affect both global and gene specific transcription programs. 
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 6.4.1 Kinase Cascades, Overall NAD(P)H Reductive Capacity of a Cell, and 
Pyridine Nucleotide Metabolism Are Inputs Determining CtBP 
Transcription Regulation 
 
CtBP proteins are unique not only in their switchable bridging function, but also 
in the large number of factors, or inputs, that are integrated into the physically determined 
decision of whether to dimerize.  PAK phosphorylation site residues (CtBP1 S158 or 
CtBP2 S164), are at extreme ends of the CtBP heterodimer interaction interface, and 
affect the ability of Bt2cAMP to induce CYP17 transcription (Figure 5.7C).  The location 
of both S100, juxtaposed to NADH in the catalytic domains of the homodimeric crystal 
structure (165), and S158, at the ends of the dimerization interface closest to the NADH 
binding sites (240) support a role for PAK-mediated exclusion of NADH from monomers 
assembling into oligomeric CtBP during the shift to activation of CYP17 transcription.  It 
is not clear if PAK affects only NADH binding to CtBP or also affects dimer stability, 
and hence, dimerization propensity. 
  CtBP proteins are 2-hydroxy acid dehydrogenases, and as such, their oligomeric 
state is linked to dehydrogenase activity, which is therefore also considered an input 
linked to CtBP ability to repress transcription.  S158 phosphorylation of CtBP1 has been 
shown to inactivate dehydrogenase activity (240) consistent with a direct role of CtBP 
dehydrogenase activity in modulating target gene repression or activation.  Thus, 
dehydrogenase activity of CtBP1 likely affects tighter binding to SF-1 in the absence of 
PAK signaling, such that the CtBP1 S158A mutation prevents Bt2cAMP derepression of 
CYP17, while, in contrast, mutation of the cognate residue in CtBP2, S164A, causes 
CtBP2 to lose basal repressive capacity (Figure 5.7C).  Therefore, the two homologs of 
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 CtBP in the nucleus of H295R cells are likely not equivalent in how their dehydrogenase 
activity affects transcription of specific genes. 
Consistent with the role of PAKs in modulating CtBP dehydrogenase activity, 
CtBP1 S100 is a novel PAK6 target (Figure 5.4), and its phosphorylation is predicted to 
sterically interfere with NADH binding to CtBP1.  It is particularly interesting that 
mutation of this site decreases two hybrid interactions with both GCN5 and SF-1 (Figures 
5.6, 5.7A).  Our data showing PAK site effects on Bt2cAMP induction of CYP17 suggest 
that activation of PAK isoform(s) is linked to PKA in the adrenal cortex.  PAK signaling, 
classically downstream of serum growth factors, and upstream of ERK signaling, could 
thus link the activation of ACTH/PKA signaling and ERK pathways during steroidogenic 
gene derepression.  Progressive phosphorylation or dephosphorylation of PAK sites may 
induce multiple modes of preferential CtBP partner binding (Figure 5.9).  Interestingly, 
we have found that PAK6 is acutely phosphorylated and active in response to 
ACTH/cAMP signaling (S. Jagarlapudi, unpublished observations). 
Extrinsic dehydrogenase activity, i.e. of NAD(H)-dependent dehydrogenases 
other than CtBP, also affects CtBP activity by altering NAD+/NADH ratio, as would 
pyridine nucleotide metabolism.  For these reasons, we have become interested in 
pathways which affect the overall reductive capacity of NAD(P)+/NAD(P)H pools in a 
cell, including transhydrogenase, the pentose phosphate pathway, NAD+ kinase, NAD+ 
synthesis and salvage, metabolism of glutamine, and malic enzyme.  The first two in this 
list in particular appear to be important in NAD(P)H sensitive transcription of H295R 
adrenal cortex cells, because inhibition of the pentose phosphate pathway by 5 µM 6-
aminonicotinamide reduces CYP17 transcription by more than forty percent in both the 
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 presence and absence of Bt2cAMP (E. Dammer, unpublished observations).  On the other 
hand, acute cortisol output in response to 1 mM Bt2cAMP measured by EIA is inhibited 
only 33 percent by concentrations of this inhibitor which are five times higher (E. 
Dammer, unpublished observations).  Therefore, the pentose phosphate pathway appears 
to have an independent (if not a more central) role in providing reducing equivalents to 
pyridine nucleotides for potentiating chronic steroidogenesis, more so than it does in 
providing NAD(P)H for acute steroidogenesis by cytochromes P450.  It is an open 
question as to whether steroidogenic P450 utilization of NAD(P)H pools imparts a 
rhythm to pyridine nucleotide reduction, but this is another potential factor affecting 
CtBP dehydrogenase activities and their ability to repress specific genes. 
The net level of dehydrogenase in the nucleus is expected to affect nuclear 
NAD(P)+/NAD(P)H, and thus the dehydrogenase activity of CtBP1 and 2 in the nucleus.  
Therefore, it is extremely interesting that spikes in NADH oxidation (e.g., via acute 
pyruvate treatment; Figure 5.2) or NAD+ reduction (e.g. via PKA activation in H295R 
cells; Figure 5.1) cause rhythmic loss of CtBP1 and 2 from the nucleus and an apparent 
transient gain in the cytoplasm (Figure 5.2B, C).  Only Bt2cAMP stimulation promotes 
the apparent rhythmic co-transport of both CtBP1 and 2 (cf. Figure 5.2B, C), consistent 
with its promotion of heterodimerization. 
It is therefore of interest what the relative levels of CtBP1 and 2 are in the nuclei 
of cells of a given tissue, because the coregulator cooperativity switch may not function if 
their levels are not well matched.  In fact, in H295R cells, if CtBP1 level is adjusted 
independent of CtBP2 by transient overexpression, then the ACTH-dependent acute rise 
in nuclear NAD(P)H as measured by autofluorescence takes fifty minutes with CtBP1 
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 overexpression versus less than ten minutes without (Figure 5.1B and E. Dammer, 
unpublished observations).  In the case of CtBP2 overexpression, the rise is not delayed, 
but its amplitude is blunted by about 18 percent (E. Dammer, unpublished observations). 
The above evidence serves to illustrate the complexity of factors which CtBP 
dehydrogenase activity, and trans repression function, integrates.  We have shown that 
CtBP is a PKA target at a unique motif which is important for CtBP dimerization.  
Mutation of the dimerization motif as well as PAK6 and PKA phosphorylation targets, as 
well as modulation of the availability of reduced pyridine nucleotide, each affect the 
ability of CtBP proteins to repress CYP17 in human adrenal cortex cells.  These 
conditions affect a switch in binding partners for CtBP1 and 2, in particular facilitating 
assembly of CtBP1:CtBP2 heteromeric complexes, which appear to be required for 
efficient CYP17 transcription. 
 
6.5 Concluding Remarks and Some Implications for These Findings 
 
Nuclear receptors are well-studied representatives of the wider class of proteins 
that function as positive and negative transcription regulators.  In this work, we have 
specifically shown that even ligand-regulated transcription factor function of the SF-1 
nuclear receptor [which coordinates sequential chromatin modifications; (Chapter 3)] 
further requires dynamic protein complex formation involving interactions with ternary 
or higher-order complex members (Chapter 3), loss of interactions among CtBP 
corepressor and (co)activators (Chapter 5), and post-translational modification of SF-1 
(Chapter 4) and of the CtBP corepressors downstream of the ACTH/cAMP signal 
cascade (Chapter 5).  Metabolism and metabolites also play a gatekeeper role in 
determining the confluence of the above events (Chapter 5). 
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 An application for the above findings may be found in the treatment of cancer in 
general, where transcriptional networks suffer from rewiring of metabolic (260) and 
signaling networks, and also loss of chromatin remodeling capacity of ATPases (261) and 
dysregulation of histone post-translational modification machinery (262, 263).  For 
example, treatments which temporarily restore one or more of these networks in the 
correct order could enable transcription of intact, but epigenetically silenced, genes with 
essential roles in apoptosis.  Some specific cancers are propagated through dysregulation 
of nuclear receptors including SF-1 and a close relative, liver receptor homolog-1 (75, 
264-267).  Treatments for these cases may be designed to target the kinases and 
acetyltransferases that may be at work in a temporally coordinated fashion underlying the 
phospho-acetyl switch on the LBD of these nuclear receptors, as suggested by data in 
chapter four.  The same cases may also be responsive to metabolic manipulation of the 
functional interaction of NAD(P)H, SF-1, and CtBP, as suggested by the data in chapter 
five.  A final note to be kept in mind is that since the above work was performed in a 
human adrenal cortex cell line, it likely provides insight into the etiology of certain 
previously unexplained cases of adrenal insufficiency. 
 137
         REFERENCES 
 
 
 
1. Gumbiner B, Kelly RB 1981 Secretory Granules of an Anterior Pituitary Cell 
Line, AtT-20, Contain Only Mature Forms of Corticotropin and Beta-
Lipotropin. Proc Natl Acad Sci U S A 78:318-322 
 
2. Karolchik D, Baertsch R, Diekhans M, Furey TS, Hinrichs A, Lu YT, Roskin 
KM, Schwartz M, Sugnet CW, Thomas DJ, Weber RJ, Haussler D, Kent WJ 2003 
The UCSC Genome Browser Database; Human Gene NR3C1. Nucl Acids Res 
31:51-54 
 
3. Glass CK 2007 Nuclear Receptors, Inflammation, and Metabolic Syndrome. 
Keystone Symposium: Nuclear Receptor Pathways and Metabolic Syndrome 
March 28, 2007 
 
4. Exton JH, Friedmann N, Wong EH-A, Brineaux JP, Corbin JD, Park CR 1972 
Interaction of Glucocorticoids with Glucagon and Epinephrine in the 
Control of Gluconeogenesis and Glycogenolysis in Liver and of Lipolysis in 
Adipose Tissue. J Biol Chem 247:3579-3588 
 
5. Wing SS, Goldberg AL 1993 Glucocorticoids Activate the ATP-Ubiquitin-
Dependent Proteolytic System in Skeletal Muscle During Fasting. Am J 
Physiol Endocrinol Metab 264:E668-676 
 
6. Miller WL 1995 Mitochondrial Specificity of the Early Steps in 
Steroidogenesis. J Steroid Biochem Mol Biol 55:607-616 
 
7. Sugawara T, Holt JA, Driscoll D, Strauss Jf, III, Lin D, Miller WL, Patterson D, 
Clancy KP, Hart IM, Clark BJ, Stocco DM 1995 Human Steriodogenic Acute 
Regulatory Protein: Functional Activity in COS-1 Cells, Tissue-Specific 
Expression, and Mapping of the Structural Gene to 8p11.2 and a Pseudogene 
to Chromosome 13. Proc Natl Acad Sci U S A 92:4778-4782 
 
8. Kraemer FB, Shen W-J, Harada K, Patel S, Osuga J-i, Ishibashi S, Azhar S 2004 
Hormone-Sensitive Lipase Is Required for High-Density Lipoprotein 
Cholesteryl Ester-Supported Adrenal Steroidogenesis. Mol Endocrinol 
18:549-557 
 
9. Arakane F, King SR, Du Y, Kallen CB, Walsh LP, Watari H, Stocco DM, Strauss 
Iii JF 1997 Phosphorylation of Steroidogenic Acute Regulatory Protein 
(StAR) Modulates Its Steroidogenic Activity. J Biol Chem 272:32656-32662 
 
 138
 10. Liu J, Rone MB, Papadopoulos V 2006 Protein-Protein Interactions Mediate 
Mitochondrial Cholesterol Transport and Steroid Biosynthesis. J Biol Chem 
281:38879-38893 
 
11. Choi Y-S, Stocco DM, Freeman DA 1995 Diethylumbelliferyl Phosphate 
Inhibits Steroidogenesis by Interfering with a Long-Lived Factor Acting 
Between Protein Kinase A Activation and Induction of the Steroidogenic 
Acute Regulatory Protein (StAR). Eur J Biochem 234:680-685 
 
12. Farkash Y, Timberg R, Orly J 1986 Preparation of Antiserum to Rat 
Cytochrome P-450 Cholesterol Side Chain Cleavage, and Its Use for 
Ultrastructural Localization of the Immunoreactive Enzyme by Protein A-
Gold Technique. Endocrinology 118:1353-1365 
 
13. Sewer MB, Dammer EB, Jagarlapudi S 2007 Transcriptional Regulation of 
Adrenocortical Steroidogenic Gene Expression. Drug Metab Rev 39:1-18 
 
14. Meadus WJ, Mason JI, Squires EJ 1993 Cytochrome P450c17 from Porcine 
and Bovine Adrenal Catalyses the Formation of 5,16-Androstadien-3 Beta-ol 
from Pregnenolone in the Presence of Cytochrome b5. J Steroid Biochem Mol 
Biol 46:565-572 
 
15. Saad M, Monte-Alegre S, Saad S 1991 Cortisol Levels in Glucose-6-Phosphate 
Dehydrogenase Deficiency. Horm Res 35:1-3 
 
16. Rainey WE, Saner K, Schimmer BP 2004 Adrenocortical Cell Lines. Mol and 
Cell Endocrinol 228:23-38 
 
17. Epstein LF, Orme-Johnson NR 1991 Regulation of Steroid Hormone 
Biosynthesis. Identification of Precursors of a Phosphoprotein Targeted to 
the Mitochondrion in Stimulated Rat Adrenal Cortex Cells. J Biol Chem 
266:19739-19745 
 
18. Boggaram V, Zuber MX, Waterman MR 1984 Turnover of Newly Synthesized 
Cytochromes P-450scc and P-45011 Beta and Adrenodoxin in Bovine 
Adrenocortical Cells in Monolayer Culture: Effect of Adrenocorticotropin. 
Arch Biochem Biophys 231:518-523 
 
19. Zhang G, Veldhuis JD 2004 Requirement for Proximal Putative Sp1 and AP-2 
cis-Deoxyribonucleic Acid Elements in Mediating Basal and Luteinizing 
Hormone- and Insulin-Dependent in Vitro Transcriptional Activation of the 
CYP17 Gene in Porcine Theca Cells. Endocrinology 145:2760-2766 
 
20. Sewer MB, Nguyen VQ, Huang C-J, Tucker PW, Kagawa N, Waterman MR 
2002 Transcriptional Activation of Human CYP17 in H295R Adrenocortical 
Cells Depends on Complex Formation among p54nrb/NonO, Protein-
 139
 Associated Splicing Factor, and SF-1, a Complex That Also Participates in 
Repression of Transcription. Endocrinology 143:1280-1290 
 
21. Lehoux J-G, Fleury A, Ducharme L 1998 The Acute and Chronic Effects of 
Adrenocorticotropin on the Levels of Messenger Ribonucleic Acid and 
Protein of Steroidogenic Enzymes in Rat Adrenal in Vivo. Endocrinology 
139:3913-3922 
 
22. Rainey WE, Naville D, Mason JI 1991 Regulation of 3 Beta-Hydroxysteroid 
Dehydrogenase in Adrenocortical Cells: Effects of Angiotensin-II and 
Transforming Growth Factor Beta. Endocr Res 17:281-296 
 
23. Bassett MH, White PC, Rainey WE 2004 The Regulation of Aldosterone 
Synthase Expression. Mol Cell Endocrinol 217:67-74 
 
24. Auchus RJ, Lee TC, Miller WL 1998 Cytochrome b5 Augments the 17,20-
Lyase Activity of Human P450c17 without Direct Electron Transfer. J Biol 
Chem 273:3158-3165 
 
25. Tee MK, Dong Q, Miller WL 2008 Pathways Leading to Phosphorylation of 
P450c17 and to the Posttranslational Regulation of Androgen Biosynthesis. 
Endocrinology 149:2667-2677 
 
26. Bassett MH, Suzuki T, Sasano H, de Vries CJM, Jimenez PT, Carr BR, Rainey 
WE 2004 The Orphan Nuclear Receptor NGFIB Regulates Transcription of 
3ß-Hydroxysteroid Dehydrogenase: Implications for the Control of Adrenal 
Functional Zonation. J Biol Chem 279:37622-37630 
 
27. Larsen PR, Kronenberg HM, Melmed S, Polonsky KS 2002 Williams Textbook 
of Endocrinology. 10th ed. New York: WB Saunders 
 
28. Zhao L, Bakke M, Hanley NA, Majdic G, Stallings NR, Jeyasuria P, Parker KL 
2004 Tissue-Specific Knockouts of Steroidogenic Factor 1. Mol Cell 
Endocrinol 215:89-94 
 
29. Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A, Boe AF, 
Boguski MS, Brockway KS, Byrnes EJ, Chen L, Chen L, Chen T-M, Chi Chin M, 
Chong J, Crook BE, Czaplinska A, Dang CN, Datta S, Dee NR, Desaki AL, Desta 
T, Diep E, Dolbeare TA, Donelan MJ, Dong H-W, Dougherty JG, Duncan BJ, 
Ebbert AJ, Eichele G, Estin LK, Faber C, Facer BA, Fields R, Fischer SR, Fliss 
TP, Frensley C, Gates SN, Glattfelder KJ, Halverson KR, Hart MR, Hohmann JG, 
Howell MP, Jeung DP, Johnson RA, Karr PT, Kawal R, Kidney JM, Knapik RH, 
Kuan CL, Lake JH, Laramee AR, Larsen KD, Lau C, Lemon TA, Liang AJ, Liu 
Y, Luong LT, Michaels J, Morgan JJ, Morgan RJ, Mortrud MT, Mosqueda NF, 
Ng LL, Ng R, Orta GJ, Overly CC, Pak TH, Parry SE, Pathak SD, Pearson OC, 
Puchalski RB, Riley ZL, Rockett HR, Rowland SA, Royall JJ, Ruiz MJ, Sarno 
 140
 NR, Schaffnit K, Shapovalova NV, Sivisay T, Slaughterbeck CR, Smith SC, 
Smith KA, Smith BI, Sodt AJ, Stewart NN, Stumpf K-R, Sunkin SM, Sutram M, 
Tam A, Teemer CD, Thaller C, Thompson CL, Varnam LR, Visel A, Whitlock 
RM, Wohnoutka PE, Wolkey CK, Wong VY, Wood M, Yaylaoglu MB, Young 
RC, Youngstrom BL, Feng Yuan X, Zhang B, Zwingman TA, Jones AR 2007 
Genome-Wide Atlas of Gene Expression in the Adult Mouse Brain. Nature 
445:168-176 
 
30. Zhao L, Kim KW, Ikeda Y, Anderson KK, Beck L, Chase S, Tobet SA, Parker 
KL 2008 Central Nervous System-Specific Knockout of Steroidogenic Factor 
1 Results in Increased Anxiety-Like Behavior. Mol Endocrinol 22:1403-1415 
 
31. Fowkes RC, Desclozeaux M, Patel MV, Aylwin SJB, King P, Ingraham HA, 
Burrin JM 2003 Steroidogenic Factor-1 and The Gonadotrope-Specific 
Element Enhance Basal and Pituitary Adenylate Cyclase-Activating 
Polypeptide-Stimulated Transcription of the Human Glycoprotein Hormone 
α-Subunit Gene in Gonadotropes. Mol Endocrinol 17:2177-2188 
 
32. Luo X, Ikeda Y, Parker KL 1994 A Cell-Specific Nuclear Receptor Is Essential 
for Adrenal and Gonadal Development and Sexual Differentiation. Cell 
77:481-490 
 
33. Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ 2006 
Anatomical Profiling of Nuclear Receptor Expression Reveals a Hierarchical 
Transcriptional Network. Cell 126:789-799 
 
34. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, 
Blumberg B, Kastner P, Mark M, Chambon P, Evans RM 1995 The Nuclear 
Receptor Superfamily: The Second Decade. Cell 83:835-839 
 
35. Gustafsson J-Å, Wikstrom A, Denis M 1989 The Non-Activated Glucocorticoid 
Receptor: Structure and Activation. J Steroid Biochem 34:53-62 
 
36. Centenera MM, Harris JM, Tilley WD, Butler LM 2008 The Contribution of 
Different Androgen Receptor Domains to Receptor Dimerization and 
Signaling. Mol Endocrinol:me.2008-0017 
 
37. Pedram A, Razandi M, Sainson RCA, Kim JK, Hughes CC, Levin ER 2007 A 
Conserved Mechanism for Steroid Receptor Translocation to the Plasma 
Membrane. J Biol Chem 282:22278-22288 
 
38. Wong C-W, McNally C, Nickbarg E, Komm BS, Cheskis BJ 2002 Estrogen 
Receptor-Interacting Protein That Modulates Its Nongenomic Activity-
Crosstalk with Src/Erk Phosphorylation Cascade. Proc Natl Acad Sci U S A 
99:14783-14788 
 
 141
 39. Barettino D, Vivanco Ruiz MdM, Stunnenberg HG 1994 Characterization of the 
Ligand-Dependent Transactivation Domain of Thyroid Hormone Receptor. 
EMBO J 13:3039-3049 
 
40. Cavailles V, Dauvois S, Danielian PS, Parker MG 1994 Interaction of Proteins 
with Transcriptionally Active Estrogen Receptors. Proc Natl Acad Sci U S A 
91:10009-10013 
 
41. Durand B, Saunders M, Gaudon C, Roy B, Losson R, Chambon P 1994 
Activation Function 2 (AF-2) of Retinoic Acid Rreceptor and 9-cis Retinoic 
Acid Rreceptor: Presence of a Conserved Autonomous Constitutive 
Activating Domain and Influence of the Nature of the Response Element on 
AF-2 Activity. EMBO J 13:5370-5382 
 
42. Copik AJ, Webb MS, Miller AL, Wang Y, Kumar R, Thompson EB 2006 
Activation Function 1 of Glucocorticoid Receptor Binds TATA-Binding 
Protein in Vitro and in Vivo. Mol Endocrinol 20:1218-1230 
 
43. Little TH, Zhang Y, Matulis CK, Weck J, Zhang Z, Ramachandran A, Mayo KE, 
Radhakrishnan I 2006 Sequence-Specific Deoxyribonucleic Acid (DNA) 
Recognition by Steroidogenic Factor 1: A Helix at the Carboxy Terminus of 
the DNA Binding Domain Is Necessary for Complex Stability. Molecular 
Endocrinology 20:831-843 
 
44. Li Y, Choi M, Cavey G, Daugherty J, Suino K, Kovach A, Bingham NC, Kliewer 
SA, Xu HE 2005 Crystallographic Identificatioon and Functional 
Characterization of Phospholipids as Ligands for the Orphan Nuclear 
Receptor Steroidogenic Factor-1. Mol Cell 17:491-502 
 
45. Ortlund EA, Lee Y, Solomon IH, Hager JM, Safi R, Choi Y, Ziqiang G, Tripathy 
A, Raetz CRH, McDonnell DP, Moore DD, Redinbo MR 2005 Modulation of 
Human Nuclear Receptor LRH-1 Activity by Phospholipids and SHP. Nat 
Struct Mol Biol 12:357-363 
 
46. Chen W-Y, Juan L-J, Chung B-c 2005 SF-1 (Nuclear Recxeptor 5A1) Activity 
Is Activated by Cyclic AMP via p300-Mediated Recruitment to Active Foci, 
Acetylation, and Increased DNA Binding. Mol Cell Biol 25:10442-10453 
 
47. Feng Q, Yi P, Wong J, O'Malley BW 2006 Signaling within a Coactivator 
Complex: Methylation of SRC-3/AIB1 Is a Molecular Switch for Complex 
Disassembly. Mol Cell Biol 26:7846-7857 
 
48. Lewis AE, Rusten M, Hoivik EA, Vikse EL, Hansson ML, Wallberg AE, Bakke 
M 2008 Phosphorylation of Steroidogenic Factor 1 Is Mediated by Cyclin-
Dependent Kinase 7. Mol Endocrinol 22:91-104 
 
 142
 49. Hammer GD, Krylova I, Zhang Y, Darimont BD, Simpson K, Weigel NL, 
Ingraham HA 1999 Phosphorylation of the Nuclear Receptor SF-1 Modulates 
Cofactor Recruitment: Integration of Hormone Signaling in Reproduction 
and Stress.  Mol Cell 3:521-526 
 
50. Desclozeaux M, Krylova IN, Horn F, Fletterick R, Ingraham HA 2002 
Phosphorylation and Intramolecular Stabilization of the Ligand Binding 
Domain in the Nuclear Receptor Steroidogenic Factor 1. Mol Cell Biol 
22:7193-7203 
 
51. Chen W-Y, Lee W-C, Hsu N-C, Huang F, Chung B-c 2004 SUMO Modification 
of Repression Domains Modulates Function of Nuclear Receptor 5A1 
(Steroidogenic Factor-1). J Biol Chem 279:38730-38735 
 
52. Komatsu T, Mizusaki H, Mukai T, Ogawa H, Baba D, Shirakawa M, Hatakeyama 
S, Nakayama KI, Yamamoto H, Kikuchi A, Morohashi K 2004 Small Ubiquitin-
Like Modifier 1 (SUMO-1) Modification of the Synergy Control Motif of Ad4 
Binding Protein/Steroidogenic Factor 1 (Ad4BP/SF-1) Regulates Synergistic 
Transcription between Ad4BP/SF-1 and Sox9. Mol Endocrinol 18:2451-2462 
 
53. Lee MB, Lebedeva LA, Suzawa M, Wadekar SA, Desclozeaux M, Ingraham HA 
2005 The DEAD-Box Protein DP103 (Ddx20 or Gemin-3) Represses Orphan 
Nuclear Receptor Activity via SUMO Modification. Mol Cell Biol 25:1879-
1890 
 
54. Mellon SH, Bair SR, Depoix C, Vigne J-L, Hecht NB, Brake PB 2007 Translin 
Coactivates Steroidogenic Factor-1-Stimulated Transcription. Mol Endocrinol 
21:89-105 
 
55. Desclozeaux M, Krylova IN, Horn F, Fletterick RJ, Ingraham HA 2002 
Phosphorylation and Intramolecular Stabilization of the Ligand Binding 
Domain in the Nuclear Receptor Steroidogenic Factor 1. Mol Cell Biol 
22:7193-7203 
 
56. Ingraham HA, Redinbo MR 2005 Orphan Nuclear Receptors Adopted by 
Crystallography. Curr Opin Struct Biol 15:708-715 
 
57. Gronemeyer H, Gustafsson J-Å, Laudet V 2004 Principles for Modulation of 
the Nuclear Receptor Superfamily. Nat Rev Drug Disc 3:950-964 
 
58. Crawford PA, Polish JA, Ganpule G, Sadovsky Y 1997 The Activation 
Function-2 Hexamer of Steroidogenic Factor-1 Is Required, but Not 
Sufficient for Potentiation by SRC-1. Mol Endocrinol 11:1626-1635 
 
 143
 59. Jacob AL, Lund J 1998 Mutations in the Activation Function-2 Core Domain 
of Steroidogenic Factor-1 Dominantly Suppresses PKA-dependent 
Transactivation of the Bovine CYP17 Gene. J Biol Chem 273:13391-13394 
 
60. Faivre EJ, Daniel AR, Hillard CJ, Lange CA 2008 Progesterone Receptor Rapid 
Signaling Mediates Serine 345 Phosphorylation and Tethering to Specificity 
Protein 1 Transcription Factors. Mol Endocrinol 22:823-837 
 
61. Torra IP, Ismaili N, Feig JE, Xu C-F, Cavasotto C, Pancratov R, Rogatsky I, 
Neubert TA, Fisher EA, Garabedian MJ 2008 Phosphorylation of Liver X 
Receptor α Selectively Regulates Target Gene Expression in Macrophages. 
Mol Cell Biol 28:2626-2636 
 
62. Matthews J, Wihlén B, Thomsen J, Gustafsson J-Å 2005 Aryl Hydrocarbon 
Receptor-Mediated Transcription: Ligand-Dependent Recruitment of 
Estrogen Receptor α to 2,3,7,8-Tetrachlorodibenco-p-Dioxin-Responsive 
Promoters. Mol Cell Biol 25:5317-5328 
 
63. Ohtake F, Takeyama K-I, Matsumoto T, Kitagawa H, Yamamoto Y, Nohara K, 
Tohyama C, Krust A, Mimura J, Chambon P, Yanagisawa J, Fujii-Kuriyama Y, 
Kato S 2003 Modulation of Oestrogen Receptor Signalling by Association 
with the Activated Dioxin Receptor. Nat Rev 423 
 
64. Krylova IN, Sablin EP, Moore J, Xu RX, Waitt GM, MacKay JA, Juzumiene D, 
Bynum JM, Madauss K, Montana V, Lebedeva L, Suzawa M, Williams JD, 
Williams SP, Guy RK, Thornton JW, Fletterick RJ, Willson TM, Ingraham HA 
2005 Structural Analyses Reveal Phosphatidyl Inositols as Ligands for the 
NR5 Orphan Receptors SF-1 and LRH-1. Cell 120:343-355 
 
65. Wang W, Zhang C, Marimuthu A, Krupka HI, Tabrizizad M, Shelloe R, Mehra U, 
Eng K, Nguyen H, Settachatgul C, Powell B, Milburn MV, West BL 2005 The 
Crystal Structures of Human Steroidogenic Factor-1 and Liver Receptor 
Homolog-1. Proc Natl Acad Sci U S A 102:7505-7510 
 
66. Heery DM, Kalkhoven E, Hoare S, Parker MG 1997 A Signature Motif in 
Transcriptional Co-activators Mediates Binding to Nuclear Receptors. Nature 
387:733-736 
 
67. Gurevich I, Flores AM, Aneskievich BJ 2007 Corepressors of Agonist-Bound 
Nuclear Receptors. Toxicol Appl Pharmacol 223:288-298 
 
68. Perissi V, Staszewski LM, McInerney EM, Kurokawa R, Krones A, Rose DW, 
Lambert MH, Milburn MV, Glass CK, Rosenfeld MG 1999 Molecular 
Determinants of Nuclear Receptor-Corepressor Interaction. Genes Dev 
13:3198-3208 
 
 144
 69. Hu X, Lazar MA 1999 The CoRNR Motif Controls the Recruitment of 
Corepressors by Nuclear Hormone Receptors. Nature 402:93-96 
 
70. Li Y, Kimura T, Huyck RW, Laity JH, Andrews GK 2008 Zinc-Induced 
Formation of a Coactivator Complex Containing the Zinc-Sensing 
Transcription Factor MTF-1, p300/CBP, and Sp1. Mol Cell Biol 28:4275-
4284 
 
71. Seitz M, Maillard LT, Obrecht D, Robinson JA 2008 Molecular 
Characterization of the NCoA-1-STAT 6 Interaction. ChemBioChem 9:1318-
1322 
 
72. Iwahana E, Akiyama M, Miyakawa K, Uchida A, Kasahara J, Fukunaga K, 
Hamada T, Shibata S 2004 Effect of Lithium on the Circadian Rhythms of 
Locomotor Activity and Glycogen Synthase Kinase-3 Protein Expression in 
the Mouse Suprachiasmatic Nuclei. Eur J Neurosci 19:2281-2287 
 
73. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M 2000 Cofactor Dynamics and 
Sufficiency in Estrogen Receptor-Regulated Transcription. Cell 103:843-852 
 
74. Urs AN, Dammer E, Sewer MB 2006 Sphingosine Regulates the Transcription 
of CYP17 by Binding to Steroidogenic Factor-1. Endocrinology 147:5249-5258 
 
75. Doghman M, Karpova T, Rodrigues GA, Arhatte M, De Moura J, Cavalli LR, 
Virolle V, Barbry P, Zambetti GP, Figueiredo BC, Heckert LL, Lalli E 2007 
Increased Steroidogenic Factor-1 Dosage Triggers Adrenocortical Cell 
Proliferation and Cancer. Mol Endocrinol 21:2968-2987 
 
76. Ozbay T, Rowan A, Leon A, Sewer MB 2005 cAMP-Dependent Sphingosine-1-
Phosphate Biosynthesis Induces Human CYP17 Gene Transcription by 
Activating Cleavage of Sterol Regulatory Element Binding Protein 1. 
Endocrinology 147:1427-1437 
 
77. Li D, Urs AN, Allegood J, Leon A, Merrill AH, Jr., Sewer MB 2007 cAMP-
Stimulated Interaction Between Steroidogenic Factor-1 and Diacylglycerol 
Kinase Facilitates Induction of CYP17. Mol Cell Biol 27:6669-6685 
 
78. Fan W, Yanase T, Wu Y, Kawate H, Saitoh M, Oba K, Nomura M, Okabe T, 
Goto K, Yanagisawa J, Kato S, Takayanagi R, Nawata H 2004 Protein Kinase A 
Potentiates Adrenal 4 Binding Protein/Steroidogenic Factor 1 
Transactivation by Reintegrating the Subcellular Dynamic Interaction of the 
Nuclear Receptor with Its Cofactors, General Control nonderepressed-
5/Transformation/Transcription Domain-Associated Protein, and 
Suppressor, Dosage-Sensitive Sex Reversal-1: a Laser Confocal Imaging 
Study in Living KGN Cells. Mol Endocrinol 18:127-141 
 
 145
 79. Luger K, Mäder AW, Richmond RK, Sargent DF, Richmond TJ 1997 Crystal 
Structure of the Nucleosome Core Particle at 2.8 Å Resolution. Nature 
389:251-260 
 
80. Dorigo B, Schalch T, Kulangara A, Duda S, Schroeder RR, Richmond TJ 2005 
Nucleosome Arrays Reveal the Two-Start Organization of the Chromatin 
Fiber. Science 306:1571-1573 
 
81. Kepper N, Foethke D, Stehr R, Wedemann G, Rippe K 2008 Nucleosome 
Geometry and Internucleosomal Interactions Control the Chromatin Fiber 
Conformation. Biophys J:biophysj.107.121079 
 
82. Mellor J 2005 The Dynamics of Chromatin Remodeling at Promoters. Mol 
Cell 19:147-157 
 
83. Segal E, Fondufe-Mettendorf Y, Chen L, Thåström A, Field Y, Moore IK, Wang 
J-PZ, Widom J 2006 A Genomic Code for Nucleosome Positioning. Nature 
442:772-778 
 
84. Sewack GF, Hansen U 1997 Nucleosome Positioning and Transcription-
associated Chromatin Alterations on the Human Estrogen-responsive pS2 
Promoter. J Biol Chem 272:31118-31129 
 
85. Morohashi K-I, Honda S-I, Inomata Y, Handa H, Omura T 1992 A Common 
trans-Acting Factor, Ad4-binding Protein, to the Promoters of Steroidogenic 
P-450s. J Biol Chem 267:17913-17919 
 
86. Reid G, Hübner MR, Métivier R, Brand H, Denger S, Manu D, Beaudouin J, 
Ellenberg J, Gannon F 2003 Cyclic, Proteasome-Mediated Turnover of 
Unliganded and Liganded ERα on Responsive Promoters Is an Integral 
Feature of Estrogen Signaling. Mol Cell 11:695-707 
 
87. Métivier R, Penot G, Hübner MR, Reid G, Brand H, Kos M, Gannon F 2003 
Estrogen Receptor-α Directs Ordered, Cyclical, and Combinatorial 
Recruitment of Cofactors on a Natural Target Promoter. Cell 115:751-763 
 
88. Kang Z, Pirskanen A, Janne OA, Palvimo JJ 2002 Involvement of Proteasome 
in the Dynamic Assembly of the Androgen Receptor Transcription Complex. 
J Biol Chem 277:48366-48371 
 
89. Sharma D, Fondell JD 2002 Ordered Recruitment of Histone 
Acetyltransferases and the TRAP/Mediator Complex to Thyroid Hormone-
Responsive Promoters in Vivo. Proc Natl Acad Sci 99:7934-7939 
 
 146
 90. Väisänen S, Dunlop TW, Sinkkonen L, Frank C, Carlberg C 2005 Spatio-
Temporal Activation of Chromatin on the Human CYP24 Promoter in the 
Presence of 1,25-Dihydroxyvitamin D3. J Mol Biol 350:65-77 
 
91. Szak ST, Mays D, Pietenpol JA 2001 Kinetics of p53 Binding to Promoter Sites 
In Vivo. Mol Cell Biol 21:3375-3386 
 
92. Saccani S, Pantano S, Natoli G 2001 Two Waves of Nuclear Factor {kappa}B 
Recruitment to Target Promoters. J Exp Med 193:1351-1360 
 
93. Métivier R, Penot G, Carmouche RP, Hübner MR, Reid G, Denger S, Manu D, 
Brand H, Ko M, Benes V, Gannon F 2004 Transcriptional Complexes Engaged 
by Apo-Estrogen Receptor-alpha Isoforms Have Divergent Outcomes. EMBO 
J 23:3653-3666 
 
94. Métivier R, Reid G, Gannon F 2006 Transcription in Four Dimensions: 
Nuclear Receptor-Directed Initiation of Gene Expression. EMBO Rep 7:161-
167 
 
95. Turjanski AG, Gutkind JS, Best RB, Hummer G 2008 Binding-Induced Folding 
of a Natively Unstructured Transcription Factor. PLoS Comput Biol 
4:e1000060 
 
96. Chirinos M, Hernández F, Palacián E 1999 Transcription of DNA Templates 
Associated with Histone (H3 · H4)2 Tetramers. Arch Biochem Biophys 
370:222-230 
 
97. Ucker DS, Yamamoto KR 1984 Early Events in the Stimulation of Mammary 
Tumor Virus RNA Synthesis by Glucocorticoids. Novel Assays of 
Transcription Rates. J Biol Chem 259:7416-7420 
 
98. Izban MG, Luse DS 1991 Transcription on Nucleosomal Templates by RNA 
Polymerase II in Vitro: Inhibition of Elongation with Enhancement of 
Sequence-Specific Pausing. Genes Dev 5:683-696 
 
99. Reinberg D, Roeder RG 1987 Factors Involved in Specific Transcription by 
Mammalian RNA Polymerase II. Transcription Factor IIS Stimulates 
Elongation of RNA Chains. J Biol Chem 262:3331-3337 
 
100. Rayasam GV, Elbi C, Walker DA, Wolford R, Fletcher TM, Edwards DP, Hager 
GL 2005 Ligand-Specific Dynamics of the Progesterone Receptor in Living 
Cells and during Chromatin Remodeling In Vitro. Mol Cell Biol 25:2406-
2418 
 
101. Fischle W, Wang Y, Allis CD 2003 Binary Switches and Modification 
Cassettes in Histone Biology and Beyond. Nature 425:475-479 
 147
  
102. Ruthenburg AJ, Li H, Patel DJ, Allis CD 2007 Multivalent Engagement of 
Chromatin Modifications by Linked Binding Modules. Nat Rev Mol Cell Biol 
8:983-994 
 
103. Jenuwein T, Allis CD 2001 Translating the Histone Code. Science 293:1074-
1080 
 
104. Bruno M, Flaus A, Stockdale C, Rencurel C, Ferreira H, Owen-Hughes T 2003 
Histone H2A/H2B Dimer Exchange by ATP-Dependent Chromatin 
Remodeling Activities. Mol Cell 12:1599-1606 
 
105. Lorch Y, Maier-Davis B, Kornberg RD 2006 Chromatin Remodeling by 
Nucleosome Disassembly in Vitro. Proc Natl Acad Sci U S A 103:3090-3093 
 
106. Cosgrove MS, Wolberger C 2005 How Does the Histone Code Work? Biochem 
Cell Biol 83:468-476 
 
107. Chen J, Kinyamu K, Archer TK 2006 Changes in Attitude, Changes in 
Latitude: Nuclear Receptors Remodeling Chromatin to Regulate 
Transcription. Mol Endocrinology 20:1-13 
 
108. Inoue H, Furukawa T, Giannakopoulos S, Zhou S, King DS, Tanese N 2002 
Largest Subunits of the Human SWI/SNF Chromatin-remodeling Complex 
Promote Transcriptional Activation by Steroid Hormone Receptors. J Biol 
Chem 277:41674-41685 
 
109. Nie Z, Xue Y, Yang D, Zhou S, Deroo BJ, Archer TK, Wang W 2000 A 
Specificity and Targeting Subunit of a Human SWI/SNF Family-Related 
Chromatin-Remodeling Complex. Mol Cell Biol 20:8879-8888 
 
110. Zhang B, Chambers KJ, Faller DV, Wang S 2007 Reprogramming of the 
SWI//SNF complex for co-activation or co-repression in prohibitin-mediated 
estrogen receptor regulation. Oncogene 26:7153-7157 
 
111. Dai Y, Ngo D, Jacob J, Forman LW, Faller DV 2008 Prohibitin and the 
SWI/SNF ATPase Subunit BRG1 Are Required for Effective Androgen-
Antagonist-Mediated Transcriptional Repression of Androgen Receptor-
Regulated Genes. Carcinogenesis Epub May 16. 
 
112. John S, Sabo PJ, Johnson TA, Sung M-H, Biddie SC, Lightman SL, Voss TC, 
Davis SR, Meltzer PS, Stamatoyannopoulos JA, Hager GL 2008 Interaction of 
the Glucocorticoid Receptor with the Chromatin Landscape. Mol Cell 
29:611-624 
 
 148
 113. Kim J, Daniel J, Espejo A, Lake A, Krishna M, Xia L, Zhang Y, Bedford MT 
2006 Tudor, MBT and Chromo Domains Gauge the Degree of Lysine 
Methylation. EMBO Rep 7:397-403 
 
114. Parnell TJ, Huff JT, Cairns BR 2008 RSC Regulates Nucleosome Positioning at 
Pol II genes and Density at Pol III Genes. EMBO J 27:100-110 
 
115. Metivier R, Gallais R, Tiffoche C, Le Peron C, Jurkowska RZ, Carmouche RP, 
Ibberson D, Barath P, Demay F, Reid G, Benes V, Jeltsch A, Gannon F, Salbert G 
2008 Cyclical DNA Methylation of a Transcriptionally Active Promoter. 
Nature 452:45-50 
 
116. Gilbert N, Thomson I, Boyle S, Allan J, Ramsahoye B, Bickmore WA 2007 DNA 
Methylation Affects Nuclear Organization, Histone Modifications, and 
Linker Histone Binding but Not Chromatin Compaction. J Cell Biol 177:401-
411 
 
117. Bannister AJ, Zegerman P, Partridge JF, Miska EA, Thomas JO, Allshire RC, 
Kouzarides T 2001 Selective Recognition of Methylated Lysine 9 on Histone 
H3 by the HP1 Chromo Domain. Nature 410:120-124 
 
118. Ganapathi M, Singh GP, Sandhu KS, Brahmachari SK, Brahmachari V 2007 A 
Whole Genome Analysis of 5' Regulatory Regions of Human Genes for 
Putative Cis-acting Modulators of Nucleosome Positioning. Gene 391:242-251 
 
119. Fan Y, Nikitina T, Zhao J, Fleury TJ, Bhattacharyya R, Bouhassira EE, Stein A, 
Woodcock CL, Skoultchi AI 2005 Histone H1 Depletion in Mammals Alters 
Global Chromatin Structure but Causes Specific Changes in Gene 
Regulation. Cell 123:1199-1212 
 
120. Pelka P, Ablack JNG, Fonseca GJ, Yousef AF, Mymryk JS 2008 Intrinsic 
Structural Disorder in Adenovirus E1A: a Viral Molecular Hub Linking 
Multiple Diverse Processes. J Virol:JVI.00104-00108 
 
121. Kabe Y, Goto M, Shima D, Imai T, Wada T, Morohashi K-i, Shirakawa M, 
Hirose S, Handa H 1999 The Role of Human MBF1 as a Transcriptional 
Coactivator. J Biol Chem 274:34196-34202 
 
122. Ju B-G, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW, Glass CK, Rosenfeld 
MG 2006 A Topoisomerase IIß-Mediated dsDNA Break Required for 
Regulated Transcription. Science 312:1798-1802 
 
123. Khobta A, Ferri F, Lotito L, Montecucco A, Rossi R, Capranico G 2006 Early 
Effects of Topoisomerase I Inhibition on RNA Polymerase II Along 
Transcribed Genes in Human Cells. J Mol Biol 357:127-138 
 
 149
 124. Perissi V, Aggarwal A, Glass CK, Rose DW, Rosenfeld MG 2004 A 
Corepressor/Coactivator Exchange Complex Required for Transcriptional 
Activation by Nuclear Receptors and Other Regulated Transcription 
Factors. Cell 116:511-526 
 
125. Keogh M-C, Kurdistani SK, Morris SA, Ahn SH, Podolny V, Collins SR, 
Schuldiner M, Chin K, Punna T, Thompson NJ, Boone C, Emili A, Weissman JS, 
Hughes TR, Strahl BD, Grunstein M, Greenblatt JF, Buratowski S, Krogan NJ 
2005 Cotranscriptional Set2 Methylation of Histone H3 Lysine 36 Recruits a 
Repressive Rpd3 Complex. Cell 123:593-605 
 
126. Carrozza MJ, Li B, Florens L, Suganuma T, Swanson SK, Lee KK, Shia W-J, 
Anderson S, Yates J, Washburn MP, Workman JL 2005 Histone H3 Methylation 
by Set2 Directs Deacetylation of Coding Regions by Rpd3S to Suppress 
Spurious Intragenic Transcription. Cell 123:581-592 
 
127. Edmunds JW, Mahadevan LC, Clayton AL 2008 Dynamic Histone H3 
Methylation during Gene Induction: HYPB/Setd2 Mediates all H3K36 
Trimethylation. EMBO J 27:406-420 
 
128. Denslow SA, Wade PA The Human Mi-2//NuRD Complex and Gene 
Regulation. Oncogene 26:5433-5438 
 
129. van Holde K, Zlatanova J 1994 Unusual DNA Structures, Chromatin and 
Transcription. Bioessays 16:59-68 
 
130. Yang X-J, Seto E 2008 The Rpd3/Hda1 Family of Lysine Deacetylases: from 
Bacteria and Yeast to Mice and Men. Nat Rev Mol Cell Biol 9:206-218 
 
131. Komatsu T, Mizusaki H, Mukai T, Ogawa H, Baba D, Shirakawa M, Hatakeyama 
S, Nakayama K, Yamamoto H, Kikuchi A, Morohashi K-I 2004 Small 
Ubiquitin-Like Modifier 1 (SUMO-1) Modification of the Synergy Control 
Motif of Ad4 Binding Protein/Steroidogenic Factor 1 (Ad4BP/SF-1) 
Regulates Synergistic Transcription Between Ad4BP/SF-1 and Sox9. Mol 
Endocrinol 18:2451-2462 
 
132. Sentis S, Le Romancer M, Bianchin C, Rostan M-C, Corbo L 2005 Sumoylation 
of the Estrogen Receptor α Hinge Region Regulates Its Transcriptional 
Activity. Mol Endocrinol 19:2671-2684 
 
133. Lee MH, Lee SW, Lee EJ, Choi SJ, Chung SS, Lee JI, Cho JM, Seol JH, Baek 
SH, Kim KI, Chiba T, Tanaka K, Bang OS, Chung CH 2006 SUMO-Specific 
Protease SUSP4 Positively Regulates p53 by Promoting Mdm2 Self-
Ubiquitination. Nat Cell Biol 8:1424-1431 
 
 150
 134. Lyst MJ, Nan X, Stancheva I 2006 Regulation of MBD1-Mediated 
Transcriptional Repression by SUMO and PIAS Proteins. EMBO J 25:5317-
5328 
 
135. Wang C, Fu M, Angeletti RH, Siconolfi-Baez L, Reutens AT, Albanese C, Lisanti 
MP, Katzenellenbogen BS, Kato S, Hopp T, Fuqua SAW, Lopez GN, Kushner PJ, 
Pestell RG 2001 Direct Acetylation of the Estrogen Receptor alpha Hinge 
Region by p300 Regulates Transactivation and Hormone Sensitivity. J Biol 
Chem 276:18375-18383 
 
136. Leader JE, Wang C, Popov VM, Fu M, Pestell RG 2006 Epigenetics and the 
Estrogen Receptor. Ann NY Acad Sci 1089:73-87 
 
137. Jacob AL, Lund J, Martinez P, Hedin L 2001 Acetylation of Steroidogenic 
Factor 1 Protein Regulates Its Transcriptional Activity and Recruits the 
Coactivator GCN5. J Biol Chem 276:37659-37644 
 
138. Trigon S, Serizawa H, Conaway JW, Conaway RC, Jackson SP, Morange M 1998 
Characterization of the Residues Phosphorylated in Vitro by Different C-
terminal Domain Kinases. J Biol Chem 273:6769-6775 
 
139. Hirose Y, Ohkuma Y 2007 Phosphorylation of the C-terminal Domain of RNA 
Polymerase II Plays Central Roles in the Integrated Events of Eucaryotic 
Gene Expression. J Biochem 141:601-608 
 
140. Drané P, Compe E, Catez P, Chymkowitch P, Egly J-M 2004 Selective 
Regulation of Vitamin D Receptor-Responsive Genes by TFIIH. Mol Cell 
16:187-197 
 
141. Chen D, Riedl T, Washbrook E, Pace PE, Coombes RC, Egly J-M, Ali S 2000 
Activation of Estrogen Receptor α by S118 Phosphorylation Involves a 
Ligand-Dependent Interaction with TFIIH and Participation of CDK7. Mol 
Cell 6:127-137 
 
142. Rochette-Egly C, Adam S, Rossignol M, Egly J-M, Chambon P 1997 
Stimulation of RARα Activation Function AF-1 through Binding to the 
General Transcription Factor TFIIH and Phosphorylation by CDK7. Cell 
90:97-107 
 
143. Krstic MD, Rogatsky I, Yamamoto KR, Garabedian MJ 1997 Mitogen-Activated 
and Cyclin-Dependent Protein Kinases Selectively and Differentially 
Modulate Transcriptional Enhancement by the Glucocorticoid Receptor. Mol 
Cell Biol 17:3947-3954 
 
144. Zhang Y, Beck CA, Poletti A, Clement JPIV, Prendergast P, Yip T-T, Hutchens 
TW, Edwards DP, Weigel NL 1997 Phosphorylation of Human Progesterone 
 151
 Receptor by Cyclin-Dependent Kinase 2 on Three Sites That Are Authentic 
Basal Phosphorylation Sites In Vivo. Mol Endocrinol 11:823-832 
 
145. Yi P, Wu R-C, Sandquist J, Wong J, Tsai SY, Tsai M-J, Means AR, O'Malley 
BW 2005 Peptidyl-Prolyl Isomerase 1 (Pin1) Serves as a Coactivator of 
Steroid Receptor by Regulating the Activity of Phosphorylated Steroid 
Receptor by Regulating the Activity of Phosphorylated Steroid Receptor 
Coactivator 3 (SRC-3/AIB1). Mol Cell Biol 25:9687-9699 
 
146. Monje P, Hernandez-Losa J, Lyons RJ, Castellone MD, Gutkind JS 2005 
Regulation of the Transcriptional Activity of c-Fos by Erk: A Novel Role for 
the Prolyl Isomerase Pin1. J Biol Chem 280:35081-35084 
 
147. Lee Y-K, Choi Y-H, Chua S, Park YJ, Moore DD 2006 Phosphorylation of the 
Hinge Domain of the Nuclear Hormone Receptor LRH-1 Stimulates 
Transactivation. J Biol Chem 281:7850-7855 
 
148. Sewer MB, Waterman MR 2003 cAMP-Dependent Protein Kinase A (PKA) 
Enhances CYP17 Transcription via MKP-1 Activation in H295R Human 
Adrenocortical Cells. J Biol Chem 278:8106-8111 
 
149. Bey P, Gorostizaga AB, Maloberti PM, Lozano RC, Poderoso C, Maciel FC, 
Podesta EJ, Paz C 2003 Adrenocorticotropin Induces Mitogen-Activated 
Protein Kinase Phosphatase 1 in Y1 Mouse Adrenocortical Tumor Cells. 
Endocrinology 144:1399-1406 
 
150. Winnay JN, Hammer GD 2006 ACTH-Mediated Signaling Cascades 
Coordinate a Cyclic Pattern of SF-1-Dependent Transcriptional Activation. 
Mol Endocrinol 20:147-166 
 
151. Rochette-Egly C 2003 Nuclear Receptors: Integration of Multiple Signalling 
Pathways through Phosphorylation. Cell Sig 15:355-366 
 
152. Perissi V, Scafoglio C, Zhang J, Ohgi KA, Rose DW, Glass CK, Rosenfeld MG 
2008 TBL1 and TBLR1 Phosphorylation on Regulated Gene Promoters 
Overcomes Dual CtBP and NCoR/SMRT Transcriptional Repression 
Checkpoints. Mol Cell 29:755-766 
 
153. Blanquart C, Mansouri R, Paumelle R, Fruchart J-C, Staels B, Glineur C 2004 
The Protein Kinase C Signaling Pathway Regulates a Molecular Switch 
between Transactivation and Transrepression Activity of the Peroxisome 
Proliferator-Activated Receptor α. Mol Endocrinol 18:1906-1918 
 
154. Wu R-C, Feng Q, Lonard DM, BW OM 2007 SRC-3 Coactivator Functional 
Lifetime Is Regulated by a Phospho-Dependent Ubiquitin Time Clock. Cell 
129:1125-1140 
 152
 155. Higashimoto K, Kuhn P, Desai D, Cheng X, Xu W 2007 Phosphorylation-
Mediated Inactivation of Coactivator-Associated Arginine Methyltransferase 
1. Proc Natl Acad Sci 104:12318-12323 
 
156. Yang W, Hong YH, Shen X-Q, Frankowski C, Camp HS, Leff T 2001 
Regulation of Transcription by AMP-activated Protein Kinase. 
Phosphorylation of p300 Blocks Its Interaction with Nuclear Receptors. J 
Biol Chem 276:38341-38344 
 
157. Rainey WE, Bird IM, Mason JI 1994 The NCI-H295 Cell Line:  A Pluripotent 
Model for Human Adrenocortical Studies. Mol Cell Endocrinol 100:45-50 
 
158. Staels B, Hum DW, Miller WL 1993 Regulation of Steroidogenesis in NCI-
H295 Cells: A Cellular Model of the Human Fetal Adrenal. Mol 
Endocrinology 7:423-433 
 
159. Trievel RC, Rojas JR, Sterner DE, Venkataramani RN, Wang L, Zhou J, Allis 
CD, Berger SL, Marmorstein R 1999 Crystal Structure and Mechanism of 
Histone Acetylation of the Yeast GCN5 Transcriptional Coactivator. Proc 
Natl Acad Sci 96:8931-8936 
 
160. Kim J-H, Cho E-J, Kim S-T, Youn H-D 2005 CtBP Represses p300-Mediated 
Transcriptional Activation by Direct Association with its Bromodomain. Nat 
Struct Mol Biol 12:423-428 
 
161. Urs AN, Dammer E, Sewer MB 2006 Sphingosine Regulates the Transcription 
of CYP17 by Binding to Steroidogenic Factor-1. Endocrinology 147:5249-5258 
 
162. Weinmann A, Farnham P 2002 Identification of Unknown Target Genes of 
Human Transcription Factors Using Chromatin Immunoprecipitation. 
Methods 26:37-47 
 
163. Johnson K, Bresnick E 2002 Dissecting Long-Range Transcriptional 
Mechanisms by Chromatin Immunoprecipitation. Methods 26:27-36 
 
164. Sewer MB, Waterman MR 2002 ACTH/cAMP-mediated Transcription of the 
Human CYP17 Gene in the Adrenal Cortex is Dependent on Phosphatase 
Activity. Endocrinology 143:1769-1777 
 
165. Kumar V, Carlson JE, Ohgi KA, Edwards TA, Rose DW, Escalante CR, 
Rosenfeld MG, Aggarwal AK 2002 Transcription Corepressor CtBP Is an 
NAD+-Regulated Dehydrogenase. Molecular Cell 10:857-869 
 
166. Guex N, Peitsch M 1997 SWISS-MODEL and the Swiss-PdbViewer: an 
Environment for Comparative Protein Modeling. Electrophoresis 18:2714-
2723 
 153
  
167. Kedinger C, Gniazdowski M, Mandel J, Jr., Gissinger F, Chambon P 1970 Alpha-
amanitin: a Specific Inhibitor of One of Two DNA-dependent RNA 
Polymerase Activities from Calf Thymus. Biochem Biophys Res Commun 
38:165-171 
 
168. Oster H, Damerow S, Hut RA, Eichele G 2006 Transcriptional Profiling in the 
Adrenal Gland Reveals Circadian Regulation of Hormone Biosynthesis 
Genes and Nucleosome Assembly Genes. J Biol Rhythms 21:350-361 
 
169. Nguyen VT, Giannoni F, Dubois MF, Seo SJ, Vigneron M, Kedinger C, Bensaude 
O 1996 In Vivo Degradation of RNA Polymerase II Largest Subunit 
Triggered by α-Amanitin. Nucl Acids Res 24:2924-2929 
 
170. Lee K-B, Wang D, Lippard SJ, Sharp PA 2002 Transcription-coupled and DNA 
Damage-dependent Ubiquitination of RNA Polymerase II in Vitro. Proc Natl 
Acad Sci U S A 99:4239-4244 
 
171. Lee D, Ezhkova E, Li B, Pattenden SG, Tansey WP, Workman JL 2005 The 
Proteasome Regulatory Particle Alters the SAGA Coactivator to Enhance Its 
Interactions with Transcriptional Activators. Cell 123:423-436 
 
172. Urs AN, Dammer EB, Sewer MB 2006 Sphingosine Regulates the 
Transcription of CYP17 by Binding to Steroidogenic Factor-1. Endocrinology 
 
173. Shibata H, Kobayashi S, Kurihara I, Saito I, Saruta T 2003 Nuclear Receptors 
and Co-Regulators in Adrenal Tumors. Horm Res 59:85-93 
 
174. Ito M, Yu RN, Jameson JL 1998 Steroidogenic Factor-1 Contains a Carboxy-
Terminal Transcriptional Activation Domain That Interacts with Steroid 
Receptor Coactivator-1. Mol Endocrinol 12:290-301 
 
175. Børud B, Hoang T, Bakke M, Jacob AL, Lund J, Mellgren G 2002 The Nuclear 
Receptor Coactivators p300/CBP/Cointegrator-Associated Protein (p/CIP) 
and Transcription Intermediary Factor 2 (TIF2) Differentially Regulate 
PKA-Stimulated Transcriptional Activity of Steroidogenic Factor 1. Mol 
Endocrinol 16:757-773 
 
176. Hinojos CAD, Sharp ZD, Mancini MA 2005 Molecular Dynamics and Nuclear 
Receptor Function. Trends Endocrinol Metab 16:12-18 
 
177. Hiroi H, Christenson LK, Chang L, Sammel MD, Berger SL, Strauss JF III 2004 
Temporal and Spatial Changes in Transcription Factor Binding and Histone 
Modifications at the Steroidogenic Acute Regulatory Protein (StAR) Locus 
Associated with StAR Transcription. Mol Endocrinol 18:791-806 
 
 154
 178. Grunstein M 1997 Histone Acetylation in Chromatin Structure and 
Transcription. Nature 389:349-352 
 
179. Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, 
Nakatani Y, Evans RM 1997 Nuclear Receptor Coactivator ACTR Is a Novel 
Histone Acetyltransferase and Forms a Multimeric Activation Complex with 
P/CAF and CBP/p300. Cell 90:569-580 
 
180. Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, Mizzen CA, McKenna NJ, 
Oñate SA, Tsai SY, Tsai M-J, O'Malley BW 1997 Steroid Receptor 
Coactivator-1 Is a Histone Acetyltransferase. Nature 389:194-198 
 
181. Ma H, Hong H, Huang S-M, Irvine RA, Webb P, Kushner PJ, Coetzee GA, 
Stallcup MR 1999 Multiple Signal Input and Output Domains of the 160-
Kilodalton Nuclear Receptor Coactivator Proteins. Mol Cell Biol 19:6164-
6173 
 
182. Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK, Rosenfeld MG 
1997 The Transcriptional Coactivator p/CIP Binds CBP and Mediates 
Nuclear-Receptor Function. Nature 387:677-684 
 
183. Anafi M, Yang Y-F, Barlev NA, Govindan MVB, Shelly L., Butt TR, Walfish PG 
2000 GCN5 and ADA Adaptor Proteins Regulate Triiodothyronine/GRIP1 
and SRC-1 Coactivator-Dependent Gene Activation by the Human Thyroid 
Hormone Receptor. Mol Endocrinol 14:718-732 
 
184. Grozinger CM, Hassig CA, Schreiber SL 1999 Three Proteins Define a Class of 
Human Histone Deacetylases Related to Yeast Hda1p. Proc Natl Acad Sci U S 
A 96:4868-4873 
 
185. Hörlein AJ, Näär AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, Ryan A, 
Kamei Y, Södeström M, Glass CK, Rosenfeld MG 1995 Ligand-Independent 
Repression by the Thyroid Hormone Receptor Mediated by a Nuclear 
Receptor Co-Repressor. Nature 377:397-403 
 
186. Chen JD, Evans RM 1995 A Transcriptional Co-Repressor That Interacts 
with Nuclear Hormone Receptors. Nature 377:454-457 
 
187. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB 1997 The 
Partial Agonist Activity of Antagonist-Occupied Steroid Receptors Is 
Controlled by a Novel Hinge Domain-Binding Coactivator L7/SPA and the 
Corepressors N-CoR or SMRT. Mol Endocrinol 11:693-705 
 
188. Cavaillès V, Dauvois S, L'Horset F, Lopez G, Hoare S, Kushner PJ, Parker MG 
1995 Nuclear Factor RIP140 Modulates Transcriptional Activation by the 
Estrogen Receptor. EMBO J 14:3741-3751 
 155
  
189. Mathur M, Tucker PW, Samuels HH 2001 PSF Is a Novel Corepressor That 
Mediates Its Effect through Sin3A and the DNA Binding Domain of Nuclear 
Hormone Receptors. Mol Cell Biol 21:2298-2311 
 
190. Schaeper U, Boyd JM, Verma S, Uhlmann E, Subramanian T, Chinnadurai G 
1995 Molecular Cloning and Characterization of a Cellular Phosphoprotein 
that Interacts with a Conserved C-Terminal Domain of Adenovirus E1A 
involved in Negative Modulation of Oncogenic Transformation. Proc Natl 
Acad Sci U S A 92:10467-10471 
 
191. Senyuk V, Chakraborty S, Mikhail FM, Zhao R, Chi Y, Nucifora G 2002 The 
Leukemia-Associated Transcription Repressor AML1/MDS1/EVI1 Requires 
CtBP to Induce Abnormal Growth and Differentiation of Murine 
Hematopoietic Cells. Oncogene 21:3232-3240 
 
192. Senyuk V, Li D, Zakharov A, Mikhail FM, Nucifora G 2005 The Distal Zinc 
Finger Domain of AML1/MDS1/EVI1 Is an Oligomerization Domain 
Involved in Induction of Hematopoietic Differentiation Defects in Primary 
Cells in Vitro. Cancer Res 65:7603-7611 
 
193. Zhang Q, Wang S-Y, Nottke ACN, Rocheleau JV, Piston DW, Goodman RH 
2006 Redox Sensor CtBP Mediates Hypoxia-Induced Tumor Cell Migration. 
Proc Natl Acad Sci U S A 103:9029-9033 
 
194. Shi Y, Sawada J-i, Sui G, Affar EB, Whetstine JR, Lan F, Ogawa H, Luke MP-S, 
Nakatani Y, Shi Y 2003 Coordinated Histone Modifications Mediated by a 
CtBP Co-Repressor Complex. Nature 422:735-738 
 
195. Zhang Q, Piston DW, Goodman RH 2002 Regulation of Corepressor Function 
by Nuclear NADH. Science 295:1895-1897 
 
196. Balasubramanian P, Zhao L-J, Chinnadurai G 2003 Nicotinamide Adenine 
Dinucleotide Stimulates Oligomerization, Interaction with Adenovirus E1A 
and an Intrinsic Dehydrogenase Activity of CtBP. FEBS Lett 537:157-160 
 
197. Schmitz F, Königstorfer A, Südhof TC 2000 RIBEYE, a Component of 
Synaptic Ribbons: A Protein's Journey through Evolution Provides Insight 
into Synaptic Ribbon Function. Neuron 28:857-872 
 
198. Meloni AR, Lai C-H, Yao T-P, Nevins JR 2005 A Mechanism of COOH-
Terminal Binding Protein-Mediated Repression. Mol Cancer Res 3:575-583 
 
199. Senyuk V, Sinha KK, Nucifora G 2005 Corepressor CtBP1 Interacts with and 
Specifically Inhibits CBP Activity. Arch Biochem Biophys 441:168-173 
 
 156
 200. Vo N, Fjeld C, Goodman RH 2001 Acetylation of Nuclear Hormone Receptor-
Interacting Protein RIP140 Regulates Binding of the Transcriptional 
Corepressor CtBP. Mol Cell Biol 21:6181-6188 
 
201. Fong YW, Zhou Q 2001 Stimulatory Effect of Splicing Factors on 
Transcriptional Elongation. Nature 414:929-933 
 
202. Verger A, Quinlan KGR, Crofts LA, Spanò S, Corda D, Kable EPW, Braet F, 
Crossley M 2006 Mechanisms Directing the Nuclear Localization of the CtBP 
Family Proteins. Mol Cell Biol 26:4882-4894 
 
203. Alpatov R, Munguba C, Caton P, Joo JH, Shi Y, Shi Y, Hunt ME, Sugrue SP 
2004 Nuclear Speckle-Associated Protein Pnn/DRS Binds to the 
Transcriptional Corepressor CtBP and Relieves CtBP-Mediated Repression 
of the E-Cadherin Gene. Mol Cell Biol 24:10223-10235 
 
204. Castet A, Boulahtouf A, Versini G, Bonnet S, Augereau P, Vignon F, Khochbin 
S, Jalaguier S, Cavaillès V 2004 Multiple Domains of the Receptor-Interacting 
Protein 140 Contribute to Transcription Inhibition. Nucleic Acids Res 
32:1957-1966 
 
205. Lee DY, Teyssier C, Strahl BD, Stallcup MR 2005 Role of Protein Methylation 
in Regulation of Transcription. Endocr Rev 26:147-170 
 
206. Talasz H, Lindner HH, Sarg B, Helliger W 2005 Histone H4-Lysine 20 
Monomethylation Is Increased in Promoter and Coding Regions of Active 
Genes and Correlates with Hyperacetylation. J Biol Chem 280:38814-38822 
 
207. Santos-Rosa H, Schneider R, Bernstein BE, Karabetsou N, Morillon A, Weise C, 
Schreiber SL, Mellor J, Kouzarides T 2003 Methylation of Histone H3 K4 
Mediates Association of the Isw1p ATPase with Chromatin. Mol Cell 
12:1225-1232 
 
208. Aesoy R, Mellgren G, Morohashi K, Lund J 2002 Activation of cAMP-
dependent Protein Kinase Increases the Protein Level of Steroidogenic 
Factor-1. Endocrinology 143:295-303 
 
209. Hammer GD, Krylova I, Zhang Y, Darimont BD, Simpson K, Weigel NL, 
Ingraham HA 1999 Phosphorylation of the Nuclear Receptor SF-1 Modulates 
Cofactor Recruitment: Integration of Hormone Signaling in Reproduction 
and Stress. Mol Cell 3:521-526 
 
210. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, 
Lane TF, Hla T 2001 Overexpression of Cyclooxygenase-2 is Sufficient to 
Induce Tumorigenesis in Transgenic Mice. J Biol Chem 276:18563-18569 
 
 157
 211. Hagen T, Vidal-Puig A 2002 Characterisation of the Phosphorylation of Beta-
catenin at the GSK-3 Priming Site Ser45. Biochem Biophys Res Commun 
294:324-328 
 
212. Casaday RJ, Bailey JR, Kalb SR, Brignole EJ, Loveland AN, Cotter RJ, Gibson 
W 2004 Assembly Protein Precursor (pUL80.5 Homolog) of Simian 
Cytomegalovirus is Phosphorylated at a Glycogen Synthase Kinase 3 Site 
and Its Downstream "Priming" Site: Phosphorylation affects Interactions of 
Protein with Itself and with Major Capsid Protein. J Virol 78:13501-13511 
 
213. Amit S, Hatzubai A, Birman Y, Andersen JS, Ben-Shushan E, Mann M, Ben-
Neriah Y, Alkalay I 2002 Axin-mediated CKI Phosphorylation of Beta-catenin 
at Ser 45: a Molecular Switch for the Wnt Pathway. Genes Dev 16:1066-1076 
 
214. Yin L, Wang J, Klein PS, Lazar MA 2006 Nuclear Receptor Rev-erbα Is a 
Critical Lithium-Sensitive Component of the Circadian Clock. Science 
311:1002-1005 
 
215. Hedgepeth CM, Conrad LJ, Zhang J, Huang HC, Lee VM, Klein PS 1997 
Activation of the Wnt Signaling Pathway: a Molecular Mechanism for 
Lithium Action. Dev Biol 185:82-91 
 
216. Lewis AE, Rusten M, Hoivik EA, Vikse EL, Hansson ML, Wallberg AE, Bakke 
M 2008 Phosphorylation of Steroidogenic Factor 1 is Mediated by Cyclin-
dependent Kinase 7. Mol Endocrinol 22:91-104 
 
217. Dammer EB, Leon A, Sewer MB 2007 Coregulator Exchange and 
Sphingosine-Sensitive Cooperativity of Steroidogenic Factor-1, General 
Control Nonderepressed 5, p54, and p160 Coactivators Regulate Cyclic 
Adenosine 3',5'-Monophosphate-Dependent Cytochrome P450c17 
Transcription Rate. Mol Endocrinol 21:415-438 
 
218. Szyszka R, Grankowski N, Felczak K, Shugar D 1995 Halogenated 
Benzimidazoles and Benzotriazoles as Selective Inhibitors of Protein Kinases 
CK I and CK II from Saccharomyces cerevisiae and Other Sources. Biochem 
Biophys Res Commun 208:418-424 
 
219. Sarno S, Reddy H, Meggio F, Ruzzene M, Davies SP, Donella-Deana A SD, 
Pinna LA 2001 Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP Site-
directed Inhibitor of Protein Kinase CK2 ('casein kinase-2'). FEBS Lett 
496:44-48 
 
220. Luger K 2006 Dynamic Nucleosomes. Chromosome Res 14:5-16 
 
 158
 221. Segal E, Fondufe-Mittendorf Y, Chen L, Thastrom A, Field Y, Moore IK, Wang 
JP, Widom J 2006 A Genomic Code for Nucleosome Positioning. Nature 
442:772-778 
 
222. Sewer MB, Waterman MR 2002 cAMP-Dependent Transcription of 
Steroidogenic Genes in the Human Adrenal Cortex Requires a Dual-
specificity Phosphatase in Addition to PKA. J Mol Endocrinol 29:163-174 
 
223. Winnay JN, Hammer GD 2006 Adrenocorticotropic Hormone-Mediated 
Signaling Cascades Coordiate a Cyclic Pattern of Steroidogenic Factor 1-
Dependent Transcriptional Activation. Mol Endocrinol 20:147-166 
 
224. Wang W, Zhang C, Marimuthu A, Krupka HI, Tabrizizad M, Shelloe R, Mehra U, 
Eng K, Nguyen H, Settachatgul C, Powell B, Milburn MV, West BL 2005 The 
Crystal Structures of Human Steroidogenic Factor-1 and Liver Receptor 
Homologue-1. Proc Natl Acad Sci U S A 102:7505-7510 
 
225. Li Y, Choi M, Cavey G, Daugherty J, Suino K, Kovach A, Bingham NC, Kliewer 
SA, Xu HE 2005 Crystallographic Identification and Functional 
Characterization of Phospholipids as Ligands for the Orphan Nuclear 
Receptor Steroidogenic Factor-1. Mol Cell 17:491-502 
 
226. Krylova IN, Sablin EP, Moore J, Xu RX, Waitt GM, MacKay JA, Juzuniene D, 
Bynum JM, Madauss K, Montana V, Lebedeva L, Suzawa M, Williams JD, 
Williams SP, Guy RK, Thornton JW, Fletterick RJ, Willson TM, Ingraham HA 
2005 Structural Analyses Reveal Phosphatidyl Inositols as Ligands for the 
NR5 Orphan Receptors SF-1 and LRH-1. Cell 120:343-355 
 
227. Popov VM, Wang C, Shirley LA, Rosenberg A, Li S, Nevalainen M, Fu M, 
Pestell RG 2007 The Functional Significance of Nuclear Receptor Acetylation. 
Steroids 72:221-230 
 
228. Faus H, Haendler B 2006 Post-translational Modifications of Steroid 
Receptors. Biomed Pharmacother 60:520-529 
 
229. Jacob AL, Lund J, Martinez P, Hedin L 2001 Acetylation of steroidogenic 
factor 1 Protein Regulates Its Transcriptional Activity and Recruits the 
Coactivator GCN5. J Biol Chem 276:37659-37664 
 
230. Ishihara SL, Morohashi K 2005 A Boundary for Histone Acetylation Allows 
Distinct Expression Patterns of the Ad4BP/SF-1 and GCNF Loci in Adrenal 
Cortex Cells. Biochem Biophys Res Commun 329:554-562 
 
231. Chen WY, Juan LJ, Chung BC 2005 SF-1 (Nuclear Receptor 5A1) Activity Is 
Activated by Cyclic AMP via p300-mediated Recruitment to Active Foci, 
Acetylation, and Increased DNA Binding. Mol Cell Biol 25:10442-10453 
 159
  
232. Sterner DE, Berger SL 2000 Acetylation of Histones and Transcription-
Related Factors. Microbiol Mol Biol Rev 64:435-459 
 
233. Dammer EB, Leon A, Sewer MB 2007 Coregulator Exchange and 
Sphingosine-Sensitive Cooperativity of Steroidogenic Factor-1, General 
Control Nonderepressed 5, p54, and p160 Coactivators Regulate Cyclic 
Adenosine 3',5'-Monophosphate-Dependent Cytochrome P450c17 
Transcription Rate. Mol Endocrinol 21:415-438 
 
234. Frederiks WM, Kummerlin IPED, Bosch KS, Vreeling-Sindelarova H, Jonker A, 
Van Noorden CJF 2007 NADPH Production by the Pentose Phosphate 
Pathway in the Zona Fasciculata of Rat Adrenal Gland. J Histochem 
Cytochem 55:975-980 
 
235. Shorin IP, Shershnev VN, Iakobson GS 1976 [Activity of Adrenal Cytoplasmic 
Dehydrogenase Following Prolonged ACTH Administration]. Biull Eksp Biol 
Med 81:173-175 
 
236. Feo F, Ruggiu M, Lenzerini L, Garcea R, Daino L, Frassetto S, Addis V, Gaspa 
L, Pascale R 1987 Benzo(a)pyrene Metabolism by Lymphocytes from Normal 
Individuals and Individuals Carrying the Mediterranean Variant of Glucose-
6-Phosphate Dehydrogenase. Int J Cancer 39:560-564 
 
237. Pascale R, Ruggiu M, Simile M, Daino L, Vannini G, Seddaiu M, Satta G, Feo F 
1990 Dependence of Benzo(a)pyrene Metabolism on NADPH Pool in Normal 
and Glucose-6-Phosphate Dehydrogenase Deficient Human Fibroblasts. Res 
Commun Chem Pathol Pharmacol 69:361-364 
 
238. Costa Rosa L-FBP, Curi R, Murphy C, Newsholme P 1995 Effect of Adrenaline 
and Phorbol Myristate Acetate or Bacterial Lipopolysaccharide on 
Stimulation of Pathways of Macrophage Glucose, Glutamine, and O2 
Metabolism. Evidence for Cyclic AMP-Dependent Protein Kinase Mediate 
Inhibition of Glucose-6-Phosphate Dehydrogenase and Activation of NADP+-
dependent 'Malic' Enzyme. Biochem J 310:709-714 
 
239. Williamson DH, Lund P, Krebs HA 1967 The Redox State of Free 
Nicotinamide-Adenine Dinucleotide in the Cytoplasm and Mitochondria of 
Rat Liver. Biochem J 103:514-527 
 
240. Barnes CJ, Vadlamudi RK, Mishra SK, Jacobson RH, Li F, Kumar R 2003 
Functional Inactivation of a Transcriptional Corepressor by a Signaling 
Kinase. Nat Struct Biol 10:622-628 
 
241. Quinlan KGR, Verger A, Kwok A, Lee SHY, Perdomo J, Nardini M, Bolognesi 
M, Crossley M 2006 Role of the C-Terminal Binding Protein PXDLS Motif 
 160
 Binding Cleft in Protein Interactions and Transcriptional Repression. Mol 
Cell Biol 26:8202-8213 
 
242. Reeve JN 2003 Archaeal Chromatin and Transcription. Mol Microbiol 
48:587-598 
 
243. Phelps C, Gburcik V, Suslova E, Dudek P, Forafonov F, Bot N, MacLean M, 
Fagan RJ, Picard D 2006 Fungi and Animals May Share a Common Ancestor 
to Nuclear Receptors.  103:7077-7081 
 
244. Boulikas T, Wiseman JM, Garrard WT 1980 Points of Contact between Histone 
H1 and the Histone Octamer. Proc Natl Acad Sci U S A 77:127-131 
 
245. Antonio LA, Loren JM, Juliana JC, Becky AM, Serge B, Valerie C, Anthony PO, 
Jennifer B, John BH, Michael DC 2007 A Coactivator Trap Identifies NONO 
(p54nrb) as a Component of the cAMP-Signaling Pathway. Proc Natl Acad Sci 
U S A 104:20314-20319 
 
246. Langst G, Becker PB 2001 Nucleosome Mobilization and Positioning by ISWI-
Containing Chromatin-Remodeling Factors. J Cell Sci 114:2561-2568 
 
247. Gummow BM, Winnay JN, Hammer GD 2003 Convergence of Wnt Signaling 
and Steroidogenic Factor-1 (SF-1) on Transcription of the Rat Inhibin α 
Gene. J Biol Chem 278:26572-26579 
 
248. Aigueperse C, Val P, Pacot C, Darne C, Lalli E, Sassone-Corsi P, Veyssiere G, 
Jean C, Martinez A 2001 SF-1 (Steroidogenic Factor-1), C/EBPß 
(CCAAT/Enhancer Binding Protein), and Ubiquitous Transcription Factors 
NF1 (Nuclear Factor 1) and Sp1 (Selective Promoter Factor 1) Are Required 
for Regulation of the Mouse Aldose Reductase-Like Gene (AKR1B7) 
Expression in Adrenocortical Cells. Mol Endocrinol 15:93-111 
 
249. Flück CE, Miller WL 2004 GATA-4 and GATA-6 Modulate Tissue-Specific 
Transcription of the Human Gene for P450c17 by Direct Interaction with 
Sp1. Mol Endocrinol 18:1144-1157 
 
250. Jimenez P, Saner K, Mayhew B, Rainey WE 2003 GATA-6 Is Expressed in the 
Human Adrenal and Regulates Transcription of Genes Required for Adrenal 
Androgen Biosynthesis. Endocrinology 144:4285-4288 
 
251. Tremblay JJ, Viger RS 2003 A Mutated Form of Steroidogenic Factor 1 (SF-1 
G35E) that Causes Sex Reversal in Humans Fails to Synergize with 
Transcription Factor GATA-4. J Biol Chem 278:42637-42642 
 
 161
 252. Tremblay JJ, Viger RS 1999 Transcription Factor GATA-4 Enhances 
Müllerian Inhibiting Substance Gene Transcription through a Direct 
Interaction with the Nuclear Receptor SF-1. Mol Endocrinol 13:1388-1401 
 
253. Tremblay JJ, Viger RS 2001 Nuclear Receptor Dax-1 Represses the 
Transcriptional Cooperation between GATA-4 and SF-1 in Sertoli Cells. 
Biology of Reporduction 64:1191-1199 
 
254. Fischle W, Wang Y, Allis CD 2003 Binary Switches and Modification 
Cassettes in Histone Biology and Beyond. Nature 425:475-479 
 
255. Wang J, Scully K, Zhu X, Cai L, Zhang J, Prefontaine GG, Krones A, Ohgi KA, 
Zhu P, Garcia-Bassets I, Liu F, Taylor H, Lozach J, Jayes FL, Korach KS, Glass 
CK, Fu X-D, Rosenfeld MG 2007 Opposing LSD1 Complexes Function in 
Developmental Gene Activation and Repression Programmes. Nature 
446:882-887 
 
256. Subramanian T, Chinnadurai G 2003 Association of Class I Histone 
Deacetylases with Transcriptional Corepressor CtBP. FEBS Lett 540:255-258 
 
257. Lopez-Garcia J, Periyasamy M, Thomas RS, Christian M, Leao M, Jat P, Kindle 
KB, Heery DM, Parker MG, Buluwela L, Kamalati T, Ali S 2006 ZNF366 Is an 
Estrogen Receptor Corepressor That Acts through CtBP and Histone 
Deacetylases. Nucl Acids Res 34:6126-6136 
 
258. Quinlan KGR, Verger A, Yaswen P, Crossley M 2007 Amplification of Zinc 
Finger Gene 217 (ZNF217) and Cancer: When Good Fingers Go Bad. 
Biochim Biophys Acta 1775:333-340 
 
259. Zhang Q, Wang S-Y, Fleuriel C, Leprince D, Rocheleau JV, Piston DW, 
Goodman RH 2007 Metabolic Regulation of SIRT1 Transcription via a 
HIC1:CtBP Corepressor Complex. Proc Natl Acad Sci U S A 104:829-833 
 
260. DeBerardinis RJ, Sayed N, Ditsworth D, Thompson CB 2008 Brick by Brick:  
Metabolism and Tumor Cell Growth. Curr Opin Genet Dev 18:54-61 
 
261. Glaros S, Cirrincione GM, Muchardt C, Kleer CG, Michael CW, Reisman D 2007 
The Reversible Epigenetic Silencing of BRM: Implications for Clinical 
Targeted Therapy. Oncogene 26:7058-7066 
 
262. Yamamichi N, Yamamichi-Nishina M, Mizutani T, Watanabe H, Minoguchi S, 
Kobayashi N, Kimura S, Ito T, Yahagi N, Ichinose M, Omata M, Iba H 2005 The 
Brm Gene Suppressed at the Post-Transcriptional Level in Various Human 
Cell Lines is Inducible by Transient HDAC Inhibitor Treatment, which 
Exhibits Antioncogenic Potential. Oncogene 24:5471-5481 
 
 162
  163
263. Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJM, Anzalone L, 
Pezzani L, Di Giacomo AM, Fonsatti E, Colizzi F, Altomonte M, Calabrò L, 
Maio M 2007 Epigenetic Drugs as Pleiotropic Agents in Cancer Treatment: 
Biomolecular Aspects and Clinical Applications. J Cell Physiol 212:330-344 
 
264. Sirianni R, Chimento A, Malivindi R, Mazzitelli I, Ando S, Pezzi V 2007 Insulin-
Like Growth Factor-I, Regulating Aromatase Expression through 
Steroidogenic Factor 1, Supports Estrogen-Dependent Tumor Leydig Cell 
Proliferation. Cancer Res 67:8368-8377 
 
265. Zhou J, Suzuki T, Kovacic A, Saito R, Miki Y, Ishida T, Moriya T, Simpson ER, 
Sasano H, Clyne CD 2005 Interactions between Prostaglandin E2, Liver 
Receptor Homologue-1, and Aromatase in Breast Cancer. Cancer Res 65:657-
663 
 
266. Bouchard MF, Taniguchi H, Viger RS 2005 Protein Kinase A-Dependent 
Synergism between GATA Factors and the Nuclear Receptor, Liver 
Receptor Homolog-1, Regulates Human Aromatase (CYP19) PII Promoter 
Activity in Breast Cancer Cells. Endocrinology 146:4905-4916 
 
267. Hadizadeh S, King DN, Shah S, Sewer MB 2008 Sphingosine-1-Phosphate 
Regulates the Expression of the Liver Receptor Homologue-1. Mol Cell 
Endocrinol 283:104-113 
 
 
 
